PT J
AU Kent, LM
   Worsley, A
AF Kent, Lillian M.
   Worsley, Anthony
TI Trends in BMI, diet and lifestyle between 1976 and 2005 in North Sydney
SO ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE BMI; diet; lifestyle; prudent lifestyle; Western lifestyle
ID body-mass index; energy-expenditure; childhood obesity; physical-activity; us children; consumption; prevalence; overweight; pattern; drinks
AB Although the prevalence of overweight and obesity in Australia has increased during the past 30 years, little is known about the dietary and behavioural antecedents of body mass index (BMI). We examined changes in mean BMI, diet, and other lifestyle behaviours between 1976 and 2005 and described the cross-sectional associations between these factors and BMI. A series of biennial biomedical surveys by Sydney Adventist Hospital from 1976 to 2005 allowed examination of BMI trends, while the selection of three surveys enabled detailed examination of likely dietary and lifestyle associations. Subjects included in this study were: 384 men and 338 women in 1976: 160 men and 146 women in 1978; 166 men and 141 women in 1980. 164 men and 142 women in 1982; 177 men and 13 women in 1984; 239 men and 227 women in 1986; 210 men and 225 women in 1988; 165 men and 148 women in 1990; 138 men and 167 women in 1992 and 270 men and 62 women in 2005. Height and weight were measured by hospital staff. Mean BMI increased in the early 1990s. Salt, coffee, cola.. alcohol and meat consumption, dieting to lose weight and eating between meals were positively associated with BMI while physical activity, food variety, large breakfasts and consumption of spreads were negatively associated. Food consumption and daily activities have important associations with BMI, though their specific associations differ by sex. "Affluent" lifestyle patterns appear to contribute to higher BMI, while a more "prudent" lifestyle seems to protect from such increases.
C1 [Kent, Lillian M.] Murdoch Childrens Res Inst, Ctr Adolescent Hlth, Parkville, Vic 3052, Australia.
   [Worsley, Anthony] Univ Wollongong, Sch Hlth Sci, Wollongong, NSW, Australia.
C3 Murdoch Children's Research Institute; University of Wollongong
RP Kent, LM (corresponding author), Murdoch Childrens Res Inst, Ctr Adolescent Hlth, 2 Gatehouse St, Parkville, Vic 3052, Australia.
EM lillian.kent@mcri.edu.au
FU Deakin University, Melbourne, Australia; Sanitarium Health Food Company; Australian Research Council
CR *ABS, 1979, NEW S WAL YB, V0, P0
   *ABS, 2003, SOC IND AR AUSTR 200, V0, P0
   *ABS, 2004, OV OB AD AUSTR 2004, V0, P0
   *ABS, 2006, AUSTR HIST POP STAT, V0, P0
   *ABS, 2000, NAT NUTR SURV SEL HI, V0, P0
   Allman-Farinelli MA, 2008, EUR J CLIN NUTR, V62, P898, DOI 10.1038/sj.ejcn.1602769
   Unknown -, 1997, CURR THER, V0, P0
   Unknown -, 2002, DIET, V0, P0
   ARMSTRONG T, 2000, 10 AIHW CVD, V0, P0
   Barr E, 2006, AUSTR DIABETES OBESI, V0, P0
   Bjorntorp P, 2001, OBES REV, V2, P73, DOI 10.1046/j.1467-789x.2001.00027.x
   BORTNER RW, 1969, J CHRON DIS, V22, P87, DOI 10.1016/0021-9681(69)90061-7
   Cameron AJ, 2003, MED J AUSTRALIA, V178, P427, DOI 10.5694/j.1326-5377.2003.tb05283.x
   CASHEL K, 2001, CHANGING PATTERNS EA, V0, P0
   Catford JC, 2003, MED J AUSTRALIA, V179, P577, DOI 10.5694/j.1326-5377.2003.tb05703.x
   Cho S, 2003, J AM COLL NUTR, V22, P296, DOI 10.1080/07315724.2003.10719307
   DECASTRO JM, 1995, PHYSIOL BEHAV, V57, P287, DOI 10.1016/0031-9384(94)00229-X
   Drewnowski A, 2004, AM J CLIN NUTR, V79, P6
   Elfhag K, 2005, OBES REV, V6, P67, DOI 10.1111/j.1467-789X.2005.00170.x
   Harnack L, 1999, J AM DIET ASSOC, V99, P436, DOI 10.1016/S0002-8223(99)00106-6
   Jahns L, 2001, J PEDIATR-US, V138, P493, DOI 10.1067/mpd.2001.112162
   James J, 2004, BMJ-BRIT MED J, V328, P1237, DOI 10.1136/bmj.38077.458438.EE
   JENKINS CD, 1967, J CHRON DIS, V20, P371, DOI 10.1016/0021-9681(67)90010-0
   Kent LM, 2009, PUBLIC HEALTH NUTR, V12, P472, DOI 10.1017/S1368980008002334
   Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1
   McDevitt RM, 2000, AM J CLIN NUTR, V72, P369
   National Health and Medical Research Council, 2003, DIET GUID AUSTR AD, V0, P0
   *NSW, 2003, STAT FOOD NUTR NSW S, V0, P0
   Organisation mondiale de la sante, 1999, OBESITY: PREVENTING AND MANAGING THE GLOBAL EPIDEMIC, V0, P0
   PEETERS A, 2007, DIS TRENDS RES SUMM, V0, P0
   Quatromoni PA, 2002, J AM DIET ASSOC, V102, P1240
   Rippe JM, 1998, J AM DIET ASSOC, V98, PS31, DOI 10.1016/S0002-8223(98)00708-1
   RISING R, 1994, AM J CLIN NUTR, V59, P800, DOI 10.1093/ajcn/59.4.800
   Song WO, 2005, J AM DIET ASSOC, V105, P1373, DOI 10.1016/j.jada.2005.06.002
   Sorensen TIA, 1998, INT J OBESITY, V22, P73, DOI 10.1038/sj.ijo.0800548
   Visscher TLS, 2001, ANNU REV PUBL HEALTH, V22, P355, DOI 10.1146/annurev.publhealth.22.1.355
   Westenhoefer J, 1999, INT J EAT DISORDER, V26, P53, DOI 10.1002/(SICI)1098-108X(199907)26:1<53::AID-EAT7>3.0.CO;2-N
   Westerterp KR, 1997, INT J OBESITY, V21, P184, DOI 10.1038/sj.ijo.0800385
   Wing RR, 2005, AM J CLIN NUTR, V82, P222S, DOI 10.1093/ajcn/82.1.222S
   Zimmet P, 2000, THE ASIA-PACIFIC PERSPECTIVE: REDEFINING OBESITY AND ITS TREATMENT, V0, P0
NR 40
TC 16
Z9 22
U1 0
U2 7
PU H E C PRESS, HEALTHY EATING CLUB PTY LTD
PI MCKINNON
PA PO BOX 4121, MCKINNON, VIC 3204, AUSTRALIA
SN 0964-7058
EI 1440-6047
J9 ASIA PAC J CLIN NUTR
JI Asia Pac. J. Clin. Nutr.
PD JUN 15
PY 2009
VL 18
IS 3
BP 453
EP 461
DI 
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 507FD
UT WOS:000270836300019
PM 19786395
DA 2025-04-28
ER

PT J
AU Dean, S
   Braakhuis, A
   Paton, C
AF Dean, Sara
   Braakhuis, Andrea
   Paton, Carl
TI The Effects of EGCG on Fat Oxidation and Endurance Performance in Male Cyclists
SO INTERNATIONAL JOURNAL OF SPORT NUTRITION AND EXERCISE METABOLISM
LA English
DT Article
DE epigallocatechin-3-gallate; caffeine; cycling; athletes
ID diet-induced obesity; green tea; caffeine ingestion; energy-expenditure; weight maintenance; insulin-secretion; lipid-metabolism; adipose-tissue; exercise; leptin
AB Researchers have long been investigating strategies that can increase athletes' ability to oxidize fatty acids and spare carbohydrate, thus potentially improving endurance capacity. Green-tea extract (epigallocatechin-3-gallate; EGCG) has been shown to improve endurance capacity in mice. If a green-tea extract can stimulate fat oxidation and as a result spare glycogen stores, then athletes may benefit through improved endurance performance. Eight male cyclists completed a study incorporating a 3-way crossover, randomized, placebo-controlled, double-blinded, diet-controlled research design. All participants received 3 different treatments (placebo 270 mg, EGCG 270 mg, and placebo 270 mg + caffeine 3 mg/kg) over a 6-day period and 1 hr before exercise testing. Each participant completed 3 exercise trials consisting of 60 min of cycling at 60% maximum oxygen uptake (VO2max) immediately followed by a self-paced 40-km cycling time trial. The study found little benefit in consuming green-tea extract on fat oxidation or cycling performance, unlike caffeine, which did benefit cycling performance. The physiological responses observed during submaximal cycling after caffeine ingestion were similar to those reported previously, including an increase in heart rate (EGCG 147 +/- 17, caffeine 146 +/- 19, and placebo 144 +/- 15 beats/min), glucose at the 40-min exercise time point (placebo 5.0 +/- 0.8, EGCG 5.4 +/- 1.0, and caffeine 5.8 +/- 1.0 mmo/L), and resting plasma free fatty acids and no change in the amount of carbohydrate and fat being oxidized. Therefore, it was concluded that green-tea extract offers no additional benefit to cyclists over and above those achieved by using caffeine.
C1 [Dean, Sara; Braakhuis, Andrea] Waikato Inst Technol, Sch Sport & Exercise Sci, Hamilton, New Zealand.
   [Paton, Carl] Eastern Inst Technol, Hawkes Bay, New Zealand.
C3 Waikato Institute of Technology; Eastern Institute of Technology
RP Dean, S (corresponding author), Waikato Inst Technol, Sch Sport & Exercise Sci, Hamilton, New Zealand.
FU Wintec Research Fund
CR Ahrén B, 1999, AM J PHYSIOL-REG I, V277, PR959, DOI 10.1152/ajpregu.1999.277.4.R959
   Anderson RA, 2002, J AGR FOOD CHEM, V50, P7182, DOI 10.1021/jf020514c
   Ashida H, 2004, BIOFACTORS, V22, P135, DOI 10.1002/biof.5520220126
   Batterham AM, 2005, SPORTSCIENCE, V9, P6
   Bell DG, 2003, MED SCI SPORT EXER, V35, P1348, DOI 10.1249/01.MSS.0000079071.92647.F2
   Bell DG, 2002, J APPL PHYSIOL, V93, P1227, DOI 10.1152/japplphysiol.00187.2002
   Belza A, 2005, EUR J CLIN NUTR, V59, P733, DOI 10.1038/sj.ejcn.1602121
   Bennard P, 2005, CAN J APPL PHYSIOL, V30, P475, DOI 10.1139/h05-134
   Bérubé-Parent S, 2005, BRIT J NUTR, V94, P432, DOI 10.1079/BJN20051502
   Bouassida A, 2006, J SPORT SCI MED, V5, P172
   Chen LS, 1997, DRUG METAB DISPOS, V25, P1045
   Chesley A, 1998, AM J PHYSIOL-REG I, V275, PR596, DOI 10.1152/ajpregu.1998.275.2.R596
   Choo JJ, 2003, J NUTR BIOCHEM, V14, P671, DOI 10.1016/j.jnutbio.2003.08.005
   Conway KJ, 2003, J APPL PHYSIOL, V94, P1557, DOI 10.1152/japplphysiol.00911.2002
   Cox GR, 2002, J APPL PHYSIOL, V93, P990, DOI 10.1152/japplphysiol.00249.2002
   Doherty M, 2005, SCAND J MED SCI SPOR, V15, P69, DOI 10.1111/j.1600-0838.2005.00445.x
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Engels HJ, 1999, INT J SPORT NUTR, V9, P361, DOI 10.1123/ijsn.9.4.361
   Graham TE, 2000, J PHYSIOL-LONDON, V529, P837, DOI 10.1111/j.1469-7793.2000.00837.x
   Graham TE, 2001, SPORTS MED, V31, P785, DOI 10.2165/00007256-200131110-00002
   Greer F, 2000, J APPL PHYSIOL, V89, P1837, DOI 10.1152/jappl.2000.89.5.1837
   Hawley JA, 1998, SPORTS MED, V25, P241, DOI 10.2165/00007256-199825040-00003
   Hunter AM, 2002, INT J SPORT NUTR EXE, V12, P438, DOI 10.1123/ijsnem.12.4.438
   Hwa J, 1997, BIOCHEMISTRY-US, V36, P633, DOI 10.1021/bi962141c
   Jacobson TL, 2001, EXP PHYSIOL, V86, P137, DOI 10.1113/eph8602072
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   Kao YH, 2006, MOL NUTR FOOD RES, V50, P188, DOI 10.1002/mnfr.200500109
   Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926
   Kovacs EMR, 2004, BRIT J NUTR, V91, P431, DOI 10.1079/BJN20041061
   Kovacs EMR, 1998, J APPL PHYSIOL, V85, P709, DOI 10.1152/jappl.1998.85.2.709
   Magkos Faidon, 2004, SPORTS MED, V34, P871, DOI 10.2165/00007256-200434130-00002
   McMurray RG, 2005, SPORTS MED, V35, P393, DOI 10.2165/00007256-200535050-00003
   Mukhtar H, 2000, AM J CLIN NUTR, V71, P1698S, DOI 10.1093/ajcn/71.6.1698S
   Murase T, 2006, AM J PHYSIOL-REG I, V290, PR1550, DOI 10.1152/ajpregu.00752.2005
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Murase T, 2005, AM J PHYSIOL-REG I, V288, PR708, DOI 10.1152/ajpregu.00693.2004
   Perusse L, 1997, J APPL PHYSIOL, V83, P5, DOI 10.1152/jappl.1997.83.1.5
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   Sale C, 2006, INT J OBESITY, V30, P764, DOI 10.1038/sj.ijo.0803209
   Sayama K, 2000, IN VIVO, V14, P481
   Shimotoyodome A, 2005, MED SCI SPORT EXER, V37, P1884, DOI 10.1249/01.mss.0000178062.66981.a8
   Tanizawa Y, 1997, ENDOCRINOLOGY, V138, P4513, DOI 10.1210/en.138.10.4513
   Tokimitsu I, 2004, BIOFACTORS, V22, P141, DOI 10.1002/biof.5520220127
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   Wolfram S, 2005, ANN NUTR METAB, V49, P54, DOI 10.1159/000084178
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
   Yang CS, 2000, J NUTR, V130, P2409, DOI 10.1093/jn/130.10.2409
   Zheng GD, 2004, IN VIVO, V18, P55
   Zuntz N, 1901, PFLUGERS ARCH, V83, P557, DOI 10.1007/BF01746509
NR 49
TC 46
Z9 49
U1 0
U2 33
PU HUMAN KINETICS PUBL INC
PI CHAMPAIGN
PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA
SN 1526-484X
EI 1543-2742
J9 INT J SPORT NUTR EXE
JI Int. J. Sport Nutr. Exerc. Metab.
PD DEC 15
PY 2009
VL 19
IS 6
BP 624
EP 644
DI 10.1123/ijsnem.19.6.624
PG 21
WC Nutrition & Dietetics; Sport Sciences
SC Nutrition & Dietetics; Sport Sciences
GA 534ER
UT WOS:000272879500005
PM 20175431
DA 2025-04-28
ER

PT J
AU Narita, Y
   Inouye, K
AF Narita, Yusaku
   Inouye, Kuniyo
TI Kinetic Analysis and Mechanism on the Inhibition of Chlorogenic Acid and Its Components against Porcine Pancreas α-Amylase Isozymes I and II
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE alpha-Amylase inhibitor; caffeic acid; chlorogenic acid; enzyme kinetics; mixed-type inhibition
ID human matrix-metalloproteinase-7 matrilysin; green coffee beans; maltopentaose hydrolysis; human salivary; caffeic acid; thermolysin; derivatives; activation; substrate; chloride
AB Chlorogenic acid (5-caffeoylquinic acid, 5-CQA) is a kind of polyphenol and is richly included in green coffee beans. The inhibitory effects of 5-CQA and its components, caffeic acid (CA) and quinic acid (QA), on the two porcine pancreas (alpha-amylase (PPA) isozymes, PPA-I and PPA-II, were investigated using p-nitrophenyl-alpha-D-maltoside as substrate at pH 6.9 and 30 degrees C. The inhibition potencies of the respective inhibitors against both PPA isozymes were almost the same and in the order of 5-CQA > CA >> QA. Their IC50 values were 0.07-0.08 mM, 0.37-0.40 mM, and 25.3-26.5 mM, respectively. The inhibition mechanisms of 5-CQA and CA were investigated by kinetic analyses, and the inhibitor constants K-i and K-i' (for the free enzyme and enzyme-substrate complex, respectively) were determined. It was indicated that 5-CQA and CA showed mixed-type inhibition with Ki > Ki' against both PPA-I and PPA-II. The binding of PPA-I or PPA-II with 5-CQA or CA was all exothermic and enthalpy-driven. CIA is a poor inhibitor, and its inhibitory mode was unique and hardly analyzed by a simple Michaelis-Menten-type interaction between the enzyme and inhibitor. However, it was shown that the inhibitory activity of CA was enhanced 5 times by ester-bond formation with QA in the form of 5-CQA. These results provide us with significant hints for the development of alpha-amylase inhibitors useful for the prevention of diabetes and obesity.
C1 [Narita, Yusaku; Inouye, Kuniyo] Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Sakyo Ku, Kyoto 6068502, Japan.
   [Narita, Yusaku] UCC Ueshima Coffee Co Ltd, R&D Ctr, Takatsuki, Osaka 5690036, Japan.
C3 Kyoto University
RP Inouye, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Sakyo Ku, Kyoto 6068502, Japan.
EM inouye@kais.kyoto-u.ac.jp
FU Japan Society for the Promotion of Science [17380065, 20380061]; Grants-in-Aid for Scientific Research [17380065] Funding Source: KAKEN
CR Al Kazaz M, 1998, EUR J BIOCHEM, V252, P100, DOI 10.1046/j.1432-1327.1998.2520100.x
   Alkazaz M, 1996, EUR J BIOCHEM, V241, P787, DOI 10.1111/j.1432-1033.1996.00787.x
   Unknown -, 1976, BIOCHEM J, V0, P0
   Clifford MN, 2006, J AGR FOOD CHEM, V54, P1957, DOI 10.1021/jf0601665
   Clifford MN, 1999, J SCI FOOD AGR, V79, P362, DOI 10.1002/(SICI)1097-0010(19990301)79:3<362::AID-JSFA256>3.0.CO;2-D
   CLIFFORD MN, 1987, FOOD CHEM, V26, P59, DOI 10.1016/0308-8146(87)90167-1
   Cornish-Bowden A, 2002, J BIOSCIENCES, V27, P121, DOI 10.1007/BF02703768
   Cornish-Bowden A, 1976, PRINCIPLES OF ENZYME KINETICS, V0, P52
   CORNISHBA, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143
   Desseaux V, 2002, BIOLOGIA, V57, P163
   Inouye K, 1996, BIOCHEM J, V315, P133, DOI 10.1042/bj3150133
   INOUYE K, 1994, J BIOCHEM-TOKYO, V116, P530, DOI 10.1093/oxfordjournals.jbchem.a124557
   Islam MS, 2002, J AGR FOOD CHEM, V50, P3718, DOI 10.1021/jf020120l
   Iwai K, 2004, J AGR FOOD CHEM, V52, P4893, DOI 10.1021/jf040048m
   Jencks WP, 1969, CATALYSIS CHEM ENZYM, V0, P282
   Jin UH, 2005, LIFE SCI, V77, P2760, DOI 10.1016/j.lfs.2005.02.028
   KLUH I, 1981, FEBS LETT, V136, P231, DOI 10.1016/0014-5793(81)80624-2
   KOMIYAMA T, 1975, ARCH BIOCHEM BIOPHYS, V171, P727, DOI 10.1016/0003-9861(75)90085-5
   Kono Y, 1997, BBA-GEN SUBJECTS, V1335, P335, DOI 10.1016/S0304-4165(96)00151-1
   Ky CL, 2001, FOOD CHEM, V75, P223, DOI 10.1016/S0308-8146(01)00204-7
   LEVITZKI A, 1974, EUR J BIOCHEM, V41, P171, DOI 10.1111/j.1432-1033.1974.tb03257.x
   MARCHISMOUREN G, 1967, BIOCHIM BIOPHYS ACTA, V140, P366, DOI 10.1016/0005-2795(67)90478-3
   MARUTA Y, 1995, J AGR FOOD CHEM, V43, P2592, DOI 10.1021/jf00058a007
   MELOUN B, 1980, COLLECT CZECH CHEM C, V45, P2572, DOI 10.1135/cccc19802572
   Muta Y, 2002, J BIOCHEM, V132, P945, DOI 10.1093/oxfordjournals.jbchem.a003308
   NAKAMURA Y, 1984, GENE, V28, P263, DOI 10.1016/0378-1119(84)90265-8
   NISHIDE T, 1986, GENE, V41, P299
   Oneda H, 2004, J BIOCHEM, V135, P421, DOI 10.1093/jb/mvh050
   Oneda H, 2003, J BIOCHEM, V133, P571, DOI 10.1093/jb/mvg073
   Oneda H, 2001, J BIOCHEM, V129, P429, DOI 10.1093/oxfordjournals.jbchem.a002874
   PASERO L, 1986, BIOCHIM BIOPHYS ACTA, V869, P147, DOI 10.1016/0167-4838(86)90289-X
   ROBYT JF, 1970, J BIOL CHEM, V245, P3917
   Rohn S, 2002, J AGR FOOD CHEM, V50, P3566, DOI 10.1021/jf011714b
   SAKANO Y, 1983, DEMPUN KAGAKU, V30, P30
   Segel IH, 1975, ENZYME KINETICS BEHA, V0, P161
   Sharp K, 2001, PROTEIN SCI, V10, P661, DOI 10.1110/ps.37801
   Takenaka M, 2003, J AGR FOOD CHEM, V51, P793, DOI 10.1021/jf020735i
   Tormo MA, 2006, BRIT J NUTR, V96, P539, DOI 10.1079/BJN20061836
   TRONRUD DE, 1986, EUR J BIOCHEM, V157, P261, DOI 10.1111/j.1432-1033.1986.tb09664.x
   Tsujita T, 2008, J NUTR SCI VITAMINOL, V54, P82, DOI 10.3177/jnsv.54.82
   YAMASHITA H, 1991, J BIOCHEM-TOKYO, V110, P605, DOI 10.1093/oxfordjournals.jbchem.a123627
NR 41
TC 104
Z9 110
U1 2
U2 55
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD OCT 14
PY 2009
VL 57
IS 19
BP 9218
EP 9225
DI 10.1021/jf9017383
PG 8
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science & Technology
SC Agriculture; Chemistry; Food Science & Technology
GA 502LM
UT WOS:000270461500068
PM 19807164
DA 2025-04-28
ER

PT J
AU Sharma, S
   De Roose, E
   Cao, X
   Pokiak, A
   Gittelsohn, J
   Corriveau, A
AF Sharma, Sangita
   De Roose, Elsie
   Cao, Xia
   Pokiak, Anita
   Gittelsohn, Joel
   Corriveau, Andre
TI Dietary Intake in a Population Undergoing a Rapid Transition in Diet and Lifestyle: The Inuvialuit in the Northwest Territories of Arctic Canada
SO CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE
LA English
DT Article
DE Nutrition transition; food and nutrient intake; Quantitative Food Frequency Questionnaire (QFFQ); Inuvialuit; nutritional intervention; Northwest Territories (NWT)
ID food-frequency questionnaires; intervention; obesity; nations; inuit
AB Objectives: To: 1) characterize diet in Inuvialuit; 2) determine the foods and nutrients to be targeted for a nutritional intervention program; and 3) develop a Quantitative Food Frequency Questionnaire (QFFQ) to evaluate the program and monitor nutrition transition for Inuvialuit in the Northwest Territories (NWT), Canada. Methods: Twenty-four-hour dietary recalls were collected among 101 Inuvialuit aged 19 years and over in two communities in the NWT. All foods reported in the recall were tabulated for inclusion in the QFFQ. Results: Forty-eight men and 53 women (mean age 49 and 45 yrs, respectively) completed the recalls. Mean energy intake was 2,352 kcal and 1,739 kcal for men and women, respectively. Mean daily intakes of many nutrients including dietary fibre, calcium, and vitamins A, C and E, and total folate were much lower than recommended. The most frequently reported foods were non-nutrient-dense store-bought foods. Most traditional foods (TF) were reported one time by one person. The top two contributors to energy intake, 'sugar added to tea and coffee' and 'sweetened juices and drinks', were targeted by the intervention program. A 145-item QFFQ was developed including 41 TF and 8 categories of consumption frequency. Conclusions: This study has provided dietary intake data previously unavailable for Inuvialuit and highlighted nutrients and foods to be targeted for the intervention program. The QFFQ is up-to-date, culturally appropriate, and currently being used to evaluate the intervention program, Healthy Foods North, which aims to reduce dietary- and lifestyle-related risk factors for chronic disease in Inuvialuit.
C1 [Sharma, Sangita; Cao, Xia] Univ N Carolina Chapel Hill, Inst Nutr Res, Kannapolis, NC 28081 USA.
   [Sharma, Sangita; Cao, Xia] Univ Hawaii, Canc Etiol Program, Canc Res Ctr, Honolulu, HI 96822 USA.
   [Gittelsohn, Joel] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Ctr Human Nutr, Baltimore, MD 21218 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill; Cancer Research Center of Hawaii; University of Hawaii System; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health
RP Sharma, S (corresponding author), Univ N Carolina Chapel Hill, Inst Nutr Res, 500 Laureate Way,Rm 4201, Kannapolis, NC 28081 USA.
EM sangita_sharma@unc.edu
CR Unknown -, 2005, DIET REF INT EN CARB, V0, P0
   Unknown -, 2004, IMP WARM ARCT, V0, P0
   Batal Malek, 2005, INT J CIRCUMPOLAR HEALTH, V64, P46
   Bélanger-Ducharme F, 2005, OBES REV, V6, P183, DOI 10.1111/j.1467-789X.2005.00179.x
   Bjerregaard P, 2002, INT J OBESITY, V26, P1503, DOI 10.1038/sj.ijo.0802082
   Blanchet C, 2000, CAN J DIET PRACT RES, V61, P50
   Cade J, 2002, PUBLIC HEALTH NUTR, V5, P567, DOI 10.1079/PHN2001318
   Campbell ML, 1997, CAN J PUBLIC HEALTH, V88, P105, DOI 10.1007/BF03403871
   Collings P, 1998, ARCTIC, V51, P301
   Ebbesson SOK, 1998, DIABETES CARE, V21, P563, DOI 10.2337/diacare.21.4.563
   Katzmarzyk PT, 2008, OBESITY, V16, P184, DOI 10.1038/oby.2007.51
   Knowler William C, 2002, N ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512
   Kuhnlein HV, 2007, J NUTR, V137, P1110, DOI 10.1093/jn/137.4.1110
   Kuhnlein HV, 2004, J NUTR, V134, P1447, DOI 10.1093/jn/134.6.1447
   Lawn J, 2001, CHANGE NUTR FOOD SEC, V0, P0
   LEBRUN JB, 1993, CAN J PUBLIC HEALTH, V84, P394
   Nakano Tomoko, 2005, INT J CIRCUMPOLAR HEALTH, V64, P137
   Receveur O, 1997, J NUTR, V127, P2179, DOI 10.1093/jn/127.11.2179
   Sharma S, 2008, PUBLIC HEALTH NUTR, V11, P831, DOI 10.1017/S1368980007001218
   Sharma S, 2007, PUBLIC HEALTH NUTR, V10, P464, DOI 10.1017/S1368980007220531
   Sharma S, 2007, PUBLIC HEALTH NUTR, V10, P948, DOI 10.1017/S1368980007662302
   Smith T, 1989, POLAR REC, V25, P93, DOI 10.1017/S003224740001038X
   Stark A, 2002, ECOL FOOD NUTR, V41, P35, DOI 10.1080/03670240212531
   Statistics Canada, 2007, 2006 COMM PROF 2006, V0, P0
   Vastine A, 2005, AM J HEALTH BEHAV, V29, P57, DOI 10.5993/AJHB.29.1.5
   Whiting SJ, 1998, NUTR REV, V56, P248, DOI 10.1111/j.1753-4887.1998.tb01757.x
   Willett WC, 1998, NUTR EPIDEMIOLOGY, V0, P0
   Young TK, 2000, CAN MED ASSOC J, V163, P561
NR 34
TC 39
Z9 41
U1 0
U2 7
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 0008-4263
EI 1920-7476
J9 CAN J PUBLIC HEALTH
JI Can. J. Public Health-Rev. Can. Sante Publ.
PD NOV-DEC 15
PY 2009
VL 100
IS 6
BP 442
EP 448
DI 10.1007/BF03404341
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA V16JB
UT WOS:000207864800009
PM 20209738
DA 2025-04-28
ER

PT J
AU Seliske, LM
   Pickett, W
   Boyce, WF
   Janssen, I
AF Seliske, Laura M.
   Pickett, William
   Boyce, William F.
   Janssen, Ian
TI Association between the food retail environment surrounding schools and overweight in Canadian youth
SO PUBLIC HEALTH NUTRITION
LA English
DT Article
DE Overweight; Food retailers; Adolescents; Residence characteristics
ID socioeconomic-status; physical-activity; neighborhood characteristics; multilevel analysis; income inequality; obesity; restaurants; health; prevalence; mortality
AB Introduction: There is growing interest in how the physical environment influences obesity. Few studies have considered how the food retail environment surrounding schools influences overweight in students. Objective: To determine whether there is a relationship between food retailers surrounding schools and overweight among Canadian Youth. Design: Cross-sectional study. Setting/methods/subjects: The number of food retailers was obtained within a 1 kin and 5 kin radius around 178 schools in Canada. Retailers included full-service restaurants, fast-food restaurants, sub/sandwich retailers, doughnut/coffee shops, convenience stores and grocery stores. An index of total food retailer exposure was also created. Multilevel analyses were used to control for individual-and area-level covariates. Results: None of the individual food retailers was associated with an increased likelihood of overweight. The total food retailer index was most strongly related to overweight, but in the opposite direction to that hypothesized. At 1 kin, students attending schools with at least one food retailer had a lower relative odds of overweight (OR = 0.70, 95 % CI 0.61: 0.81). At 5 km, Students attending schools with the highest exposure to the total food retailer index had a lower relative odds of overweight (OR = 0.56, 95% CI 0.47, 0.68) compared With Students attending schools with no exposure. Conclusions: Exposure to various types of food retailers in school neighbourhoods was not associated with an increased likelihood of overweight in Canadian school-aged Youth. The opportunity to make healthy choices from a variety of options and the unique Canadian context may explain the findings.
C1 [Seliske, Laura M.; Pickett, William; Boyce, William F.; Janssen, Ian] Queens Univ, Dept Epidemiol & Community Hlth, Kingston, ON K7L 3N6, Canada.
   [Pickett, William] Queens Univ, Dept Emergency Med, Kingston, ON K7L 3N6, Canada.
   [Boyce, William F.] Queens Univ, Social Program, Evaluat Grp, Fac Educ, Kingston, ON K7L 3N6, Canada.
   [Janssen, Ian] Queens Univ, Sch Kinesiol & Hlth Studies, Kingston, ON K7L 3N6, Canada.
C3 Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada
RP Janssen, I (corresponding author), Queens Univ, Dept Epidemiol & Community Hlth, Kingston, ON K7L 3N6, Canada.
EM ian.janssen@queensu.ca
FU Canadian Institutes of Health Research [2004MEP-CHI-128223-C]; Public Health Agency of Canada [HT089-05205/001/SS]; Empire Life Insurance company; Canadian Institutes Of Health Research; Ontario Ministry of Research and Innovation
CR Apparicio P, 2007, INT J HEALTH GEOGR, V6, P0, DOI 10.1186/1476-072X-6-4
   Austin SB, 2005, AM J PUBLIC HEALTH, V95, P1575, DOI 10.2105/AJPH.2004.056341
   Block JP, 2004, AM J PREV MED, V27, P211, DOI 10.1016/j.amepre.2004.06.007
   Boehmer TK, 2007, INT J OBESITY, V31, P968, DOI 10.1038/sj.ijo.0803531
   Burdette HL, 2004, PREV MED, V38, P57, DOI 10.1016/j.ypmed.2003.09.029
   Cohen DA, 2006, PEDIATRICS, V118, PE1381, DOI 10.1542/peds.2006-1226
   Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240
   Cummins S, 2006, INT J EPIDEMIOL, V35, P100, DOI 10.1093/ije/dyi276
   Cummins SCJ, 2005, AM J PREV MED, V29, P308, DOI 10.1016/j.amepre.2005.06.011
   Currie C, 2001, HEALTH BEHAVIOR IN SCHOOL-AGED CHILDREN: A WORLD HEALTH ORGANIZATION CROSS-NATIONAL STUDY: RESEARCH PROTOCOL FOR THE 2001/02 SURVEY, V0, P0
   Diez-Roux AV, 2000, ANNU REV PUBL HEALTH, V21, P171, DOI 10.1146/annurev.publhealth.21.1.171
   Gordon-Larsen P, 2006, PEDIATRICS, V117, P417, DOI 10.1542/peds.2005-0058
   Janssen I, 2006, AM J CLIN NUTR, V83, P139
   Maddock J, 2004, AM J HEALTH PROMOT, V19, P137, DOI 10.4278/0890-1171-19.2.137
   McGinn AP, 2007, J URBAN HEALTH, V84, P162, DOI 10.1007/s11524-006-9136-4
   Moore LV, 2006, AM J PUBLIC HEALTH, V96, P325, DOI 10.2105/AJPH.2004.058040
   Morland K, 2006, AM J PREV MED, V30, P333, DOI 10.1016/j.amepre.2005.11.003
   Morland K, 2002, AM J PREV MED, V22, P23, DOI 10.1016/S0749-3797(01)00403-2
   Norman Gregory J, 2006, J PHYS ACT HEALTH, V3, PS118, DOI 10.1123/jpah.3.s1.s118
   Oliver LN, 2005, CAN J PUBLIC HEALTH, V96, P415, DOI 10.1007/BF03405180
   Oude Luttikhuis H, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001872.pub2
   Parsons TJ, 1999, INT J OBESITY, V23, P0
   Reidpath DD, 2002, HEALTH PLACE, V8, P141, DOI 10.1016/S1353-8292(01)00028-4
   Roberts C, 2007, J PUBLIC HEALTH-HEID, V15, P179, DOI 10.1007/s10389-007-0100-x
   Ross NA, 2005, J URBAN HEALTH, V82, P101, DOI 10.1093/jurban/jti012
   Ross NA, 2000, BRIT MED J, V320, P898, DOI 10.1136/bmj.320.7239.898
   Shields Margot, 2006, HEALTH REP, V17, P27
   Simpson K, 2005, J EPIDEMIOL COMMUN H, V59, P1072, DOI 10.1136/jech.2005.036723
   *STAT CAN, 2003, 81229XIB STAT CAN, V0, P0
   *STAT CAN, 2001, 92378XIE2002 STAT CA, V0, P0
   Sturm R, 2005, PUBLIC HEALTH, V119, P1059, DOI 10.1016/j.puhe.2005.05.007
   Veugelers PJ, 2005, CAN MED ASSOC J, V173, P607, DOI 10.1503/cmaj.050445
   Veugelers PJ, 2001, AM J EPIDEMIOL, V154, P725, DOI 10.1093/aje/154.8.725
   Wang MC, 2007, J EPIDEMIOL COMMUN H, V61, P491, DOI 10.1136/jech.2006.051680
NR 34
TC 65
Z9 83
U1 1
U2 24
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1368-9800
EI 1475-2727
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD SEP 15
PY 2009
VL 12
IS 9
BP 1384
EP 1391
DI 10.1017/S1368980008004084
PG 8
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA 488HL
UT WOS:000269339900010
PM 19087383
DA 2025-04-28
ER

PT J
AU Gyntelberg, F
   Hein, HO
   Suadicani, P
AF Gyntelberg, Finn
   Hein, Hans Ole
   Suadicani, Poul
TI Sugar in coffee or tea and risk of obesity: A neglected issue
SO INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION
LA English
DT Article
DE Health awareness; lifestyle; obesity; sucrose; sugar use
ID weight; consumption; sucrose; fat
AB Aim In the Copenhagen Male Study sugar intake in coffee or tea is inversely associated with obesity. We analyzed the association of sugar intake with obesity among men with and without lifestyle factors indicating health awareness. Methods A cross-sectional study of 3,290 men aged 53-75 years including information about smoking, alcohol, physical activity, tea and coffee use, avoidance of fatty food, social class, self-assessed health, and family obesity. Results Overall, 291 men (8.8%) were obese, body mass index >= 30. Among men using sugar in coffee or tea (36%), the prevalence was 6.2%; among others, 10.3% (odds ratio [95% confidence interval] = 0.6 [0.4-0.8]). An inverse association between use of sugar in hot beverages and prevalence of obesity was consistent in subgroups, and most pronounced among the least health-conscious [odds ratio [95% confidence interval] = 0.4 [0.2-0.8]). Interpretation The results indicate a weight-controlling or reducing effect of small amounts of sucrose ingested several times a day.
C1 [Suadicani, Poul] Bispebjerg Hosp, Epidemiol Res Unit, Copenhagen Male Study, Clin Occupat & Environm Med, DK-2400 Copenhagen NV, Denmark.
   [Hein, Hans Ole] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Copenhagen, Denmark.
C3 University of Copenhagen; Bispebjerg Hospital; Copenhagen University Hospital; University of Copenhagen; Copenhagen University Hospital
RP Suadicani, P (corresponding author), Bispebjerg Hosp, Epidemiol Res Unit, Copenhagen Male Study, Clin Occupat & Environm Med, DK-2400 Copenhagen NV, Denmark.
EM ps11@bbh.regionh.dk
FU The King Christian X's Foundation; The Danish Medical Research Council; The Danish Heart Foundation; The Else & Mogens Wedell-Wedellsborg Foundation
CR ANDERSON GH, 1995, AM J CLIN NUTR S, V62, P195
   Bray GA, 2004, AM J CLIN NUTR, V79, P537
   GYNTELBERG F, 1975, DAN MED BULL, V22, P81
   Kirkwood L, 2007, INT J FOOD SCI NUTR, V58, P383, DOI 10.1080/09637480701252336
   Lindroos AK, 1996, INT J OBESITY, V20, P634
   Macdiarmid JI, 1998, INT J OBESITY, V22, P1053, DOI 10.1038/sj.ijo.0800724
   Meier JJ, 2002, EUR J PHARMACOL, V440, P269, DOI 10.1016/S0014-2999(02)01434-6
   Murphy KG, 2004, EXP PHYSIOL, V89, P507, DOI 10.1113/expphysiol.2004.027789
   OLSEN NJ, 2008, INTAKE CALORICALLY S, V0, P0
   Suadicani P, 2005, EUR J CARDIOV PREV R, V12, P236, DOI 10.1097/00149831-200506000-00009
   SUADICANI P, 1994, INT J EPIDEMIOL, V23, P293, DOI 10.1093/ije/23.2.293
   West JA, 2001, INT J OBESITY, V25, P1122, DOI 10.1038/sj.ijo.0801652
   WHO, 2000, WHO TECHN REP SER, V894, P0
NR 13
TC 11
Z9 11
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0963-7486
EI 1465-3478
J9 INT J FOOD SCI NUTR
JI Int. J. Food Sci. Nutr.
PD JUN 15
PY 2009
VL 60
IS 
BP 56
EP 64
DI 10.1080/09637480802668471
PG 9
WC Food Science & Technology; Nutrition & Dietetics
SC Food Science & Technology; Nutrition & Dietetics
GA 535BQ
UT WOS:000272942000006
PM 19194815
DA 2025-04-28
ER

PT J
AU Arsenault, BJ
   Earnest, CP
   Després, JP
   Blair, SN
   Church, TS
AF Arsenault, B. J.
   Earnest, C. P.
   Despres, J-P
   Blair, S. N.
   Church, T. S.
TI Obesity, coffee consumption and CRP levels in postmenopausal overweight/obese women: importance of hormone replacement therapy use
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE obesity; coffee; CRP; postmenopausal women; hormone replacement therapy
ID c-reactive protein; type-2 diabetes-mellitus; risk; markers; serum; inflammation; population; healthy; disease
AB Background/Objectives: Obesity is associated with an inflammatory state that is often characterized by elevated plasma C-reactive protein (CRP) levels. Although coffee is broadly consumed in Western societies, few studies have examined the relationship between obesity, coffee consumption and CRP levels. The objective of this study was to assess the relationship between obesity, coffee consumption and variation in CRP in postmenopausal, overweight/obese women with or without hormone replacement therapy (HRT) use. Subjects/Methods: Cross-sectional analyses of 344 healthy sedentary, overweight/obese postmenopausal women (mean age = 57.1 +/- 6.4 years and mean body mass index (BMI) = 36.1 +/- 3.9 kg/m(2)). Plasma CRP levels were measured by a highly sensitive immunoassay that used monoclonal antibodies coated with polystyrene particles. Diet was assessed using the Food Intake and Analysis System semiquantitative food frequency questionnaire. Results: Plasma CRP was positively associated with BMI (P < 0.001) and negatively associated with coffee consumption (P <= 0.05). In women using HRT, plasma CRP was positively associated with BMI in women consuming less than one cup of coffee per month (r(2) = 0.15 (P < 0.001)), one cup per day (0.14 (P = 0.02)) and more than one cup per day (0.12 (P = 0.03)). In women who did not use HRT, CRP was associated with BMI only in women consuming less than one cup of coffee per day (r(2) = 0.16 (P < 0.001)) but not in women consuming one cup per day (0.06 (P = 0.10)) or more than one daily cup of coffee (0.03 (P = 0.27)). Conclusions: Among overweight/obese postmenopausal women, coffee consumption is negatively associated with CRP. Coffee consumption appears to attenuate the association between BMI and CRP, but only in women not using HRT. European Journal of Clinical Nutrition (2009) 63, 1419-1424; doi:10.1038/ejcn.2009.112; published online 16 September 2009
C1 [Earnest, C. P.; Church, T. S.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA.
   [Arsenault, B. J.; Despres, J-P] Ctr Rech Inst Univ Cardiol & Pneumol Quebec, Dept Cardiol, Quebec City, PQ, Canada.
   [Arsenault, B. J.] Univ Laval, Fac Med, Dept Anat & Physiol, Quebec City, PQ G1K 7P4, Canada.
   [Despres, J-P] Univ Laval, Div Kinesiol, Dept Social & Prevent Med, Quebec City, PQ G1K 7P4, Canada.
   [Blair, S. N.] Univ S Carolina, Dept Exercise Sci, Arnold Sch Publ Hlth, Columbia, SC 29208 USA.
   [Blair, S. N.] Univ S Carolina, Dept Epidemiol & Biostat, Arnold Sch Publ Hlth, Columbia, SC 29208 USA.
C3 Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Laval University; Laval University; University of South Carolina System; University of South Carolina Columbia; University of South Carolina System; University of South Carolina Columbia
RP Church, TS (corresponding author), Louisiana State Univ Syst, Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.
EM tim.church@pbrc.edu
FU National Institutes of Health [HL66262, HL071900]
CR Brett KM, 2001, HORMONE REPLACEMENT, V0, P0
   Buchbinder S, 2008, SCAND J CLIN LAB INV, V68, P140, DOI 10.1080/00365510701487727
   Chung TW, 2004, FASEB J, V18, P1670, DOI 10.1096/fj.04-2126com
   Church TS, 2007, JAMA-J AM MED ASSOC, V297, P2081, DOI 10.1001/jama.297.19.2081
   COOPER BC, 2007, AM J OBSTET GYNECOL, V196, P123
   Danesh J, 2004, NEW ENGL J MED, V350, P1387, DOI 10.1056/NEJMoa032804
   Dehghan A, 2007, DIABETES CARE, V30, P2695, DOI 10.2337/dc07-0348
   Andersen LF, 2006, AM J CLIN NUTR, V83, P1039, DOI 10.1093/ajcn/83.5.1039
   Ganmaa D, 2008, INT J CANCER, V122, P2071, DOI 10.1002/ijc.23336
   Kotani K, 2008, CLIN CHEM LAB MED, V46, P1434, DOI 10.1515/CCLM.2008.286
   Ledue TB, 1998, ANN CLIN BIOCHEM, V35, P745, DOI 10.1177/000456329803500607
   Lemieux I, 2001, ARTERIOSCL THROM VAS, V21, P961, DOI 10.1161/01.ATV.21.6.961
   Lopez-Garcia E, 2006, AM J CLIN NUTR, V84, P888, DOI 10.1093/ajcn/84.4.888
   Morss GM, 2004, MED SCI SPORT EXER, V36, P336, DOI 10.1249/01.MSS.0000113738.06267.E5
   Nakamura H, 2008, DIABETES RES CLIN PR, V79, P330, DOI 10.1016/j.diabres.2007.09.004
   Nanri A, 2007, ASIAN PAC J CANCER P, V8, P167
   Ridker PM, 1999, CIRCULATION, V100, P713, DOI 10.1161/01.CIR.100.7.713
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   Silvestri A, 2003, CIRCULATION, V107, P3165, DOI 10.1161/01.CIR.0000074208.02226.5E
   Storey ML, 2006, J AM DIET ASSOC, V106, P1992, DOI 10.1016/j.jada.2006.09.009
   *U TX H, 1996, FOOD INT AN SYST COM, V0, P0
   van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   Zampelas A, 2004, AM J CLIN NUTR, V80, P862, DOI 10.1093/ajcn/80.4.862
NR 24
TC 27
Z9 29
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0954-3007
EI 1476-5640
J9 EUR J CLIN NUTR
JI Eur. J. Clin. Nutr.
PD DEC 15
PY 2009
VL 63
IS 12
BP 1419
EP 1424
DI 10.1038/ejcn.2009.112
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 525WN
UT WOS:000272248200006
PM 19756031
DA 2025-04-28
ER

PT J
AU Vanselow, MS
   Pereira, MA
   Neumark-Sztainer, D
   Raatz, SK
AF Vanselow, Michelle S.
   Pereira, Mark A.
   Neumark-Sztainer, Dianne
   Raatz, Susan K.
TI Adolescent beverage habits and changes in weight over time: findings from Project EAT
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID body-mass index; sugar-sweetened beverages; food frequency questionnaire; early sexual-maturation; us children; metabolic syndrome; drink consumption; childhood obesity; overweight status; risk-factors
AB Background: Obesity in adolescence has been increasing in the past several decades. Beverage habits among adolescents include increased consumption of sugar-sweetened beverages and decreased consumption of milk. Objective: This study aimed to examine the association between beverage consumption and 5-y body weight change in 2294 adolescents. Design: Project EAT (Eating Among Teens) is a 5-y longitudinal study of eating patterns among adolescents. Surveys were completed in 1998-1999 (time 1) and in 2003-2004 (time 2). Multivariable linear regression was used to examine the association between beverage consumption at time 2 and change in body mass index from time 1 to time 2, with adjustments for age, socioeconomic status, race, cohort, physical activity, sedentary behavior, coffee, tea, time 1 body mass index, and beverage variables. Results: In prospective analyses, consumption of beverages was not associated with weight gain, except for consumption of low-calorie soft drinks (positive association, P = 0.002) and white milk (inverse association, P = 0.03), but these associations did not appear to be a monotonic linear dose-response relation. The positive association with low-calorie soft drinks was no longer present after adjustment for dieting and parental weight-related concerns, which suggests that the use of low-calorie soft drinks is a marker for more general dietary behaviors and weight concerns. Conclusions: We showed no association between sugar-sweetened beverage consumption, juice consumption, and adolescent weight gain over a 5-y period. A direct association between diet beverages and weight gain appeared to be explained by dieting practices. Adolescents who consumed little or no white milk gained significantly more weight than their peers who consumed white milk. Future research that examines beverage habits and weight among adolescents should address portion sizes, adolescent maturation, and dieting behaviors. Am J Clin Nutr 2009;90:1489-95.
C1 [Vanselow, Michelle S.; Pereira, Mark A.; Neumark-Sztainer, Dianne] Univ Minnesota, Div Epidemiol & Community Hlth, Sch Publ Hlth, Minneapolis, MN 55454 USA.
   [Raatz, Susan K.] Univ Minnesota, Div Endocrinol & Diabet, Dept Med, Minneapolis, MN 55454 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities
RP Pereira, MA (corresponding author), Univ Minnesota, Div Epidemiol & Community Hlth, Sch Publ Hlth, 1300 S 2nd St,Suite 300, Minneapolis, MN 55454 USA.
EM map@umn.edu
FU PHS HHS [R40 MC 00319] Funding Source: Medline
CR Ackard DM, 2003, PEDIATRICS, V111, P67, DOI 10.1542/peds.111.1.67
   Berkey CS, 2004, OBES RES, V12, P778, DOI 10.1038/oby.2004.94
   Berkey CS, 2005, ARCH PEDIAT ADOL MED, V159, P543, DOI 10.1001/archpedi.159.6.543
   Cadogan J, 1997, BMJ-BRIT MED J, V315, P1255, DOI 10.1136/bmj.315.7118.1255
   CHAN GM, 1995, J PEDIATR-US, V126, P551, DOI 10.1016/S0022-3476(95)70348-9
   Dhingra R, 2007, CIRCULATION, V116, P480, DOI 10.1161/CIRCULATIONAHA.107.689935
   Duffey KJ, 2007, OBESITY, V15, P2739, DOI 10.1038/oby.2007.326
   Ebbeling CB, 2006, PEDIATRICS, V117, P673, DOI 10.1542/peds.2005-0983
   Field AE, 2003, PEDIATRICS, V112, P900, DOI 10.1542/peds.112.4.900
   Forshee RA, 2008, AM J CLIN NUTR, V87, P1662, DOI 10.1093/ajcn/87.6.1662
   Forshee RA, 2009, AM J CLIN NUTR, V89, P439, DOI 10.3945/ajcn.2008.27089
   GODIN G, 1985, CANADIAN JOURNAL OF APPLIED SPORT SCIENCES, V10, P141
   Godin G, 1997, MED SCI SPORTS EXERC, V0, PS36
   Gortmaker SL, 1999, ARCH PEDIAT ADOL MED, V153, P409, DOI 10.1001/archpedi.153.4.409
   Haines J, 2006, PEDIATRICS, V117, PE209, DOI 10.1542/peds.2005-1242
   Haines J, 2007, OBESITY, V15, P2748, DOI 10.1038/oby.2007.327
   Harper A, 2007, BRIT J NUTR, V97, P579, DOI 10.1017/S0007114507339846
   Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847
   Himes JH, 2005, ANN EPIDEMIOL, V15, P272, DOI 10.1016/j.annepidem.2004.08.010
   Himes JH, 2004, OBES RES, V12, P64S, DOI 10.1038/oby.2004.270
   Hoffman WH, 2005, OBES RES, V13, P2195, DOI 10.1038/oby.2005.272
   James J, 2004, BMJ-BRIT MED J, V328, P1237, DOI 10.1136/bmj.38077.458438.EE
   Koplan JP, 1999, JAMA-J AM MED ASSOC, V282, P1579, DOI 10.1001/jama.282.16.1579
   Libuda L, 2008, BRIT J NUTR, V99, P1370, DOI 10.1017/S0007114507862362
   Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1
   Lutsey PL, 2008, CIRCULATION, V117, P754, DOI 10.1161/CIRCULATIONAHA.107.716159
   Malik VS, 2009, AM J CLIN NUTR, V89, P438, DOI 10.3945/ajcn.2008.26980
   Merrilees MJ, 2000, EUR J NUTR, V39, P256, DOI 10.1007/s003940070004
   Mrdjenovic G, 2003, J PEDIATR-US, V142, P604, DOI 10.1067/mpd.2003.200
   MUST A, 1991, AM J CLIN NUTR, V54, P773, DOI 10.1093/ajcn/54.5.773
   MUST A, 1991, AM J CLIN NUTR, V53, P839, DOI 10.1093/ajcn/53.4.839
   Neumark-Sztainer D, 2003, PREV MED, V37, P198, DOI 10.1016/S0091-7435(03)00114-2
   Neumark-Sztainer D, 2006, J AM DIET ASSOC, V106, P559, DOI 10.1016/j.jada.2006.01.003
   Neumark-Sztainer D, 2002, AM J PUBLIC HEALTH, V92, P844, DOI 10.2105/AJPH.92.5.844
   Neumark-Sztainer D, 2002, J PSYCHOSOM RES, V53, P963, DOI 10.1016/S0022-3999(02)00486-5
   Neumark-Sztainer D, 2006, PREV MED, V43, P52, DOI 10.1016/j.ypmed.2006.03.014
   Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728
   Ogden CL, 2008, JAMA-J AM MED ASSOC, V299, P2401, DOI 10.1001/jama.299.20.2401
   Phillips SM, 2004, OBES RES, V12, P461, DOI 10.1038/oby.2004.52
   RESNICK MD, 1993, J PAEDIATR CHILD H, V29, PS3, DOI 10.1111/j.1440-1754.1993.tb02257.x
   ROCKETT HRH, 1995, J AM DIET ASSOC, V95, P336, DOI 10.1016/S0002-8223(95)00086-0
   Rockett HRH, 1997, PREV MED, V26, P808, DOI 10.1006/pmed.1997.0200
   Stice E, 2005, J CONSULT CLIN PSYCH, V73, P195, DOI 10.1037/0022-006X.73.2.195
   Stice E, 1999, J CONSULT CLIN PSYCH, V67, P967, DOI 10.1037/0022-006X.67.6.967
   Striegel-Moore RH, 2006, J PEDIATR-US, V148, P183, DOI 10.1016/j.jpeds.2005.11.025
   Wang YF, 2002, PEDIATRICS, V110, P903, DOI 10.1542/peds.110.5.903
NR 47
TC 83
Z9 99
U1 0
U2 19
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD DEC 1
PY 2009
VL 90
IS 6
BP 1489
EP 1495
DI 10.3945/ajcn.2009.27573
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 522XZ
UT WOS:000272034900008
PM 19864412
DA 2025-04-28
ER

PT J
AU Kent, LM
   Worsley, A
AF Kent, Lillian M.
   Worsley, Anthony
TI Does the prescriptive lifestyle of Seventh-day Adventists provide 'immunity' from the secular effects of changes in BMI?
SO PUBLIC HEALTH NUTRITION
LA English
DT Article
DE Lifestyle; Diet; Body mass index; Seventh-day Adventist; Physical activity
ID self-reported height; cardiovascular-disease; portion sizes; risk-factors; body-mass; obesity; overweight; mortality; weight
AB Objective.. To examine the effect of Seventh-day Adventist (SDA) membership on 'immunity' to the secular effects of changes in BMI. Design: Three independent, cross-sectional, screening surveys conducted by Sydney Adventist Hospital in 1976, 1986 and 1988 and a survey conducted among residents of Melbourne in 2006. Subjects: Two hundred and fifty-two SDA and 464 non-SDA in 1976; 166 SDA and 291 non-SDA in 1986; 120 SDA and 300-non SDA in 1988; and 251 SDA and 294 non-SDA in 2006. Measurements: Height and weight measured by hospital staff in 1976, 1986 and 1988; self-reported by respondents in 2006. Results: The mean BMI of non-SDA men increased between 1986 and 2006 (P< 0-001) but did not change for SDA men or non-SDA women. Despite small increases in SDA women's mean BMI (P= 0-030) between 1988 and 2006, this was no different to that of SDA men and non-SDA women in 2006. The diet and eating patterns of SDA men and women were more 'prudent' than those of non-SDA men and women, including more fruit, vegetables, grains, nuts and legumes, and less alcohol, meat, sweetened drinks and coffee. Many of these factors were found to be predictors of lower BMI. Conclusion: The 'prudent' dietary and lifestyle prescriptions of SDA men appear to have 'immunised' them to the secular effects of changes that occurred among non-SDA men's BMI. The dietary and lifestyle trends of SDA women did not reflect the increase in their BMI observed in 2006
C1 [Kent, Lillian M.] Deakin Univ, Sch Exercise & Nutr Sci, Fac Hlth & Behav Sci, Melbourne, Vic 3125, Australia.
   [Worsley, Anthony] VicHealth, Melbourne, Vic, Australia.
C3 Deakin University
RP Kent, LM (corresponding author), Deakin Univ, Sch Exercise & Nutr Sci, Fac Hlth & Behav Sci, 221 Burwood Highway, Melbourne, Vic 3125, Australia.
EM lkent@deakin.edu.au
FU Deakin University, Melbourne, Australia; Sanitarium Health Food Company, Australia; Australian Research Council
CR Alexander H, 1999, J AM COLL NUTR, V18, P127, DOI 10.1080/07315724.1999.10718840
   Unknown -, 1998, AUSTR GUIDE HLTH EAT, V0, P0
   *AUSTR BUR STAT, 2003, SOC IND AR AUSTR 200, V0, P0
   Bolton-Smith C, 2000, J EPIDEMIOL COMMUN H, V54, P143, DOI 10.1136/jech.54.2.143
   Bryant R, 2005, J CONSUM AFF, V39, P399, DOI 10.1111/j.1745-6606.2005.00021.x
   CALKINS B M, 1984, AMERICAN JOURNAL OF CLINICAL NUTRITION, V40, P887, DOI 10.1093/ajcn/40.4.887
   Cameron AJ, 2003, MED J AUSTRALIA, V178, P427, DOI 10.5694/j.1326-5377.2003.tb05283.x
   *COMM DEP HLTH AG, 1999, NAT PHYS ACT SURV, V0, P0
   Flood V, 2000, AUST NZ J PUBL HEAL, V24, P96, DOI 10.1111/j.1467-842X.2000.tb00733.x
   FONNEBO V, 1992, AM J EPIDEMIOL, V135, P504, DOI 10.1093/oxfordjournals.aje.a116317
   Fraser GE, 2003, DIET LIFE EXPECTANCY, V0, P0
   Haddad EH, 1999, AM J CLIN NUTR, V70, P586S, DOI 10.1093/ajcn/70.3.586s
   Hebert JR, 2008, J NUTR, V138, P226S, DOI 10.1093/jn/138.1.226S
   Kristal AR, 1998, J AM DIET ASSOC, V98, P40, DOI 10.1016/S0002-8223(98)00012-1
   LINDSTED K, 1991, INT J OBESITY, V15, P397
   Lindsted KD, 1998, INT J OBESITY, V22, P544, DOI 10.1038/sj.ijo.0800623
   MELBY CL, 1993, J AM COLL NUTR, V12, P262
   *MIN ASS, 1988, MIN ASS GEN C 7 DAY, V0, P0
   National Health and Medical Research Council, 2003, DIET GUID AUSTR AD, V0, P0
   Nestle M, 2003, J AM DIET ASSOC, V103, P39, DOI 10.1053/jada.2003.50007
   Organisation mondiale de la sante, 1999, OBESITY: PREVENTING AND MANAGING THE GLOBAL EPIDEMIC, V0, P0
   Spencer EA, 2002, PUBLIC HEALTH NUTR, V5, P561, DOI 10.1079/PHN2001322
   VENN AJ, 1985, MED J AUSTRALIA, V186, P458
   WHO, 2003, WHO TECHN REP SER, V0, P0
   Willett WC, 1999, AM J CLIN NUTR, V70, P434S, DOI 10.1093/ajcn/70.3.434s
   Young LR, 2002, AM J PUBLIC HEALTH, V92, P246, DOI 10.2105/AJPH.92.2.246
NR 26
TC 8
Z9 9
U1 4
U2 18
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 1368-9800
EI 1475-2727
J9 PUBLIC HEALTH NUTR
JI Public Health Nutr.
PD APR 15
PY 2009
VL 12
IS 4
BP 472
EP 480
DI 10.1017/S1368980008002334
PG 9
WC Public, Environmental & Occupational Health; Nutrition & Dietetics
SC Public, Environmental & Occupational Health; Nutrition & Dietetics
GA 423UU
UT WOS:000264522000006
PM 18457602
DA 2025-04-28
ER

PT J
AU Brigas, D
AF Brigas, Diana
TI Gastro-oesophageal Reflux Disease in an Obese Patient
SO CLINICAL DRUG INVESTIGATION
LA English
DT Article
AB A 45-year-old woman, with a body mass index of 41.8 kg/m(2) and a medical history of anxiety-depression syndrome, had iatrogenic hypothyroidism and degenerative osteoarticular pathology of the spinal column and complained of a burning sensation behind the sternum associated with ail acidic taste in her mouth. Symptoms had appeared 3 months previously and were especially prevalent when lying down, following large meals or after drinking coffee. The patient had started to experience symptoms on most days approximately 1 month earlier. Upper digestive endoscopy (UDE) revealed isolated erosions of the distal third of the oesophagus, compatible with a diagnosis of erosive reflux oesophagitis. Lifestyle changes were recommended and 8 weeks' treatment with pantoprazole 40 mg/day taken 15-30 Minutes before breakfast was prescribed. Follow-up UDE showed resolution of oesophageal lesions with no pathological changes of the mucosa. Mild regurgitation and pyrosis persisted; therefore the patient continued to receive pantoprazole 40 mg for a further 3 weeks.
C1 [Brigas, Diana] Ctr Saude Oliveira do Douro, Vila Nova De Gaia, Portugal.
RP Brigas, D (corresponding author), Rua Navegadores 145, P-4415040 Perosinho, Portugal.
EM dianabrigasmgf@hotmail.com
NR 0
TC 1
Z9 1
U1 0
U2 2
PU ADIS INT LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND
SN 1173-2563
EI 
J9 CLIN DRUG INVEST
JI Clin. Drug Invest.
PD JUN 15
PY 2009
VL 29
IS 
BP 17
EP 18
DI 10.2165/1153123-S0-000000000-00000
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 534UB
UT WOS:000272921700004
PM 19938882
DA 2025-04-28
ER

PT J
AU Nagao, T
   Meguro, S
   Hase, T
   Otsuka, K
   Komikado, M
   Tokimitsu, I
   Yamamoto, T
   Yamamoto, K
AF Nagao, Tomonori
   Meguro, Shinichi
   Hase, Tadashi
   Otsuka, Kazuhiro
   Komikado, Masanori
   Tokimitsu, Ichiro
   Yamamoto, Takashi
   Yamamoto, Kunio
TI A Catechin-rich Beverage Improves Obesity and Blood Glucose Control in Patients With Type 2 Diabetes
SO OBESITY
LA English
DT Article
ID green tea; epigallocatechin gallate; fat; polyphenols; consumption; caffeine; insulin; disease; humans; level
AB We investigated the effects of continuous ingestion of a catechin-rich beverage in patients with type 2 diabetes who were not receiving insulin (Ins) therapy in a double-blind controlled study. The participants ingested green tea containing either 582.8 mg of catechins (catechin group; n = 23) or 96.3 mg of catechins (control group; n = 20) per day for 12 weeks. At week 12, the decrease in waist circumference was significantly greater in the catechin group than in the control group. Adiponectin, which is negatively correlated with visceral adiposity, increased significantly only in the catechin group. Although the increase in Ins at week 12 was significantly greater in the catechin group than in the control group, no apparent difference was noted between the two groups in glucose and hemoglobin A(1c). In patients treated with insulinotropic agents, the increase in Ins at week 12 was significantly greater in the catechin group than in the control group. This significant increase in Ins levels was observed only in the catechin group. In the catechin group receiving other treatments, Ins levels remained unchanged. In addition, in patients treated with insulinotropic agents, the decrease in hemoglobin A(1c) at week 12 was significantly greater in the catechin group than in the control group. These results suggest that a catechin-rich beverage might have several therapeutic uses: in the prevention of obesity; in the recovery of Ins-secretory ability; and, as a way to maintain low hemoglobin A(1c) levels in type 2 diabetic patients who do not yet require Ins therapy.
C1 [Nagao, Tomonori; Otsuka, Kazuhiro; Komikado, Masanori; Tokimitsu, Ichiro] Kao Corp, Hlth Care Food Res Labs, Tokyo, Japan.
   [Meguro, Shinichi; Hase, Tadashi] Kao Corp, Biol Sci Res Labs, Tochigi, Japan.
   [Yamamoto, Takashi; Yamamoto, Kunio] Koshien Univ, Dept Nutr, Kobe, Hyogo, Japan.
C3 KAO Corporation; KAO Corporation
RP Nagao, T (corresponding author), Kao Corp, Hlth Care Food Res Labs, Tokyo, Japan.
EM nagao.tomonori@kao.co.jp
FU Kao Corporation
CR Abe I, 2000, BIOCHEM BIOPH RES CO, V268, P767, DOI 10.1006/bbrc.2000.2217
   Ajay M, 2003, LIFE SCI, V74, P603, DOI 10.1016/j.lfs.2003.06.039
   Chan PT, 1999, J NUTR, V129, P1094, DOI 10.1093/jn/129.6.1094
   Duffy SJ, 2001, CIRCULATION, V104, P151, DOI 10.1161/01.CIR.104.2.151
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Fukino Y, 2005, J NUTR SCI VITAMINOL, V51, P335, DOI 10.3177/jnsv.51.335
   GRAHAM HN, 1992, PREV MED, V21, P334, DOI 10.1016/0091-7435(92)90041-F
   Han MK, 2003, EXP MOL MED, V35, P136, DOI 10.1038/emm.2003.19
   Hosokawa Kazuhiro, 2002, NIHON RINSHO, V60 Suppl 9, P167
   Iso H, 2006, ANN INTERN MED, V144, P554, DOI 10.7326/0003-4819-144-8-200604180-00005
   Kitabchi AE, 2001, DIABETES CARE, V24, P131, DOI 10.2337/diacare.24.1.131
   Kurioka S, 2002, ENDOCR J, V49, P459, DOI 10.1507/endocrj.49.459
   MATSUMOTO N, 1993, BIOSCI BIOTECH BIOCH, V57, P525, DOI 10.1271/bbb.57.525
   Matsuzawa Y, 2002, CIRC J, V66, P987, DOI 10.1253/circj.66.987
   MURAMATSU K, 1986, J NUTR SCI VITAMINOL, V32, P613, DOI 10.3177/jnsv.32.613
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Nagao T, 2007, OBESITY, V15, P1473, DOI 10.1038/oby.2007.176
   Rankinen T, 1999, INT J OBESITY, V23, P801, DOI 10.1038/sj.ijo.0800929
   Ryo M, 2004, CIRC J, V68, P975, DOI 10.1253/circj.68.975
   Strobel P, 2005, BIOCHEM J, V386, P471, DOI 10.1042/BJ20040703
   Wolfram S, 2006, J NUTR, V136, P2512, DOI 10.1093/jn/136.10.2512
   YOSHINO K, 1994, BIOL PHARM BULL, V17, P146, DOI 10.1248/bpb.17.146
NR 24
TC 220
Z9 237
U1 5
U2 51
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1930-7381
EI 
J9 OBESITY
JI Obesity
PD FEB 15
PY 2009
VL 17
IS 2
BP 310
EP 317
DI 10.1038/oby.2008.505
PG 8
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 400VJ
UT WOS:000262897200016
PM 19008868
DA 2025-04-28
ER

PT J
AU Arçari, DP
   Bartchewsky, W
   dos Santos, TW
   Oliveira, KA
   Funck, A
   Pedrazzoli, J
   de Souza, MFF
   Saad, MJ
   Bastos, DHM
   Gambero, A
   Carvalho, PD
   Ribeiro, ML
AF Arcari, Demetrius P.
   Bartchewsky, Waldemar
   dos Santos, Tanila W.
   Oliveira, Karim A.
   Funck, Alexandre
   Pedrazzoli, Jose
   de Souza, Marina F. F.
   Saad, Mario J.
   Bastos, Deborah H. M.
   Gambero, Alessandra
   Carvalho, Patricia de O.
   Ribeiro, Marcelo L.
TI Antiobesity Effects of yerba mate Extract (Ilex paraguariensis) in High-fat Diet-induced Obese Mice
SO OBESITY
LA English
DT Article
ID necrosis-factor-alpha; adipose-tissue; uncoupling proteins; insulin-resistance; chlorogenic acid; potential role; tnf-alpha; leptin; plasma; inflammation
AB Because the potential of yerba mate (Ilex paraguariensis) has been suggested in the management of obesity, the aim of the present study was to evaluate the effects of yerba mate extract on weight loss, obesity-related biochemical parameters, and the regulation of adipose tissue gene expression in high-fat diet-induced obesity in mice. Thirty animals were randomly assigned to three groups. The mice were introduced to standard or high-fat diets. After 12 weeks on a high-fat diet, mice were randomly assigned according to the treatment (water or yerba mate extract 1.0 g/-kg). After treatment intervention, plasma concentrations of total cholesterol, high-density lipoprotein cholesterol, triglyceride, low-density lipoprotein (LDL) cholesterol, and glucose were evaluated. Adipose tissue was examined to determine the mRNA levels of several genes such as tumor necrosis factor-alpha (TNF-alpha), leptin, interleukin-6 (IL-6), C-C motif chemokine ligand-2 (CCL2), CCL receptor-2 (CCR2), angiotensinogen, plasminogen activator inhibitor-1 (PAI-1), adiponectin, resistin, peroxisome proliferator-activated receptor-gamma(2) (PPAR-gamma(2)), uncoupling protein-1 (UCP1), and PPAR-gamma coactivator-1 alpha (PGC-1 alpha). The F4/80 levels were determined by immunoblotting. We found that obese mice treated with yerba mate exhibited marked attenuation of weight gain, adiposity, a decrease in epididymal fat-pad weight, and restoration of the serum levels of cholesterol, triglycerides, LDL cholesterol, and glucose. The gene and protein expression levels were directly regulated by the high-fat diet. After treatment with yerba mate extract, we observed a recovery of the expression levels. In conclusion, our data show that yerba mate extract has potent antiobesity activity in vivo. Additionally, we observed that the treatment had a modulatory effect on the expression of several genes related to obesity.
C1 [Arcari, Demetrius P.; Bartchewsky, Waldemar; dos Santos, Tanila W.; Oliveira, Karim A.; Funck, Alexandre; Pedrazzoli, Jose; Gambero, Alessandra; Ribeiro, Marcelo L.] Univ Sao Francisco, Unidade Integrada Farmacol & Gastroenterol, BR-12900000 Braganca Paulista, SP, Brazil.
   [Arcari, Demetrius P.; de Souza, Marina F. F.; Bastos, Deborah H. M.] Univ Sao Paulo, Fac Saude Publ, Dept Nutr, Sao Paulo, Brazil.
   [Carvalho, Patricia de O.] Univ Sao Francisco, Lab Multidisciplinar Pesquisa, BR-12900000 Braganca Paulista, SP, Brazil.
   [Saad, Mario J.] Univ Estadual Campinas, Dept Med Interna, Campinas, SP, Brazil.
C3 Universidade Sao Francisco; Universidade de Sao Paulo; Universidade Sao Francisco; Universidade Estadual de Campinas
RP Ribeiro, ML (corresponding author), Univ Sao Francisco, Unidade Integrada Farmacol & Gastroenterol, BR-12900000 Braganca Paulista, SP, Brazil.
EM marcelo.ribeiro@saofrancisco.edu.br
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [06/61797-0]; Financiadora de Estudos e Projetos (FINEP); Leao Junior S/A
CR Arabbi PR, 2004, J AGR FOOD CHEM, V52, P1124, DOI 10.1021/jf0499525
   Argilés JM, 2002, BIOCHEM BIOPH RES CO, V293, P1145, DOI 10.1016/S0006-291X(02)00355-8
   Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001
   Bastos DHM, 2007, MED AROMAT PLANT SCI BIOTECHNOL, V1, P37
   Berg AH, 2005, CIRC RES, V96, P939, DOI 10.1161/01.RES.0000163635.62927.34
   Bulló M, 2002, INT J OBESITY, V26, P652, DOI 10.1038/sj.ijo.0801977
   Bulló M, 2007, PUBLIC HEALTH NUTR, V10, P1164, DOI 10.1017/S1368980007000663
   Corica F, 1999, INT J OBESITY, V23, P355, DOI 10.1038/sj.ijo.0800826
   de Sotillo DVR, 2002, J NUTR BIOCHEM, V13, P717, DOI 10.1016/S0955-2863(02)00231-0
   Han UK, 2002, J NUTR, V132, P2241, DOI 10.1093/jn/132.8.2241
   Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1
   Hemmerle H, 1997, J MED CHEM, V40, P137, DOI 10.1021/jm9607360
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697
   Kern PA, 2001, AM J PHYSIOL-ENDOC M, V280, P0
   KRUITHOF EKO, 1988, ENZYME, V40, P113, DOI 10.1159/000469153
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527
   Massiéra F, 2001, FASEB J, V15, P2727, DOI 10.1096/fj.01-0457fje
   Massiera F, 2001, ENDOCRINOLOGY, V142, P5220, DOI 10.1210/en.142.12.5220
   Miranda DDC, 2008, MUTAGENESIS, V23, P261, DOI 10.1093/mutage/gen011
   Mosimann ALP, 2006, BIOFACTORS, V26, P59, DOI 10.1002/biof.5520260106
   NARDINI M, 1995, FREE RADICAL BIO MED, V19, P541, DOI 10.1016/0891-5849(95)00052-Y
   Pang J, 2008, ARCH BIOCHEM BIOPHYS, V476, P178, DOI 10.1016/j.abb.2008.02.019
   Pomilio AB, 2002, PHYTOCHEM ANALYSIS, V13, P235, DOI 10.1002/pca.647
   PRIMROSE JN, 1992, THROMB HAEMOSTASIS, V68, P396
   Rodríguez E, 2004, OBES RES, V12, P1455, DOI 10.1038/oby.2004.182
   Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145
   SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440
   Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448
   Skurk T, 2004, INT J OBESITY, V28, P1357, DOI 10.1038/sj.ijo.0802778
   Stein FLP, 2005, BIOL RES NURS, V7, P146, DOI 10.1177/1099800405280521
   Takahashi K, 2003, J BIOL CHEM, V278, P46654, DOI 10.1074/jbc.M309895200
   TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X
   Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Xenachis C, 2001, J ENDOCRINOL INVEST, V24, P865, DOI 10.1007/BF03343943
   Yang WS, 2001, J CLIN ENDOCR METAB, V86, P3815, DOI 10.1210/jc.86.8.3815
   Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972
NR 39
TC 130
Z9 139
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD DEC 15
PY 2009
VL 17
IS 12
BP 2127
EP 2133
DI 10.1038/oby.2009.158
PG 7
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 523RD
UT WOS:000272091200002
PM 19444227
DA 2025-04-28
ER

PT J
AU Tsai, CH
   Chiu, WC
   Yang, NC
   Ouyang, CM
   Yen, YH
AF Tsai, Ch-Huing
   Chiu, Wan-Chen
   Yang, Nae-Cherng
   Ouyang, Chung-Mei
   Yen, Yue-Horng
TI A novel green tea meal replacement formula for weight loss among obese individuals: a randomized controlled clinical trial
SO INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION
LA English
DT Article
DE Green tea; meal replacement; weight loss; fat mass; blood lipid
ID food provision; reduction; extract; cholesterol; caffeine; risk; rich; fat
AB Objective To assess the efficacy and safety of a green tea meal replacement formula product for the treatment of obesity. Design A 12-week clinical trial was performed, in which 120 (25 male, 95 female) healthy, overweight and obese persons were included (each of them occupy one-third of the whole population). The green tea formula was provided in the treatment group and normal diet was provided as control. Results More weight loss was found in the treatment group than the control (6.8 versus 2.3 kg; P<0.001). Also, the treatment group had a greater changes in total cholesterol (185.2 versus 215.2 mg/dl; P = 0.011) and low-density lipoprotein cholesterol (106.7 versus 127.6 mg/dl; P<0.005). Among completers only, the treatment group again lost more weight (6.8 kg; n = 54 versus 0.8 kg; n = 56; P = 0.001) and had a greater reduced total body fat mass (7.6%; n = 37 versus 0.5%; P = 0.005). Conclusions This green tea meal replacement formula contributes to the lower body weight and reduced low-density lipoprotein cholesterol level.
C1 [Tsai, Ch-Huing; Chiu, Wan-Chen; Yen, Yue-Horng] DaYeh Univ, Dept BioInd Technol, Changhua, Taiwan.
   [Yang, Nae-Cherng] Chung Chou Inst Technol, Dept Nutr & Hlth Sci, Changhua, Taiwan.
   [Ouyang, Chung-Mei] Natl Taiwan Univ Hosp, Dept Dietet, Taipei, Taiwan.
C3 Da Yeh University; National Taiwan University; National Taiwan University Hospital
RP Yen, YH (corresponding author), DaYeh Univ, Dept BioInd Technol, Changhua, Taiwan.
EM d9414002@yahoo.com.tw
CR Allison DB, 1997, OVERWEIGHT AND WEIGHT MANAGEMENT: THE HEALTH PROFESSIONALS GUIDE TO UNDERSTANDING AND PRACTICE., V0, P557
   Allison DB, 2001, CRIT REV FOOD SCI, V41, P1, DOI 10.1080/20014091091661
   *AM DIET ASS, 1995, EXCH LISTS WEIGHT MA, V0, P0
   Anderson JW, 2001, OBES RES, V9, P326S, DOI 10.1038/oby.2001.138
   Bray GA, 1999, ENDOCR REV, V20, P805, DOI 10.1210/er.20.6.805
   DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320
   Davidson MH, 1999, JAMA-J AM MED ASSOC, V281, P235, DOI 10.1001/jama.281.3.235
   DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017
   DHURANDHAR N, 2000, EC NEUROSCI, V2, P42
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   EDLENNEZIN L, 1993, TRUTH CONSEQUENCES H, V0, P0
   FROHLICH E D, 1988, HYPERTENSION (DALLAS), V11, P0
   Heymsfield SB, 1996, AM J CLIN NUTR, V64, P478, DOI 10.1093/ajcn/64.3.478S
   Iso H, 2006, ANN INTERN MED, V144, P554, DOI 10.7326/0003-4819-144-8-200604180-00005
   JEFFERY RW, 1993, J CONSULT CLIN PSYCH, V61, P1038, DOI 10.1037/0022-006X.61.6.1038
   LOHMAN JAB, 1988, EXPERIENTIA, V44, P666, DOI 10.1007/BF01941027
   Maron DJ, 2003, ARCH INTERN MED, V163, P1448, DOI 10.1001/archinte.163.12.1448
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Pan WH, 2008, OBES REV, V9, P22, DOI 10.1111/j.1467-789X.2007.00434.x
   PETERSON L, 1982, J APPL BEHAV ANAL, V15, P477, DOI 10.1901/jaba.1982.15-477
   RAZDAN A, 1997, BR J NUTR, V76, P87
   Subramanian S, 2009, CURR OPIN LIPIDOL, V20, P39, DOI 10.1097/MOL.0b013e32831bef8b
   Vinson JA, 1989, COMP HUMAN BIOAVAILA, V0, P125
   Wing RR, 1996, INT J OBESITY, V20, P56
   Zhong LT, 2006, AM J CLIN NUTR, V84, P551, DOI 10.1093/ajcn/84.3.551
NR 25
TC 18
Z9 18
U1 0
U2 31
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0963-7486
EI 1465-3478
J9 INT J FOOD SCI NUTR
JI Int. J. Food Sci. Nutr.
PD JUN 15
PY 2009
VL 60
IS 
BP 151
EP 159
DI 10.1080/09637480903136667
PG 9
WC Food Science & Technology; Nutrition & Dietetics
SC Food Science & Technology; Nutrition & Dietetics
GA 545IB
UT WOS:000273724600014
PM 19736596
DA 2025-04-28
ER

PT J
AU Kakuta, Y
   Nakaya, N
   Nagase, S
   Fujita, M
   Koizumi, T
   Okamura, C
   Niikura, H
   Ohmori, K
   Kuriyama, S
   Tase, T
   Ito, K
   Minami, Y
   Yaegashi, N
   Tsuji, I
AF Kakuta, Yukika
   Nakaya, Naoki
   Nagase, Satoru
   Fujita, Megumi
   Koizumi, Toshimitsu
   Okamura, Chikako
   Niikura, Hitoshi
   Ohmori, Kaori
   Kuriyama, Shinichi
   Tase, Toru
   Ito, Kiyoshi
   Minami, Yuko
   Yaegashi, Nobuo
   Tsuji, Ichiro
TI Case-control study of green tea consumption and the risk of endometrial endometrioid adenocarcinoma
SO CANCER CAUSES & CONTROL
LA English
DT Article
DE Green tea; Endometrial cancer; Endometrial endometrioid adenocarcinoma; Japanese
ID food-frequency questionnaire; coffee consumption; pooled analysis; gastric-cancer; no association; cohort; japan
AB To investigate the association between green tea consumption and the risk of endometrial cancer restricted to endometrial endometrioid adenocarcinoma (EEA) using a case-control design in Japan. The cases were 152 patients with histopathologically diagnosed EEA, and the controls were 285 healthy women who were matched for age and area of residence with individual cases. The subjects completed a questionnaire regarding health-related lifestyle and reproductive history, and a food frequency questionnaire. Odds ratios (ORs) of EEA for frequency of green tea consumption were calculated by conditional logistic regression analysis. We observed a significant inverse association between green tea consumption and the risk of EEA with a dose-response relationship. The multivariate-adjusted OR of EEA was 0.77 (95% CI: 0.37-1.58) for those in the second quartile of green tea consumption (5-6 cups/week-1 cup/day), 0.61 (0.30-1.23) in the third quartile (2-3 cups/day), and 0.33 (0.15-0.75) in the highest quartile (a parts per thousand yen4 cups/day), as referenced with those in the lowest quartile (a parts per thousand currency sign4 cups/week; p for trend = 0.007). This inverse association was consistently observed regardless of the presence or absence of factors such as obesity and menopause. Green tea consumption may be associated with a lower risk of EEA.
C1 [Kakuta, Yukika; Nagase, Satoru; Fujita, Megumi; Koizumi, Toshimitsu; Niikura, Hitoshi; Ito, Kiyoshi; Yaegashi, Nobuo] Tohoku Univ, Grad Sch Med, Div Gynecol, Dept Reprod & Dev Med,Aoba Ku, Sendai, Miyagi 9808574, Japan.
   [Kakuta, Yukika; Nakaya, Naoki; Ohmori, Kaori; Kuriyama, Shinichi; Tsuji, Ichiro] Tohoku Univ, Grad Sch Med, Div Epidemiol, Dept Publ Hlth & Forens Med, Sendai, Miyagi 9808574, Japan.
   [Okamura, Chikako] Sendai City Hosp, Dept Gynecol, Sendai, Miyagi, Japan.
   [Tase, Toru] Miyagi Canc Ctr, Dept Gynecol, Sendai, Miyagi, Japan.
   [Minami, Yuko] Tohoku Univ, Sch Hlth Sci, Div Community Hlth, Sendai, Miyagi 9808574, Japan.
C3 Tohoku University; Tohoku University; Miyagi Cancer Center; Tohoku University
RP Kakuta, Y (corresponding author), Tohoku Univ, Grad Sch Med, Div Gynecol, Dept Reprod & Dev Med,Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.
EM qyp06776@nifty.com
FU Ministry of Education, Science, Sports and Culture, Japan; Ministry of Health, Labour and Welfare, Japan; Grants-in-Aid for Scientific Research [21592119] Funding Source: KAKEN
CR Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8
   BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7
   CHRISTOPHER P, 2006, DIAGNOSTIC GYNECOLOG, V0, P546
   Cooper R, 2005, J ALTERN COMPLEM MED, V11, P639, DOI 10.1089/acm.2005.11.639
   DELIGDISCH L, 1987, CANCER DETECT PREV, V10, P237
   Frei B, 2003, J NUTR, V133, P3275S, DOI 10.1093/jn/133.10.3275S
   Hirose K, 2007, CANCER SCI, V98, P411, DOI 10.1111/j.1349-7006.2007.00391.x
   Inoue M, 1998, CANCER CAUSE CONTROL, V9, P209, DOI 10.1023/A:1008890529261
   Ishikawa A, 2006, J EPIDEMIOL, V16, P185, DOI 10.2188/jea.16.185
   Kikuchi N, 2006, BRIT J CANCER, V95, P371, DOI 10.1038/sj.bjc.6603230
   Koizumi T, 2008, EUR J CANCER PREV, V17, P358, DOI 10.1097/CEJ.0b013e3282f0c02c
   Koizumi Y, 2003, CANCER EPIDEM BIOMAR, V12, P472
   Kuriyama S, 2006, JAMA-J AM MED ASSOC, V296, P1255, DOI 10.1001/jama.296.10.1255
   Liao CK, 2003, CANCER CAUSE CONTROL, V14, P357, DOI 10.1023/A:1023925010837
   Luo JH, 2007, EUR J CANCER PREV, V16, P542, DOI 10.1097/CEJ.0b013e32809b4d30
   Nagano J, 2001, CANCER CAUSE CONTROL, V12, P501, DOI 10.1023/A:1011297326696
   *NAT CANC I, 2008, SNAPSH END CANC, V0, P0
   Ogawa K, 2003, PUBLIC HEALTH NUTR, V6, P147, DOI 10.1079/PHN2002411
   OHTA H, 2000, SANFUJINKA JISSAI, V49, P1669
   *SAS I INC, 2004, SAS STAT GUID US GUI, V0, P0
   Sasazuki S, 2004, CANCER CAUSE CONTROL, V15, P483, DOI 10.1023/B:CACO.0000036449.68454.42
   SHIMAZU T, 2008, INT J CANC 0818, V0, P0
   Suzuki Y, 2005, J EPIDEMIOL, V15, P118, DOI 10.2188/jea.15.118
   Suzuki Y, 2004, BRIT J CANCER, V90, P1361, DOI 10.1038/sj.bjc.6601652
   Tsubono Y, 2001, NUTR CANCER, V39, P78, DOI 10.1207/S15327914nc391_11
   Tsubono Y, 2001, NEW ENGL J MED, V344, P632, DOI 10.1056/NEJM200103013440903
   Xu WH, 2007, AM J EPIDEMIOL, V166, P1420, DOI 10.1093/aje/kwm242
   Yang CS, 2007, TOXICOL APPL PHARM, V224, P265, DOI 10.1016/j.taap.2006.11.024
   Zaveri NT, 2006, LIFE SCI, V78, P2073, DOI 10.1016/j.lfs.2005.12.006
   Zhang M, 2002, CANCER EPIDEM BIOMAR, V11, P713
NR 30
TC 23
Z9 24
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-5243
EI 1573-7225
J9 CANCER CAUSE CONTROL
JI Cancer Causes Control
PD JUL 15
PY 2009
VL 20
IS 5
BP 617
EP 624
DI 10.1007/s10552-008-9272-0
PG 8
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 449OP
UT WOS:000266340200013
PM 19067194
DA 2025-04-28
ER

PT J
AU de Castro, JM
AF de Castro, John M.
TI When, how much and what foods are eaten are related to total daily food intake
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Eating; Meal times; Diurnal rhythms; Energy density; Breakfast
ID dietary energy density; body-mass index; meal patterns; cereal consumption; nutrient intake; breakfast consumption; social facilitation; obesity epidemic; united-states; weight-loss
AB Intake in the morning is associated with a reduction in the total intake for the day, while intake at night is associated with greater overall daily intake. These associations are macronutrient specific, with morning carbohydrate intake associated with reduced daily carbohydrate intake, morning fat intake associated with reduced daily fat intake and morning protein intake associated with reduced daily protein intake. Since different types of foods contain differing proportions of macronutrients, the present study investigated the associations of different types of foods ingested at various times of day with total daily and macronutrient intakes. The intakes of 388 male and 621 female free-living individuals reported in 7d diet diaries were reanalysed. The intakes of twenty-four different types of foods and seven different drinks occurring during the morning (04.00-10.29 hours), afternoon (10.30-16.59 hours) and evening (17.00-02.00 hours) were identified and related to overall daily intakes. Dairy foods, ice cream, beef, other meats, potatoes, pastry, nuts, chips and snacks, condiments, alcohol and soda were significantly associated with higher total intake over the day, while fruit, soup, breakfast cereal, pasta, pizza, water, coffee/tea and diet soda were either not associated or were associated with lower overall intake. Dietary energy density appeared to mediate the associations between particular foods and beverages and overall energy intake. This suggests that eating low-density foods in the morning and avoiding high-density foods at night might aid in reducing overall intake and may be useful in dietary interventions for overweight and obesity.
C1 Sam Houston State Univ, Coll Humanities & Social Sci, Huntsville, TX 77341 USA.
C3 Texas State University System; Sam Houston State University
RP de Castro, JM (corresponding author), Sam Houston State Univ, Coll Humanities & Social Sci, Huntsville, TX 77341 USA.
EM jdecastro@shsu.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK39881]
CR ADLESON SF, 1960, J AM DIET ASSOC, V36, P453
   Affenito SG, 2005, J AM DIET ASSOC, V105, P938, DOI 10.1016/j.jada.2005.03.003
   *AHA, 2003, 43 ANN C CARD DIS EP, V0, P0
   Albertson A, 2003, J AM DIET ASSOC, V103, P1613, DOI 10.1016/j.jada.2003.09.020
   BANDINI LG, 1990, AM J CLIN NUTR, V52, P421, DOI 10.1093/ajcn/52.3.421
   Barton BA, 2005, J AM DIET ASSOC, V105, P1383, DOI 10.1016/j.jada.2005.06.003
   Bazzano LA, 2005, OBES RES, V13, P1952, DOI 10.1038/oby.2005.240
   Bell EA, 2001, AM J CLIN NUTR, V73, P1010
   Boutelle K, 2002, J PEDIATR PSYCHOL, V27, P531, DOI 10.1093/jpepsy/27.6.531
   Cho S, 2003, J AM COLL NUTR, V22, P296, DOI 10.1080/07315724.2003.10719307
   de Castro JM, 2000, PHYSIOL BEHAV, V70, P343, DOI 10.1016/S0031-9384(00)00264-X
   de Castro JM, 2006, J NUTR, V136, P1382, DOI 10.1093/jn/136.5.1382
   de Castro JM, 2004, J NUTR, V134, P104, DOI 10.1093/jn/134.1.104
   de Castro JM, 1998, J NUTR, V128, P61, DOI 10.1093/jn/128.1.61
   de Castro JM, 2004, J NUTR, V134, P335, DOI 10.1093/jn/134.2.335
   de Castro JM, 2001, NUTRITION, V17, P713, DOI 10.1016/S0899-9007(01)00611-6
   de Castro JM, 1999, PROG OBES R, V0, P215
   de Castro JM, 2000, NEURAL CONTROL MACRO, V0, P43
   De Castro JM, 2007, BRIT J NUTR, V98, P1077, DOI 10.1017/S0007114507754296
   DECASTRO JM, 1991, PHYSIOL BEHAV, V50, P729, DOI 10.1016/0031-9384(91)90010-L
   DECASTRO JM, 1993, PHYSIOL BEHAV, V54, P677, DOI 10.1016/0031-9384(93)90076-R
   DECASTRO JM, 1994, APPETITE, V23, P57, DOI 10.1006/appe.1994.1034
   DECASTRO JM, 1987, PHYSIOL BEHAV, V40, P437, DOI 10.1016/0031-9384(87)90028-X
   DECASTRO JM, 1992, PHYSIOL BEHAV, V51, P121, DOI 10.1016/0031-9384(92)90212-K
   DECASTRO JM, 1989, AM J CLIN NUTR, V50, P237, DOI 10.1093/ajcn/50.2.237
   DECASTRO JM, 1994, PHYSIOL BEHAV, V56, P445, DOI 10.1016/0031-9384(94)90286-0
   DECASTRO JM, 1986, PHYSIOL BEHAV, V38, P25, DOI 10.1016/0031-9384(86)90128-9
   deCastro JM, 1997, NUTR RES, V17, P807, DOI 10.1016/S0271-5317(97)00050-X
   DECASTRO JM, 1993, PHYSIOL BEHAV, V53, P1133, DOI 10.1016/0031-9384(93)90370-U
   DECASTRO JM, 1994, APPETITE, V23, P179, DOI 10.1006/appe.1994.1045
   Flegal KM, 1999, MED SCI SPORT EXER, V31, PS509, DOI 10.1097/00005768-199911001-00004
   Forslund HB, 2002, EUR J CLIN NUTR, V56, P740, DOI 10.1038/sj.ejcn.1601387
   GERSOVITZ M, 1978, J AM DIET ASSOC, V73, P48
   GIBSON SA, 1995, J ROY SOC HEALTH, V115, P366, DOI 10.1177/146642409511500608
   GORAN MI, 1992, METABOLISM, V41, P744, DOI 10.1016/0026-0495(92)90315-2
   Haines PS, 1996, J AM DIET ASSOC, V96, P464, DOI 10.1016/S0002-8223(96)00130-7
   HEADY JA, 1961, J R STAT SOC SER A-G, V124, P336, DOI 10.2307/2343242
   JUDD CM, 1981, EVALUATION REV, V5, P602, DOI 10.1177/0193841X8100500502
   Kral TVE, 2002, APPETITE, V39, P137, DOI 10.1006/appe.2002.0498
   KRANTZLER NJ, 1982, AM J CLIN NUTR, V36, P1234, DOI 10.1093/ajcn/36.6.1234
   LIVINGSTONE MBE, 1992, AM J CLIN NUTR, V56, P29, DOI 10.1093/ajcn/56.1.29
   LIVINGSTONE MBE, 1990, BMJ-BRIT MED J, V300, P708, DOI 10.1136/bmj.300.6726.708
   LUNNEBORD CE, 1983, ELEMENTARY MULTIVARI, V0, P0
   Ma YS, 2003, AM J EPIDEMIOL, V158, P85, DOI 10.1093/aje/kwg117
   Mattes RD, 2002, J AM COLL NUTR, V21, P570, DOI 10.1080/07315724.2002.10719257
   Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519
   Nicklas TA, 2004, J AM DIET ASSOC, V104, P753, DOI 10.1016/j.jada.2004.02.030
   Poppitt SD, 1998, INT J OBESITY, V22, P1024, DOI 10.1038/sj.ijo.0800726
   Prentice AM, 1998, AM J CLIN NUTR, V67, P535S, DOI 10.1093/ajcn/67.3.535S
   Rampersaud GC, 2005, J AM DIET ASSOC, V105, P743, DOI 10.1016/j.jada.2005.02.007
   REDD M, 1992, PHYSIOL BEHAV, V52, P749, DOI 10.1016/0031-9384(92)90409-U
   Rolls BJ, 1999, AM J CLIN NUTR, V70, P448
   Rolls BJ, 2000, AM J CLIN NUTR, V72, P361
   Siega-Riz AM, 1998, AM J CLIN NUTR, V67, P748S, DOI 10.1093/ajcn/67.4.748S
   Siega-Riz AM, 2000, PREV MED, V30, P415, DOI 10.1006/pmed.2000.0651
   SINGLETON N, 1982, J SCHOOL HEALTH, V52, P529, DOI 10.1111/j.1746-1561.1982.tb04033.x
   STJEOR ST, 1983, J AM DIET ASSOC, V83, P155
   Stubbs RJ, 1998, INT J OBESITY, V22, P980, DOI 10.1038/sj.ijo.0800715
   Stubbs RJ, 1996, INT J OBESITY, V20, P651
   Thompson OM, 2006, INT J OBESITY, V30, P176, DOI 10.1038/sj.ijo.0803072
   Vanelli Maurizio, 2005, ACTA BIOMED, V76, P79
   Waller SM, 2004, J AM COLL NUTR, V23, P316, DOI 10.1080/07315724.2004.10719374
   Wyatt HR, 2002, OBES RES, V10, P78, DOI 10.1038/oby.2002.13
   Yao MJ, 2001, NUTR REV, V59, P247
NR 64
TC 78
Z9 82
U1 1
U2 25
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD OCT 28
PY 2009
VL 102
IS 8
BP 1228
EP 1237
DI 10.1017/S0007114509371640
PG 10
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 513TX
UT WOS:000271347800016
PM 19650955
DA 2025-04-28
ER

PT J
AU Richard, D
   Kefi, K
   Barbe, U
   Poli, A
   Bausero, P
   Visioli, F
AF Richard, Doriane
   Kefi, Kaouthar
   Barbe, Ullah
   Poli, Andrea
   Bausero, Pedro
   Visioli, Francesco
TI Weight and plasma lipid control by decaffeinated green tea
SO PHARMACOLOGICAL RESEARCH
LA English
DT Article
DE Green tea; Obesity; Polyphenols; Diet; Decaffeinated
ID catechin-polyphenols; hepatic steatosis; white tea; body-fat; caffeine; obesity; mice; system; rats; (-)-epigallocatechin-3-gallate
AB We investigated whether regular decaffeinated green tea intake could modulate body weight in an experimental model of obesity. Male leptin-deficient (ob/ob) mice and their C57BL/6J lean littermates (4 weeks of age; n 20/genotype) were assigned randomly to receive either decaffeinated green tea or vehicle, for 6 weeks. Body weights were recorded weekly and fluid intake was measured at each replacement. Blood was collected from the heart into collection tubes, with Li(+)-heparin as the anticoagulant. Administration of decaffeinated green tea to ob/ob mice significantly slowed their rate of weight gain, as compared with animals that were fed buffer alone. This effect is apparent after only 1 week of supplementation. No significant difference was recorded between C57BL/6J lean mice administrated decaffeinated green tea and those given buffer alone. Decaffeinated green tea consumption by ob/ob mice was also associated with significantly lower cholesterolemia, triglyceridemia, and adiponectin concentration. Fecal lipids did not change significantly throughout the experiment. In conclusion, administration of decaffeinated green tea might contribute to weight control and provides an opportunity for through-the-day consumption, without the excitatory effects of caffeine. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Richard, Doriane; Kefi, Kaouthar; Barbe, Ullah; Bausero, Pedro; Visioli, Francesco] Univ Paris 06, UR4, Lab Micronutrients & Cardiovasc Dis, F-75252 Paris 5, France.
   [Poli, Andrea] Nutr Fdn Italy, Milan, Italy.
C3 Sorbonne Universite
RP Richard, D (corresponding author), Univ Paris 06, UR4, Lab Micronutrients & Cardiovasc Dis, Bat A 5 Etage,Case Courrier 256,7 Quai St Bernard, F-75252 Paris 5, France.
EM doriane.richard@upmc.fr
FU Nutrition Foundation of Italy
CR Unknown -, 2002, WHO LIB CAT IN PUBL, V0, P0
   Auvichayapat P, 2008, PHYSIOL BEHAV, V93, P486, DOI 10.1016/j.physbeh.2007.10.009
   Babu PVA, 2007, PHARMACOL RES, V55, P433, DOI 10.1016/j.phrs.2007.01.019
   Bose M, 2008, J NUTR, V138, P1677, DOI 10.1093/jn/138.9.1677
   Bruno RS, 2008, J NUTR, V138, P323, DOI 10.1093/jn/138.2.323
   Carter O, 2007, NUTR CANCER, V58, P60, DOI 10.1080/01635580701308182
   Choo JJ, 2003, J NUTR BIOCHEM, V14, P671, DOI 10.1016/j.jnutbio.2003.08.005
   Deitel M, 2002, OBES SURG, V12, P613, DOI 10.1381/096089202321019558
   Delporte ML, 2004, AM J PHYSIOL-ENDOC M, V287, PE446, DOI 10.1152/ajpendo.00488.2003
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Fiorini RN, 2005, LIVER TRANSPLANT, V11, P298, DOI 10.1002/lt.20348
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Furuyashiki T, 2004, BIOSCI BIOTECH BIOCH, V68, P2353, DOI 10.1271/bbb.68.2353
   Galani C, 2007, INT J PUBLIC HEALTH, V52, P348, DOI 10.1007/s00038-007-7015-8
   Giannessi D, 2007, PHARMACOL RES, V56, P459, DOI 10.1016/j.phrs.2007.09.014
   Hsu TF, 2006, EUR J CLIN NUTR, V60, P1330, DOI 10.1038/sj.ejcn.1602464
   James WPT, 2008, J INTERN MED, V263, P336, DOI 10.1111/j.1365-2796.2008.01922.x
   Jin JY, 2007, PHARMACOL RES, V56, P237, DOI 10.1016/j.phrs.2007.06.004
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   Koo MWL, 2004, EUR J PHARMACOL, V500, P177, DOI 10.1016/j.ejphar.2004.07.023
   Koo SI, 2007, J NUTR BIOCHEM, V18, P179, DOI 10.1016/j.jnutbio.2006.12.005
   Lin JK, 2006, MOL NUTR FOOD RES, V50, P211, DOI 10.1002/mnfr.200500138
   Mathers CD, 2006, PLOS MED, V3, P0, DOI 10.1371/journal.pmed.0030442
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Raederstorff DG, 2003, J NUTR BIOCHEM, V14, P326, DOI 10.1016/S0955-2863(03)00054-8
   Shishikura Y, 2006, J AGR FOOD CHEM, V54, P1906, DOI 10.1021/jf051988p
   Visioli F, 2007, BRIT J NUTR, V98, P1101, DOI 10.1017/S0007114507853475
   Visioli F, 2007, PHARMACOL RES, V55, P199, DOI 10.1016/j.phrs.2007.01.008
   Wang R, 2008, CARCINOGENESIS, V29, P834, DOI 10.1093/carcin/bgn051
   WHO, 2000, WHO TECHN REP SER, V894, P0
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
NR 32
TC 41
Z9 47
U1 0
U2 17
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
EI 
J9 PHARMACOL RES
JI Pharmacol. Res.
PD MAY 15
PY 2009
VL 59
IS 5
BP 351
EP 354
DI 10.1016/j.phrs.2009.01.015
PG 4
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 442DU
UT WOS:000265821000009
PM 19416635
DA 2025-04-28
ER

PT J
AU Nelson, MC
   Story, M
AF Nelson, Melissa C.
   Story, Mary
TI Food Environments in University Dorms 20,000 Calories per Dorm Room and Counting
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID availability; obesity
AB Background: Few young adults meet national dietary recommendations. Although home food availability likely has important influences on dietary intake, little research has examined thiS issue among young adults. The objective of this research was to conduct a detailed, observational assessment of food and beverages available in college-student dormitory rooms. Methods: Dormitory-residing students (n=100) were recruited from a large, public university. Research staff completed a detailed inventory of food and beverages in the clorin rooms, including nutrient contents and purchasing Sources. Data were collected and analyzed in 2008. Results: The mean number of food and beverage items per participant was 47 (range: 0-208), with 4% of participants not having any food or beverages. More than 70% Of Students had each of the following types of items: salty snacks, cereal or granola bars, main dishes, desserts or candy, and sugar-sweetened beverages. Fewer students had low-calorie beverages, fruits and vegetables, dairy products, tea/coffee, and 100% fruit/vegetable juice. The average number of calories per dorm room was 22,888. Items purchased by parents had a higher calorie and fat content than items purchased by students. Conclusions: Findings indicate that students maintain a wide array of food and beverages in their dormitory rooms. Parents purchased a Substantial amount of food for their children's dormitory rooms, and these food items were less healthful than the food that students purchased. The foods observed in college students' living spaces may have air important impact on eating habits. Overall, young adult-oriented obesity prevention efforts are needed, and improving the various facets of campus food environments may mark an important component of such strategies. (Am J Prev Med 2009;36(6):523-526) (C) 2009 American Journal of Preventive Medicine
C1 [Nelson, Melissa C.; Story, Mary] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities
RP Nelson, MC (corresponding author), Univ Minnesota, Div Epidemiol & Community Hlth, 1300 S 2nd St,WBOB Suite 300, Minneapolis, MN 55454 USA.
EM nels5024@umn.edu
FU Maternal and Child Health Bureau, Health Resources Services Administration [T79 MC00007-13]
CR Unknown -, 2007, J AM COLL HEALTH, V55, P195, DOI 10.3200/JACH.55.4.195-206
   Brown LB, 2005, J AM DIET ASSOC, V105, P445, DOI 10.1016/j.jada.2004.12.030
   Campbell KJ, 2007, OBESITY, V15, P719, DOI 10.1038/oby.2007.553
   Cullen KW, 2003, HEALTH EDUC BEHAV, V30, P615, DOI 10.1177/1090198103257254
   NELSON MC, 2009, J AM DIET A IN PRESS, V0, P0
   NELSON MC, 2009, J NUTR ED B IN PRESS, V0, P0
   Nelson MC, 2008, OBESITY, V16, P2205, DOI 10.1038/oby.2008.365
   Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549
   Raynor HA, 2004, OBES RES, V12, P816, DOI 10.1038/oby.2004.98
NR 10
TC 47
Z9 79
U1 0
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD JUN 15
PY 2009
VL 36
IS 6
BP 523
EP 526
DI 10.1016/j.amepre.2009.01.030
PG 4
WC Public, Environmental & Occupational Health; Medicine, General & Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 446PD
UT WOS:000266132700009
PM 19356889
DA 2025-04-28
ER

PT J
AU Mueller, M
   Jungbauer, A
AF Mueller, Monika
   Jungbauer, Alois
TI Culinary plants, herbs and spices - A rich source of PPARγ ligands
SO FOOD CHEMISTRY
LA English
DT Article
DE Obesity; PPAR gamma; Diabetes; Plants; SPPAR gamma Ms; PPAR gamma-antagonists
ID activated receptor-gamma; cinnamomum-zeylanicum; biological-activity; in-vivo; insulin; extract; diet
AB Obesity and the related disorders, diabetes, hypertension and hyperlipidemia have reached epidemic proportions world-wide. The influence of 70 plants, herbs and spices on peroxisome proliferators-activated receptor (PPAR)gamma activation or antagonism, a drug target for metabolic syndrome, was investigated. Approximately 50 different plant extracts bound PPAR gamma in competitive ligand binding assay, including pomegranate, apple, clove, cinnamon, thyme, green coffee, bilberry and bay leaves. Five plant extracts transactivated PPAR gamma in chimeric GAL4-PPAR gamma-LBD system: nutmeg, licorice, black pepper, holy basil and sage. Interestingly, nearly all plant extracts antagonized rosiglitazone-mediated coactivator recruitment in time resolved fluorescence resonance energy transfer coactivator assay. The five transactivating extracts may function as selective PPAR gamma modulators (SPPAR gamma Ms), and the other extracts seem to be moderate antagonists or undetectable/weak SPPAR gamma Ms. As SPPAR gamma Ms improve insulin resistance without weight gain and PPAR gamma antagonists exert antiobesity action, a combination of these plants in diet could reduce obesity and the incidence of metabolic syndrome. (c) 2009 Elsevier Ltd. All rights reserved.
C1 [Mueller, Monika; Jungbauer, Alois] Univ Nat Resources & Appl Life Sci, Christian Doppler Lab Receptor Biotechnol, Dept Biotechnol, A-1190 Vienna, Austria.
C3 BOKU University
RP Jungbauer, A (corresponding author), Univ Nat Resources & Appl Life Sci, Christian Doppler Lab Receptor Biotechnol, Dept Biotechnol, Muthgasse 18, A-1190 Vienna, Austria.
EM alois.jungbauer@boku.ac.at
CR Alberti G, 2006, THE IDF CONSENSUS WORLDWIDE OF THE METABOLIC SYNDROME, V0, P0
   Anderson RA, 2004, J AGR FOOD CHEM, V52, P65, DOI 10.1021/jf034916b
   Bazzano LA, 2005, J AM COLL NUTR, V24, P310, DOI 10.1080/07315724.2005.10719479
   Bazzano Lydia A, 2003, CURR ATHEROSCLER REP, V5, P492, DOI 10.1007/s11883-003-0040-z
   Broadhurst CL, 2000, J AGR FOOD CHEM, V48, P849, DOI 10.1021/jf9904517
   Chaieb K, 2007, PHYTOTHER RES, V21, P501, DOI 10.1002/ptr.2124
   Crespy V, 2001, J NUTR, V131, P3227, DOI 10.1093/jn/131.12.3227
   Ehala S, 2005, J AGR FOOD CHEM, V53, P6484, DOI 10.1021/jf050397w
   Grover JK, 2002, J ETHNOPHARMACOL, V81, P81, DOI 10.1016/S0378-8741(02)00059-4
   Guo L, 2006, PHARMACOL THERAPEUT, V111, P145, DOI 10.1016/j.pharmthera.2005.10.009
   Han KL, 2008, DIABETES, V57, P737, DOI 10.2337/db07-0972
   Huang THW, 2005, TOXICOL APPL PHARM, V207, P160, DOI 10.1016/j.taap.2004.12.009
   Jarvill-Taylor KJ, 2001, J AM COLL NUTR, V20, P327, DOI 10.1080/07315724.2001.10719053
   Jeppesen PB, 2002, PHYTOMEDICINE, V9, P9, DOI 10.1078/0944-7113-00081
   Jungbauer A, 2001, J CLIN LIGAND ASSAY, V24, P270
   Justesen U, 2001, FOOD CHEM, V73, P245, DOI 10.1016/S0308-8146(01)00114-5
   Kahle K, 2007, J AGR FOOD CHEM, V55, P10605, DOI 10.1021/jf071942r
   Mae T, 2003, J NUTR, V133, P3369, DOI 10.1093/jn/133.11.3369
   Marongiu B, 2007, J AGR FOOD CHEM, V55, P10022, DOI 10.1021/jf071938f
   Mueller M, 2008, MENOPAUSE, V15, P1120, DOI 10.1097/gme.0b013e31817062ce
   Naz S, 2007, J FOOD SCI, V72, PM341, DOI 10.1111/j.1750-3841.2007.00533.x
   Proestos C, 2005, J AGR FOOD CHEM, V53, P1190, DOI 10.1021/jf040083t
   Rau O, 2006, PHARMAZIE, V61, P952
   Rieusset J, 2002, MOL ENDOCRINOL, V16, P2628, DOI 10.1210/me.2002-0036
   Seguin P, 2006, J SCI FOOD AGR, V86, P765, DOI 10.1002/jsfa.2412
   Shapiro Karen, 2002, J AM PHARM ASSOC (WASH), V42, P217, DOI 10.1331/108658002763508515
   이성계, 2008, JOURNAL OF THE KOREAN SOCIETY OF FOOD SCIENCE AND NUTRITION 한국식품영양과학회지, V37, P437
   Srinivasan K, 2005, INT J FOOD SCI NUTR, V56, P399, DOI 10.1080/09637480500512872
   Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701
   Verspohl EJ, 2005, PHYTOTHER RES, V19, P203, DOI 10.1002/ptr.1643
   Vuksan V, 2008, NUTR METAB CARDIOVAS, V18, P46, DOI 10.1016/j.numecd.2006.04.003
   Wang HF, 2004, FOOD CHEM, V87, P307, DOI 10.1016/j.foodchem.2003.12.029
   Zhang F, 2007, PPAR RES, V2007, P0, DOI 10.1155/2007/32696
   Zhang Z, 2004, J AGR FOOD CHEM, V52, P688, DOI 10.1021/jf034596w
NR 35
TC 43
Z9 47
U1 0
U2 20
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0308-8146
EI 1873-7072
J9 FOOD CHEM
JI Food Chem.
PD DEC 15
PY 2009
VL 117
IS 4
BP 660
EP 667
DI 10.1016/j.foodchem.2009.04.063
PG 8
WC Chemistry, Applied; Food Science & Technology; Nutrition & Dietetics
SC Chemistry; Food Science & Technology; Nutrition & Dietetics
GA 475UG
UT WOS:000268386200013
DA 2025-04-28
ER

PT J
AU Seliske, LM
   Pickett, W
   Boyce, WF
   Janssen, I
AF Seliske, Laura M.
   Pickett, William
   Boyce, William F.
   Janssen, Ian
TI Density and type of food retailers surrounding Canadian schools: Variations across socioeconomic status
SO HEALTH & PLACE
LA English
DT Article
DE Food; Residence characteristics; Social class; Schools
ID body-mass index; neighborhood characteristics; united-states; restaurants; children; obesity; supermarkets; availability; associations; environments
AB Lower socioeconomic status (SES) neighbourhoods may have differential access to food retailers, potentially explaining the varying area-level obesity rates. The food retail environment around 188 schools across Canada was examined, including full-service restaurants, fast food restaurants, sub/sandwich retailers, donut/coffee shops, convenience stores, and grocery stores. School addresses were linked to census data to obtain area-level SES measures. Access to food retailers was generally not associated with the neighbourhood SES in the immediate proximity. Within the broader neighbourhood, lower SES neighbourhoods had access to fewer food retailers of all types. This effect was diminished after taking population density into account. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Janssen, Ian] Queens Univ, Sch Kinesiol & Hlth Studies, Kingston, ON K7L 3N6, Canada.
   [Pickett, William] Queens Univ, Dept Emergency Med, Kingston Gen Hosp, Kingston, ON K7L 2V7, Canada.
   [Boyce, William F.] Queens Univ, Social Program, Evaluat Grp, Fac Educ, Kingston, ON K7L 3N6, Canada.
   [Seliske, Laura M.; Pickett, William; Boyce, William F.; Janssen, Ian] Queens Univ, Dept Epidemiol & Community Hlth, Kingston, ON K7L 3N6, Canada.
C3 Queens University - Canada; Queens University - Canada; Queens University Hospital; Queens University - Canada; Queens University - Canada
RP Janssen, I (corresponding author), Queens Univ, Sch Kinesiol & Hlth Studies, Kingston, ON K7L 3N6, Canada.
EM ian.janssen@queensu.ca
CR Apparicio P, 2007, INT J HEALTH GEOGR, V6, P0, DOI 10.1186/1476-072X-6-4
   Austin SB, 2005, AM J PUBLIC HEALTH, V95, P1575, DOI 10.2105/AJPH.2004.056341
   Block JP, 2004, AM J PREV MED, V27, P211, DOI 10.1016/j.amepre.2004.06.007
   Boone JE, 2008, ANN EPIDEMIOL, V18, P371, DOI 10.1016/j.annepidem.2007.11.008
   Bowman SA, 2004, PEDIATRICS, V113, P112, DOI 10.1542/peds.113.1.112
   Burdette HL, 2004, PREV MED, V38, P57, DOI 10.1016/j.ypmed.2003.09.029
   CHANDON P, 2007, J CONSUMER RES, V34, P0
   Cummins S, 2006, INT J EPIDEMIOL, V35, P100, DOI 10.1093/ije/dyi276
   Cummins SCJ, 2005, AM J PREV MED, V29, P308, DOI 10.1016/j.amepre.2005.06.011
   Janssen I, 2006, AM J CLIN NUTR, V83, P139
   JONCKHEERE AR, 1954, BIOMETRIKA, V41, P133, DOI 10.1093/biomet/41.1-2.133
   Macintyre Sally, 2005, INT J BEHAV NUTR PHYS ACT, V2, P16, DOI 10.1186/1479-5868-2-16
   Moore LV, 2006, AM J PUBLIC HEALTH, V96, P325, DOI 10.2105/AJPH.2004.058040
   Morland K, 2006, AM J PREV MED, V30, P333, DOI 10.1016/j.amepre.2005.11.003
   Oliver LN, 2005, CAN J PUBLIC HEALTH, V96, P415, DOI 10.1007/BF03405180
   Powell LA, 2007, AM J PREV MED, V33, PS240, DOI 10.1016/j.amepre.2007.07.005
   Powell LM, 2007, PREV MED, V44, P189, DOI 10.1016/j.ypmed.2006.08.008
   Reidpath DD, 2002, HEALTH PLACE, V8, P141, DOI 10.1016/S1353-8292(01)00028-4
   Shields Margot, 2006, HEALTH REP, V17, P27
   Smoyer-Tomic KE, 2008, HEALTH PLACE, V14, P740, DOI 10.1016/j.healthplace.2007.12.001
   Sturm R, 2005, PUBLIC HEALTH, V119, P1059, DOI 10.1016/j.puhe.2005.05.007
   Terpstra TJ, 1952, INDAGATIONES MATHEMA, V14, P327, DOI 10.1016/S1385-7258(52)50043-X
   Wang MC, 2007, J EPIDEMIOL COMMUN H, V61, P491, DOI 10.1136/jech.2006.051680
NR 23
TC 32
Z9 35
U1 0
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1353-8292
EI 1873-2054
J9 HEALTH PLACE
JI Health Place
PD SEP 15
PY 2009
VL 15
IS 3
BP 903
EP 907
DI 10.1016/j.healthplace.2008.11.001
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 460JI
UT WOS:000267183600030
PM 19121973
DA 2025-04-28
ER

PT J
AU Wang, S
   Sparks, LM
   Xie, H
   Greenway, FL
   de Jonge, L
   Smith, SR
AF Wang, S.
   Sparks, L. M.
   Xie, H.
   Greenway, F. L.
   de Jonge, L.
   Smith, S. R.
TI Subtyping obesity with microarrays: implications for the diagnosis and treatment of obesity
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
DE subtyping obesity; microarray; cluster analysis; clinical characteristics; weight loss
ID visceral adipose-tissue; fat oxidation; expression; muscle; genes; food
AB Objective: Obese patients respond differently to weight loss interventions. No efficient diagnostic tool exists to separate obese patients into subtypes as a means to improve prediction of response to interventions. We aimed to separate obese subjects into distinct subgroups using microarray technology to identify gene expression-based subgroups to predict weight loss. Design: A total of 72 obese men and women without family history of diabetes were enrolled in the study; 52 were treated with ephedra and caffeine (E+C) and 20 with placebo for 8 weeks. Adipose and skeletal muscle tissue biopsies were performed at baseline. RNA sample pairs were labeled and hybridized to oligonucleotide microarrays. Quantile normalization and gene shaving were performed, and a clustering algorithm was then applied to cluster subjects based on their gene expression profile. Clusters were visualized using heat maps and related to weight changes. Results: Cluster analysis of gene expression data revealed two distinct subgroups of obesity and predicted weight loss in response to the treatment with E+C. One cluster ('red') decreased to 96.87 +/- 2.35% body weight, and the second cluster ('green') decreased to 95.59 +/- 2.75% body weight (P<0.05). 'Red' cluster had less visceral adipose tissue mass ( 2.77 +/- 1.08 vs 3.43 +/- 1.49 kg; P<0.05) and decreased size of the very large fat cells (1.45 +/- 0.61 vs 2.16 +/- 1.74 mu l; P<0.05) compared to 'green' cluster. Gene expression for both skeletal muscle and adipose tissue was also different between clusters. Conclusions: Our study provides the first evidence that the combined approach of gene expression profiling and cluster analysis can identify discrete subtypes of obesity, these subtypes have different physiological characteristics and respond differently to an adrenergic weight loss therapy. This brings us that into an era of personalized treatment in the obesity
C1 [Wang, S.; Sparks, L. M.; Xie, H.; Greenway, F. L.; de Jonge, L.; Smith, S. R.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA.
C3 Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center
RP Smith, SR (corresponding author), Louisiana State Univ Syst, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA.
EM smithsr@pbrc.edu
FU Community Foundation of Southeast Michigan; PBRC CNRU NIH [P30-DK072476]
CR Alizadeh AA, 2001, J PATHOL, V195, P41, DOI 10.1002/path.889
   BJORNTORP P, 1991, INT J OBESITY, V15, P67
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   DEJONGE L, 1991, AM J PHYSIOL, V260, PE238, DOI 10.1152/ajpendo.1991.260.2.E238
   ELIA M, 1988, AM J CLIN NUTR, V47, P591, DOI 10.1093/ajcn/47.4.591
   Forner F, 2006, MOL CELL PROTEOMICS, V5, P608, DOI 10.1074/mcp.M500298-MCP200
   Gastaldelli A, 2005, DIABETOLOGIA, V48, P2090, DOI 10.1007/s00125-005-1891-3
   GUYGRAND B, 1989, LANCET, V2, P1142
   Harris RBS, 1996, J CLIN INVEST, V97, P2020, DOI 10.1172/JCI118637
   Hastie T, 2001, GENOME BIOL, V2, P0
   Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200
   KROTKIEWSKI M, 1977, INT J OBESITY, V1, P395
   LEFEVRE M, 1998, INT J OBESITY S3, V22, P0
   Levine James A, 1999, SCIENCE (WASHINGTON D C), V283, P212, DOI 10.1126/science.283.5399.212
   Merkel M, 2002, J LIPID RES, V43, P1997, DOI 10.1194/jlr.R200015-JLR200
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   REBUFFESCRIVE M, 1987, INT J OBESITY, V11, P347
   Smith SR, 1999, INT J OBESITY, V23, P329, DOI 10.1038/sj.ijo.0800834
   Smith SR, 2003, DIABETES, V52, P2914, DOI 10.2337/diabetes.52.12.2914
   Smith SR, 2001, METABOLISM, V50, P425, DOI 10.1053/meta.2001.21693
   Smith SR, 2006, ADIPOCYTES, V2, P11
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sparks LM, 2005, DIABETES, V54, P1926, DOI 10.2337/diabetes.54.7.1926
   Stunkard A, 2000, APPETITE, V34, P333, DOI 10.1006/appe.1999.0337
   Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403
   Torgerson JS, 1999, J CLIN ENDOCR METAB, V84, P4197, DOI 10.1210/jc.84.11.4197
   Ukropcova B, 2005, J CLIN INVEST, V115, P1934, DOI 10.1172/JCI24332
   Vague J, 1996, OBES RES, V4, P201, DOI 10.1002/j.1550-8528.1996.tb00535.x
   Verdich C, 2001, OBES RES, V9, P452, DOI 10.1038/oby.2001.59
   West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998
   White MA, 2002, OBES RES, V10, P107, DOI 10.1038/oby.2002.17
NR 31
TC 15
Z9 16
U1 0
U2 3
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0307-0565
EI 1476-5497
J9 INT J OBESITY
JI Int. J. Obes.
PD APR 15
PY 2009
VL 33
IS 4
BP 481
EP 489
DI 10.1038/ijo.2008.277
PG 9
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 432AW
UT WOS:000265106900011
PM 19188926
DA 2025-04-28
ER

PT J
AU Huang, YW
   Liu, Y
   Dushenkov, S
   Ho, CT
   Huang, MT
AF Huang, Yu-Wen
   Liu, Yue
   Dushenkov, Slauik
   Ho, Chi-Tang
   Huang, Mou-Tuan
TI Anti-obesity effects of epigallocatechin-3-gallate, orange peel extract, black tea extract, caffeine and their combinations in a mouse model
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Review
DE Anti-obesity, Caffeine; Orange peel extract; Epigallocatechin gallate; Black tea extract
ID diet-induced obesity; green tea; catechin-polyphenols; adipose-tissue; fat oxidation; food-intake; health; gallate; rats; mice
AB The anti-obesity effects of epigallocatechin-3-gallate (EGCG), orange peel extract (OPE), black tea extract (BTE), and caffeine (CF) in female CF-1 mice were studied. Female CF-1 mice were fed high-fat diets containing 0.1% EGCG, 0.2% OPE, 0.2% BTE and 0.05% caffeine alone and in combination for 10 weeks. The body weight gain and weights of abdominal fat and brown adipose tissue were significantly reduced in mice whose diets contained OPE, BTE, caffeine, OPE + BTE and OPE + CF. Notably, mice fed a high-fat diet supplemented daily with 0.2% OPE + 0.2% BTE + 0.05% CF prevented body weight gain by 48.8%, parametrial fat pad weight by 88.2%, retroperitoneal fat pad weight by 82.8% and brown adipose tissue by 63.7% compared with mice fed a high-fat diet. On the basis of these findings, it was concluded that oral feeding of orange peel extract, black tea extract and caffeine had anti-obesity effects by suppressing body weight gain and adipose tissue formation. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Huang, Yu-Wen; Liu, Yue; Huang, Mou-Tuan] Rutgers State Univ, Sch Pharm, Susan Lehman Cullman Lab Canc Res, Dept Biol Chem, Piscataway, NJ 08854 USA.
   [Dushenkov, Slauik] Rutgers State Univ, New Brunswick, NJ 08901 USA.
   [Ho, Chi-Tang] Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers University System; Rutgers University New Brunswick; Rutgers University System; Rutgers University New Brunswick
RP Huang, MT (corresponding author), Rutgers State Univ, Sch Pharm, Susan Lehman Cullman Lab Canc Res, Dept Biol Chem, Piscataway, NJ 08854 USA.
EM mthuang@rci.rutgers.edu
CR Bays Harold, 2006, EXPERT REV CARDIOVASC THER, V4, P871
   Cheng TO, 2006, INT J CARDIOL, V108, P301, DOI 10.1016/j.ijcard.2005.05.038
   DULLOO AG, 1993, INT J OBESITY, V17, P0
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464
   Kao Y, 2000, AM J CLIN NUTR, V72, P1232
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926
   Lai CS, 2007, CARCINOGENESIS, V28, P2581, DOI 10.1093/carcin/bgm231
   Li SM, 2009, J FUNCT FOODS, V1, P2, DOI 10.1016/j.jff.2008.09.003
   LIN JK, 2009, TEA TEA PRODUCTS CHE, V0, P0
   Mazzucotelli Anne, 2006, JOURNAL DE LA SOCIETE DE BIOLOGIE, V200, P83, DOI 10.1051/jbio:2006011
   Middleton E, 2000, PHARMACOL REV, V52, P673
   MURAMATSU K, 1986, J NUTR SCI VITAMINOL, V32, P613, DOI 10.3177/jnsv.32.613
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Nagao T, 2001, JOURNAL OF OLEO SCIENCE, V50, P717
   RACOTTA IS, 1994, PHARMACOL BIOCHEM BE, V48, P887, DOI 10.1016/0091-3057(94)90196-1
   Reeves AF, 2006, ARCH PEDIAT ADOL MED, V160, P894, DOI 10.1001/archpedi.160.9.894
   Siddiqui IA, 2004, ANTIOXID REDOX SIGN, V6, P571, DOI 10.1089/152308604773934323
   TREMBLAY A, 1988, NUTR RES, V8, P553, DOI 10.1016/S0271-5317(88)80077-0
   Vinson JA, 1998, FEBS LETT, V433, P44, DOI 10.1016/S0014-5793(98)00880-1
   Whitman SC, 2005, ATHEROSCLEROSIS, V178, P25, DOI 10.1016/j.atherosclerosis.2004.07.034
   Wolfram S, 2005, ANN NUTR METAB, V49, P54, DOI 10.1159/000084178
   YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038
   Yang CS, 1999, NUTRITION, V15, P946
   Yang MH, 2001, J NUTR BIOCHEM, V12, P14, DOI 10.1016/S0955-2863(00)00140-6
   Yang TTC, 1997, PHARMACOL RES, V35, P505, DOI 10.1006/phrs.1997.0176
   Zheng GD, 2004, IN VIVO, V18, P55
NR 30
TC 58
Z9 64
U1 2
U2 62
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1756-4646
EI 
J9 J FUNCT FOODS
JI J. Funct. Food.
PD JUL 15
PY 2009
VL 1
IS 3
BP 304
EP 310
DI 10.1016/j.jff.2009.06.002
PG 7
WC Food Science & Technology; Nutrition & Dietetics
SC Food Science & Technology; Nutrition & Dietetics
GA 684OU
UT WOS:000284560000009
DA 2025-04-28
ER

PT J
AU Nelson, MC
   Neumark-Sztainer, D
   Hannan, PJ
   Story, M
AF Nelson, Melissa C.
   Neumark-Sztainer, Dianne
   Hannan, Peter J.
   Story, Mary
TI Five-Year Longitudinal and Secular Shifts in Adolescent Beverage Intake: Findings from Project EAT (Eating Among Teens)-II
SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION
LA English
DT Article
ID food frequency questionnaire; soft drink consumption; united-states; children; trends; obesity; prevalence; overweight; adulthood; patterns
AB Detailed research examining concurrent longitudinal and secular changes in adolescent beverage intake is not currently available, particularly since the year 2000. This study's objective was to evaluate these trends in beverage intake in a large, diverse adolescent cohort. Project EAT (Eating Among Teens)-II is a 5-year longitudinal study (n=2,516) including two cohorts, which allows for the observation of longitudinal changes from early to midadolescence (junior high to high school) and from mid- to late adolescence (high school to post high school). Project EAT-II also examined secular trends in adolescent health behavior from 1999-2004 in mid-adolescence. Daily beverage servings were assessed using the Youth and Adolescent Food Frequency Questionnaire. Longitudinal findings indicate that intake of soda and sugar-sweetened beverages (including soda, sweetened iced teas, and fruit drinks) increased significantly among younger males, and alcohol increased across all groups (P<0.01). Consumption of certain beverages decreased with age: fruit juice (among all males and older females, P <= 0.02), milk (older adolescents, P<0.01), other milk beverages (all females and older males, P<0.01), diet soda (younger adolescents, P<0.01), and coffee/tea (all males and younger females, P<0.01). Significant secular decreases were observed in fruit juice and coffee/tea for males and females (P <= 0.05). Overall, these findings reflect recent secular and longitudinal shifts in adolescent beverage consumption during the critical transition period from early to mid-adolescence and mid- to late adolescence. Although additional research is needed to better understand nuances in adolescent consumption patterns, registered dietitians and other health care practitioners working with adolescents should address the importance of limiting sugar-sweetened beverages with low nutrient density.
C1 [Nelson, Melissa C.; Neumark-Sztainer, Dianne; Hannan, Peter J.; Story, Mary] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities
RP Nelson, MC (corresponding author), Univ Minnesota, Div Epidemiol & Community Hlth, 1300 S 2nd St,WBOB Suite 300, Minneapolis, MN 55454 USA.
EM nelson@epi.umn.edu
FU Maternal and Child Health Bureau [R40 MC 00319]; Health Resources and Services Administration, Department of Health and Human Services; Obesity Prevention Center at the University of Minnesota
CR Unknown -, 2011, STEPS HLTH YOU, V0, P0
   Unknown -, 2005, DIET GUID AM 2005, V0, P0
   Bray GA, 2004, AM J CLIN NUTR, V79, P537
   Cavadini C, 2000, ARCH DIS CHILD, V83, P18, DOI 10.1136/adc.83.1.18
   Demory-Luce D, 2004, J AM DIET ASSOC, V104, P1684, DOI 10.1016/j.jada.2004.07.026
   Diggle PJ, 2002, ANALYSIS OF LONGITUDINAL DATA, V2nd, P0
   French SA, 2003, J AM DIET ASSOC, V103, P1326, DOI 10.1016/S0002-8223(03)01076-9
   Fulgoni V, 2007, J AM DIET ASSOC, V107, P256, DOI 10.1016/j.jada.2006.11.007
   Gamble M, 1999, AM J HEALTH BEHAV, V23, P261, DOI 10.5993/AJHB.23.4.3
   Harnack L, 1999, J AM DIET ASSOC, V99, P436, DOI 10.1016/S0002-8223(99)00106-6
   Hawkes C, 2002, GLOBALIZATION DIETS, V0, P0
   Institute of Medicine (IOM), 2005, PUBLIC HEALTH NUTRITION, V9, P606
   Little R, 1986, INT STAT REV, V54, P137
   Nelson MC, 2008, OBESITY, V16, P2205, DOI 10.1038/oby.2008.365
   Neumark-Sztainer D, 2006, J AM DIET ASSOC, V106, P559, DOI 10.1016/j.jada.2006.01.003
   Neumark-Sztainer D, 2002, AM J PUBLIC HEALTH, V92, P844, DOI 10.2105/AJPH.92.5.844
   Nielsen Samara Joy, 2003, JAMA (JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION), V289, P450, DOI 10.1001/jama.289.4.450
   Nielsen SJ, 2004, AM J PREV MED, V27, P205, DOI 10.1016/j.amepre.2004.05.005
   Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549
   Popkin BM, 2006, AM J CLIN NUTR, V83, P529, DOI 10.1093/ajcn.83.3.529
   Powell LM, 2007, AM J PREV MED, V33, PS251, DOI 10.1016/j.amepre.2007.07.009
   Rajeshwari R, 2005, J AM DIET ASSOC, V105, P208, DOI 10.1016/j.jada.2004.11.026
   Rampersaud GC, 2003, J AM DIET ASSOC, V103, P97, DOI 10.1053/jada.2003.50006
   ROCKETT HRH, 1995, J AM DIET ASSOC, V95, P336, DOI 10.1016/S0002-8223(95)00086-0
   Rockett HRH, 1997, PREV MED, V26, P808, DOI 10.1006/pmed.1997.0200
   Sichert-Hellert W, 2001, ACTA PAEDIATR, V90, P732, DOI 10.1080/080352501750315627
NR 27
TC 44
Z9 65
U1 0
U2 7
PU AMER DIETETIC ASSOC
PI CHICAGO
PA 216 W JACKSON BLVD #800, CHICAGO, IL 60606-6995 USA
SN 0002-8223
EI 
J9 J AM DIET ASSOC
JI J. Am. Diet. Assoc.
PD FEB 15
PY 2009
VL 109
IS 2
BP 308
EP 312
DI 10.1016/j.jada.2008.10.043
PG 5
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 401CI
UT WOS:000262915500017
PM 19167959
DA 2025-04-28
ER

PT J
AU Maki, KC
   Reeves, MS
   Farmer, M
   Yasunaga, K
   Matsuo, N
   Katsuragi, Y
   Komikado, M
   Tokimitsu, I
   Wilder, D
   Jones, F
   Blumberg, JB
   Cartwright, Y
AF Maki, Kevin C.
   Reeves, Matthew S.
   Farmer, Mildred
   Yasunaga, Koichi
   Matsuo, Noboru
   Katsuragi, Yoshihisa
   Komikado, Masanori
   Tokimitsu, Ichiro
   Wilder, Donna
   Jones, Franz
   Blumberg, Jeffrey B.
   Cartwright, Yolanda
TI Green Tea Catechin Consumption Enhances Exercise-Induced Abdominal Fat Loss in Overweight and Obese Adults
SO JOURNAL OF NUTRITION
LA English
DT Article
ID low-density-lipoprotein; energy-expenditure; body-fat; oxidation; caffeine; extract; epigallocatechin-3-gallate; thermogenesis; cholesterol; polyphenols
AB This study evaluated the influence of a green tea catechin beverage on body composition and fat distribution in overweight and obese adults during exercise-induced weight loss. Participants (n = 132 with 107 completers) were randomly assigned to receive a beverage containing similar to 625 mg of catechins with 39 mg caffeine or a control beverage (39 mg caffeine, nocatechins) for 12 wk. Participants were asked to maintain constant energy intake and engage in >= 180 min/wk moderate intensity exercise, including >= 3 supervised sessions per week. Body composition (dual X-ray absorptiometry), abdominal fat areas (computed tomography), and clinical laboratory tests were measured at baseline and wk 12. There was a trend (P = 0.079) toward greater loss of body weight in the catechin group compared with the control group; least squares mean (95% Cl) changes, adjusted for baseline value, age, and sex, were -2.2 (-3.1, -1.3) and -1.0 (-1.9, -0.1) kg, respectively. Percentage changes in fat mass did not differ between the catechin [5.2 (-7.0, -3.4)] and control groups 1-3.5 (-5.4, 1.6)] (P = 0.208). However, percentage changes in total abdominal fat area [-7.7 (-11.7, -3.8) vs. -0.3 (-4.4, 3.9); P = 0.013], subcutaneous abdominal fat area [-6.2 (-10.2, -2.2) vs. 0.8 (-3.3, 4.9); P = 0.0191, and fasting serum triglycerides (TG) [-11.2 (-18.8, -3.6) vs. 1.9 (-5.9, 9.7); P = 0.023] were greater in the catechin group. These findings suggest that green tea catechin consumption enhances exercise-induced changes in abdominal fat and serum TG. J. Nutr. 139: 264-270, 2009.
C1 [Maki, Kevin C.; Reeves, Matthew S.; Wilder, Donna; Jones, Franz; Cartwright, Yolanda] Provident Clin Res, Bloomington, IN 47403 USA.
   [Maki, Kevin C.; Reeves, Matthew S.; Wilder, Donna; Jones, Franz; Cartwright, Yolanda] Provident Clin Res, Glen Ellyn, IL 60137 USA.
   [Farmer, Mildred] Meridien Res, St Petersburg, FL 33709 USA.
   [Yasunaga, Koichi; Matsuo, Noboru; Katsuragi, Yoshihisa; Komikado, Masanori; Tokimitsu, Ichiro] Kao Corp, Hlth Care Food Res Lab, Tokyo 1318501, Japan.
   [Blumberg, Jeffrey B.] Tufts Univ, Human Nutr Res Ctr Aging, Jean Mayer USDA, Antioxidants Res Lab, Boston, MA 02111 USA.
C3 KAO Corporation; United States Department of Agriculture (USDA); Tufts University
RP Maki, KC (corresponding author), Provident Clin Res, Bloomington, IN 47403 USA.
EM kmaki@providentcrc.com
FU Kao Corporation, Tokyo, Japan
CR *AM COLL SPORTS ME, 1997, ACSMS HLTH FITN FAC, V0, P0
   Unknown -, 2001, J OLEO SCI, V0, P0, DOI DOI 10.5650/JOS.50.677
   Unknown -, 2001, J OLEO SCI, V0, P0, DOI DOI 10.5650/JOS.50.657
   Bartness TJ, 1998, AM J PHYSIOL-REG I, V275, PR1399, DOI 10.1152/ajpregu.1998.275.5.R1399
   Bérubé-Parent S, 2005, BRIT J NUTR, V94, P432, DOI 10.1079/BJN20051502
   Boschmann M, 2007, J AM COLL NUTR, V26, P389S, DOI 10.1080/07315724.2007.10719627
   Bose M, 2008, J NUTR, V138, P1677, DOI 10.1093/jn/138.9.1677
   Chan PT, 1999, J NUTR, V129, P1094, DOI 10.1093/jn/129.6.1094
   Despres J P, 2006, J ENDOCRINOL INVEST, V29, P77
   Diepvens K, 2005, BRIT J NUTR, V94, P1026, DOI 10.1079/BJN20051580
   DPP Res Grp, 2002, DIABETES CARE, V25, P2165
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143
   Hase T, 2001, JOURNAL OF OLEO SCIENCE, V50, P599, DOI 10.5650/jos.50.599
   Hill AM, 2007, J AM COLL NUTR, V26, P396S, DOI 10.1080/07315724.2007.10719628
   Hsu CH, 2008, CLIN NUTR, V27, P363, DOI 10.1016/j.clnu.2008.03.007
   Ishikawa T, 1997, AM J CLIN NUTR, V66, P261, DOI 10.1093/ajcn/66.2.261
   Ito Y, 2008, BIOMED RES-TOKYO, V29, P27, DOI 10.2220/biomedres.29.27
   Kao YH, 2006, MOL NUTR FOOD RES, V50, P188, DOI 10.1002/mnfr.200500109
   Komatsu Tatsushi, 2003, JOURNAL OF MEDICAL INVESTIGATION, V50, P170
   Kovacs EMR, 2004, BRIT J NUTR, V91, P431, DOI 10.1079/BJN20041061
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Nagao T, 2001, JOURNAL OF OLEO SCIENCE, V50, P717
   Nagao T, 2007, OBESITY, V15, P1473, DOI 10.1038/oby.2007.176
   Osada K, 2001, COMP BIOCHEM PHYS C, V128, P153, DOI 10.1016/S1532-0456(00)00192-7
   PESCE M, 2006, PROVIDENT PRV06001 P, V0, P0
   Pi-Sunyer FX, 1998, OBES RES, V6, P0
   Reaven Gerald M, 1997, P357, V0, P0
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987
   Stunkard AJ, 1996, AM J MED, V100, P230, DOI 10.1016/S0002-9343(97)89464-8
   Unno T, 2005, BRIT J NUTR, V93, P543, DOI 10.1079/BJN20041379
   Volpi N, 1998, J CHROMATOGR B, V713, P433, DOI 10.1016/S0378-4347(98)00195-9
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
   WOLTHUIS RA, 1977, AM J CARDIOL, V39, P697, DOI 10.1016/S0002-9149(77)80131-8
   Yang MH, 2001, J NUTR BIOCHEM, V12, P14, DOI 10.1016/S0955-2863(00)00140-6
NR 39
TC 182
Z9 203
U1 0
U2 56
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD FEB 15
PY 2009
VL 139
IS 2
BP 264
EP 270
DI 10.3945/jn.108.098293
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 398MC
UT WOS:000262735200011
PM 19074207
DA 2025-04-28
ER

PT J
AU Ifland, JR
   Preuss, HG
   Marcus, MT
   Rourk, KM
   Taylor, WC
   Burau, K
   Jacobs, WS
   Kadish, W
   Manso, G
AF Ifland, J. R.
   Preuss, H. G.
   Marcus, M. T.
   Rourk, K. M.
   Taylor, W. C.
   Burau, K.
   Jacobs, W. S.
   Kadish, W.
   Manso, G.
TI Refined food addiction: A classic substance use disorder
SO MEDICAL HYPOTHESES
LA English
DT Article
ID excessive sugar intake; body-mass index; iv alcohol dependence; dsm-iv; drug-addiction; caffeine withdrawal; weight-loss; physical-activity; mental-disorders; obesity stigma
AB Overeating in industrial societies is a significant problem, linked to an increasing incidence of overweight and obesity, and the resultant adverse health consequences. We advance the hypothesis that a possible explanation for overeating is that processed foods with high concentrations of sugar and other refined sweeteners, refined carbohydrates, fat, salt, and caffeine are addictive substances. Therefore, many people lose control over their ability to regulate their consumption of such foods. The loss of control over these foods could account for the global epidemic of obesity and other metabolic disorders. We assert that overeating can be described as an addiction to refined foods that conforms to the DSM-IV criteria for substance use disorders. To examine the hypothesis, we relied on experience with self-identified refined foods addicts, as well as critical reading of the literature on obesity, eating behavior, and drug addiction. Reports by self-identified food addicts illustrate behaviors that conform to the 7 DSM-IV criteria for substance use disorders. The literature also supports use of the DSM-IV criteria to describe overeating as a substance use disorder. The observational and empirical data strengthen the hypothesis that certain refined food consumption behaviors meet the criteria for substance use disorders, not unlike tobacco and alcohol. This hypothesis could lead to a new diagnostic category, as well as therapeutic approaches to changing overeating behaviors. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Ifland, J. R.; Rourk, K. M.; Kadish, W.] Refined Food Addict ReFA Res Fdn, Houston, TX 77007 USA.
   [Preuss, H. G.] Georgetown Univ, Sch Med, Washington, DC 20057 USA.
   [Marcus, M. T.] Univ Texas Austin, Sch Nursing, Austin, TX 78701 USA.
   [Taylor, W. C.; Burau, K.] Univ Texas Houston, Sch Publ Hlth, Houston, TX 77225 USA.
   [Jacobs, W. S.] Univ Florida, Sch Psychiat, Gainesville, FL 32611 USA.
   [Kadish, W.] Univ Texas Houston, Sch Med, Houston, TX USA.
C3 Georgetown University; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; State University System of Florida; University of Florida; University of Texas System; University of Texas Health Science Center Houston
RP Ifland, JR (corresponding author), Refined Food Addict ReFA Res Fdn, 5355 Mem Dr,F-814, Houston, TX 77007 USA.
EM joan@refinedfoodaddiction.org
CR Acosta JI, 2005, PHARMACOL BIOCHEM BE, V80, P297, DOI 10.1016/j.pbb.2004.12.001
   Allshouse J, 1999, EC RES SERVICE STAT, V965, P1970
   Ashmore Jamile A, 2008, EAT BEHAV, V9, P203, DOI 10.1016/j.eatbeh.2007.09.006
   Association A, 2000, DIAGNOSTIC STAT MANU, V0, P0
   Avena NM, 2008, NEUROSCI BIOBEHAV R, V32, P20, DOI 10.1016/j.neubiorev.2007.04.019
   Berkey CS, 2000, PEDIATRICS, V105, P0, DOI 10.1542/peds.105.4.e56
   Bernstein GA, 2002, DRUG ALCOHOL DEPEN, V66, P1, DOI 10.1016/S0376-8716(01)00181-8
   Bernstein GA, 1998, J AM ACAD CHILD PSY, V37, P858, DOI 10.1097/00004583-199808000-00016
   Boileau I, 2003, SYNAPSE, V49, P226, DOI 10.1002/syn.10226
   BOUBLIK JH, 1983, NATURE, V301, P246, DOI 10.1038/301246a0
   Boynton-Jarrett R, 2003, PEDIATRICS, V112, P1321, DOI 10.1542/peds.112.6.1321
   Brandt AllanM, 2007, CIGARETTE CENTURY, V0, P0
   Bray GA, 2004, AM J CLIN NUTR, V79, P537
   Cardinal RN, 2004, CURR OPIN NEUROBIOL, V14, P156, DOI 10.1016/j.conb.2004.03.004
   Carr KD, 1996, NEUROCHEM RES, V21, P1455, DOI 10.1007/BF02532386
   Chen EY, 2005, OBES RES, V13, P1393, DOI 10.1038/oby.2005.168
   Colantuoni C, 2002, OBES RES, V10, P478, DOI 10.1038/oby.2002.66
   Colantuoni C, 2001, NEUROREPORT, V12, P3549, DOI 10.1097/00001756-200111160-00035
   Corwin RL, 2005, PHYSIOL BEHAV, V86, P5, DOI 10.1016/j.physbeh.2005.06.021
   Couturier EGM, 1997, CEPHALALGIA, V17, P188, DOI 10.1046/j.1468-2982.1997.1703188.x
   Dansinger ML, 2007, ANN INTERN MED, V147, P41, DOI 10.7326/0003-4819-147-1-200707030-00007
   Dubois L, 2007, J AM DIET ASSOC, V107, P924, DOI 10.1016/j.jada.2007.03.004
   Duffey KJ, 2007, OBESITY, V15, P2739, DOI 10.1038/oby.2007.326
   Duffey KJ, 2007, AM J CLIN NUTR, V85, P201, DOI 10.1093/ajcn/85.1.201
   Epstein LH, 2007, AM J CLIN NUTR, V86, P914, DOI 10.1093/ajcn/86.4.914
   Epstein LH, 2006, APPETITE, V47, P115, DOI 10.1016/j.appet.2006.02.005
   FEINGOLD A, 1995, ADDICTION, V90, P1661, DOI 10.1111/j.1360-0443.1995.tb02836.x
   Francis LA, 2003, OBES RES, V11, P143, DOI 10.1038/oby.2003.23
   Friedman AS, 1998, AM J DRUG ALCOHOL AB, V24, P169, DOI 10.3109/00952999809001705
   Gibson EL, 2006, PHYSIOL BEHAV, V89, P53, DOI 10.1016/j.physbeh.2006.01.024
   Grant BF, 1997, J SUBST ABUSE, V9, P89, DOI 10.1016/S0899-3289(97)90008-0
   Grant BF, 2007, DRUG ALCOHOL DEPEN, V86, P154, DOI 10.1016/j.drugalcdep.2006.05.019
   Griffiths R R, 2000, NIHON SHINKEI SEISHIN YAKURIGAKU ZASSHI, V20, P223
   Harrington S, 2008, J SCH NURS, V24, P3, DOI 10.1622/1059-8405(2008)024[0003:TROSBC]2.0.CO;2
   Hasin D, 1999, J STUD ALCOHOL, V60, P746, DOI 10.15288/jsa.1999.60.746
   He FJ, 2008, HYPERTENSION, V51, P629, DOI 10.1161/HYPERTENSIONAHA.107.100990
   Horgen KB, 2002, HEALTH PSYCHOL, V21, P505, DOI 10.1037/0278-6133.21.5.505
   Kalra SP, 2004, J ADDICT DIS, V23, P5, DOI 10.1300/J069v23n03_02
   Kant AK, 2002, INT J OBESITY, V26, P1194, DOI 10.1038/sj.ijo.0802024
   Kelley AE, 2005, PHYSIOL BEHAV, V86, P11, DOI 10.1016/j.physbeh.2005.06.018
   Kleiner KD, 2004, J ADDICT DIS, V23, P105, DOI 10.1300/J069v23n03_08
   Kruger R, 2006, PUBLIC HEALTH NUTR, V9, P351, DOI 10.1079/PHN2006849
   Laredo SE, 2006, BRIT MED J, V332, P609, DOI 10.1136/bmj.332.7541.609-b
   Latner JD, 2007, BODY IMAGE, V4, P147, DOI 10.1016/j.bodyim.2007.03.002
   Lindström M, 2003, EUR J PUBLIC HEALTH, V13, P306, DOI 10.1093/eurpub/13.4.306
   Miele GM, 2000, DRUG ALCOHOL DEPEN, V59, P63, DOI 10.1016/S0376-8716(99)00111-8
   MILLER WC, 1990, AM J CLIN NUTR, V52, P426, DOI 10.1093/ajcn/52.3.426
   Must A, 2007, OBESITY, V15, P1774, DOI 10.1038/oby.2007.211
   Nelson MC, 2006, OBESITY, V14, P701, DOI 10.1038/oby.2006.80
   Nesse RM, 2002, ADDICTION, V97, P470, DOI 10.1046/j.1360-0443.2002.00086.x
   Noble EP, 2000, EUR PSYCHIAT, V15, P79, DOI 10.1016/S0924-9338(00)00208-X
   OConnor TM, 2006, PEDIATRICS, V118, PE1010, DOI 10.1542/peds.2005-2348
   PATE CA, 1986, J AM DIET ASSOC, V86, P796
   Patrick K, 2004, ARCH PEDIAT ADOL MED, V158, P385, DOI 10.1001/archpedi.158.4.385
   Pelchat ML, 2002, PHYSIOL BEHAV, V76, P347, DOI 10.1016/S0031-9384(02)00757-6
   Puhl R, 2001, OBES RES, V9, P788, DOI 10.1038/oby.2001.108
   Renggli K, 1995, PRAXIS (BERN 1994), V84, P255
   Rogers PJ, 2000, PHARMACOL BIOCHEM BE, V66, P3, DOI 10.1016/S0091-3057(00)00197-0
   Roitman MF, 2004, J NEUROSCI, V24, P1265, DOI 10.1523/JNEUROSCI.3823-03.2004
   Schulze MB, 2004, JAMA-J AM MED ASSOC, V292, P927, DOI 10.1001/jama.292.8.927
   Serdula MK, 1999, JAMA-J AM MED ASSOC, V282, P1353, DOI 10.1001/jama.282.14.1353
   SILVERMAN K, 1992, NEW ENGL J MED, V327, P1109, DOI 10.1056/NEJM199210153271601
   Simansky KJ, 2005, PHYSIOL BEHAV, V86, P1, DOI 10.1016/j.physbeh.2005.06.016
   Solinas M, 2005, NEUROPSYCHOPHARMACOL, V30, P2035, DOI 10.1038/sj.npp.1300720
   Sukhotina IA, 2004, BEHAV PHARMACOL, V15, P207, DOI 10.1097/01.fbp.0000129748.60495.85
   Teachman BA, 2001, INT J OBESITY, V25, P1525, DOI 10.1038/sj.ijo.0801745
   Tekol Y, 2006, MED HYPOTHESES, V67, P1233, DOI 10.1016/j.mehy.2006.04.041
   Thornley S, 2008, MED HYPOTHESES, V71, P709, DOI 10.1016/j.mehy.2008.07.006
   Torrens M, 2004, AM J PSYCHIAT, V161, P1231, DOI 10.1176/appi.ajp.161.7.1231
   Trinko R, 2007, PHYSIOL BEHAV, V91, P499, DOI 10.1016/j.physbeh.2007.01.001
   Tunceli K, 2006, OBESITY, V14, P1637, DOI 10.1038/oby.2006.188
   Wang Gene-Jack, 2002, EXPERT OPIN THER TARGETS, V6, P601, DOI 10.1517/14728222.6.5.601
   Wang GJ, 2004, J ADDICT DIS, V23, P39, DOI 10.1300/J069v23n03_04
   Wideman CH, 2005, NUTR NEUROSCI, V8, P269, DOI 10.1080/10284150500485221
   Wiecha JL, 2006, J AM DIET ASSOC, V106, P1624, DOI 10.1016/j.jada.2006.07.007
   Wiecha JL, 2006, ARCH PEDIAT ADOL MED, V160, P436, DOI 10.1001/archpedi.160.4.436
   Zilli F, 2000, EAT WEIGHT DISORD, V5, P217
NR 77
TC 216
Z9 266
U1 1
U2 58
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD MAY 15
PY 2009
VL 72
IS 5
BP 518
EP 526
DI 10.1016/j.mehy.2008.11.035
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 426XW
UT WOS:000264742800008
PM 19223127
DA 2025-04-28
ER

PT J
AU Di Pierro, F
   Menghi, AB
   Barreca, A
   Lucarelli, M
   Calandrelli, A
AF Di Pierro, Francesco
   Menghi, Anna Borsetto
   Barreca, Angela
   Lucarelli, Maurizio
   Calandrelli, Andrea
TI GreenSelect® Phytosome as an Adjunct to a Low-Calorie Diet for Treatment of Obesity: A Clinical Trial
SO ALTERNATIVE MEDICINE REVIEW
LA English
DT Article
ID green tea extract; epigallocatechin gallate; energy-expenditure; nervous-system; thermogenesis; inhibition; polyphenols; caffeine; tyrosine; silybin
AB A recently developed oral formulation in the form of coated tablets (Monoselect Camellia (R)) (MonCam) containing highly bioavailable green tea extract (GreenSelect (R) Phytosome) was tested in obese subjects (n=100) of both genders on a hypocaloric diet. Fifty subjects were assigned to the green tea extract plus hypocaloric diet, while the other 50 subjects followed the hypocaloric diet only. After 90 days of treatment, significant weight loss and decreased body mass index (BMI) were observed in the group taking the herbal extract (14-kg loss in the green tea group compared to a 5-kg loss in the diet-only group); waistline was reduced only in male subjects. Besides the effect on weight and BMI, biochemical parameters (LDL-, HDL-, and total cholesterol, triglycerides, growth hormone, insulin-like growth factor-1, insulin, and cortisol) were improved in both groups, Leptin, not tested in the diet-only group, was reduced in patients taking MonCam. Taking into consideration the high safety profile of the product and the total absence of adverse effects observed during and after the trial, MonCam appears to be a safe and effective tool for weight loss. (Altern Med Rev 2009;14(2):154-160)
C1 [Di Pierro, Francesco] Velleja Res, I-29010 Pontenure, Piacenza, Italy.
   [Barreca, Angela] Ctr Polispecialist Ric, Rome, Italy.
   [Lucarelli, Maurizio] Terme Fontecchio Hosp, Citta Di Castello, PG, Italy.
   [Calandrelli, Andrea] Univ Cattolica Sacro Cuore, Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli
RP Di Pierro, F (corresponding author), Velleja Res, Via G Natta 28, I-29010 Pontenure, Piacenza, Italy.
EM f.dipierro@vellejaresearch.com
CR ABDULLAH AR, 2008, METAB SYNDR REL 1124, V0, P0
   Belza A, 2009, EUR J CLIN NUTR, V63, P57, DOI 10.1038/sj.ejcn.1602901
   Chen D, 2008, HISTOL HISTOPATHOL, V23, P487, DOI 10.14670/HH-23.487
   Claessens M, 2007, METABOLISM, V56, P1051, DOI 10.1016/j.metabol.2007.04.001
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Filburn CR, 2007, J VET PHARMACOL THER, V30, P132, DOI 10.1111/j.1365-2885.2007.00834.x
   Giacomelli S, 2002, LIFE SCI, V70, P1447, DOI 10.1016/S0024-3205(01)01511-9
   Hassani Alireza Shoae, 2008, PAK J BIOL SCI, V11, P1336, DOI 10.3923/pjbs.2008.1336.1341
   Hoffman Jay R, 2006, J INT SOC SPORTS NUTR, V3, P35, DOI 10.1186/1550-2783-3-1-35
   LIAO SS, 1995, BIOCHEM BIOPH RES CO, V214, P833, DOI 10.1006/bbrc.1995.2362
   Hermsdorff HHM, 2007, ARCH LATINOAM NUTR, V57, P33
   Monda M, 2008, PEPTIDES, V29, P120, DOI 10.1016/j.peptides.2007.10.016
   Moon HS, 2007, CHEM-BIOL INTERACT, V167, P85, DOI 10.1016/j.cbi.2007.02.008
   Nagle DG, 2006, PHYTOCHEMISTRY, V67, P1849, DOI 10.1016/j.phytochem.2006.06.020
   Pietta P, 1998, BIOCHEM MOL BIOL INT, V46, P895
   Seevaratnam N, 2007, DIABETES OBES METAB, V9, P669, DOI 10.1111/j.1463-1326.2006.00646.x
   Shin KO, 2007, J NUTR SCI VITAMINOL, V53, P145, DOI 10.3177/jnsv.53.145
   Shixian Q, 2006, J MED FOOD, V9, P451, DOI 10.1089/jmf.2006.9.451
   Smeets AJ, 2008, J NUTR, V138, P698, DOI 10.1093/jn/138.4.698
   van Baak MA, 2008, PHYSIOL BEHAV, V94, P178, DOI 10.1016/j.physbeh.2007.12.020
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
   Yanagawa Y, 2003, CURR MICROBIOL, V47, P244, DOI 10.1007/s00284-002-3956-6
   Zhu BT, 2008, XENOBIOTICA, V38, P130, DOI 10.1080/00498250701744641
NR 23
TC 68
Z9 71
U1 0
U2 11
PU ALTERNATIVE MEDICINE REVIEW, LLC
PI DOVER
PA PO BOX 555, DOVER, ID 83825 USA
SN 1089-5159
EI 
J9 ALTERN MED REV
JI Altern. Med. Rev.
PD JUN 15
PY 2009
VL 14
IS 2
BP 154
EP 160
DI 
PG 7
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA 474DU
UT WOS:000268263500012
PM 19594224
DA 2025-04-28
ER

PT J
AU van Dijk, AE
   Olthof, MR
   Meeuse, JC
   Seebus, E
   Heine, RJ
   van Dam, RM
AF van Dijk, Aimee E.
   Olthof, Margreet R.
   Meeuse, Joke C.
   Seebus, Elin
   Heine, Rob J.
   van Dam, Rob M.
TI Acute Effects of Decaffeinated Coffee and the Major Coffee Components Chlorogenic Acid and Trigonelline on Glucose Tolerance
SO DIABETES CARE
LA English
DT Article
ID caffeine; rats; inhibitors; glycemia; plasma; risk
AB OBJECTIVE - Coffee consumption has been associated with lower risk of type 2 diabetes. We evaluated the acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on glucose tolerance. RESEARCH DESIGN AND METHODS - We conducted a randomized crossover trial of the effects of 12 g decaffeinated coffee, 1 g chlorogenic acid, 500 mg trigonelline, and placebo (1 g mannitol) on glucose and insulin concentrations during a 2-h oral glucose tolerance test (OGTT) in 15 overweight men. RESULTS - Chlorogenic acid and trigonelline ingestion significantly reduced glucose (-0.7 mmol/l, P = 0.007, and -0.5 mmol/l, P = 0.024, respectively) and insulin (-73 pmol/l, P = 0.038, and -117 pmol/l, P = 0.007) concentrations 15 min following an OGTT compared with placebo. None of the treatments affected insulin or glucose area under the curve values during the OGTT compared with placebo. CONCLUSIONS - Chlorogenic acid and trigonelline reduced early glucose and insulin responses during an OGTT. Diabetes Care 32:1.023-1025, 2009
C1 [van Dijk, Aimee E.; Olthof, Margreet R.; Meeuse, Joke C.] Vrije Univ Amsterdam, Dept Hlth Sci, Amsterdam, Netherlands.
   [van Dijk, Aimee E.; Olthof, Margreet R.; Meeuse, Joke C.] Vrije Univ Amsterdam, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands.
   [Seebus, Elin; Heine, Rob J.] Vrije Univ Amsterdam, Dept Endocrinol, Amsterdam, Netherlands.
   [van Dam, Rob M.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   [van Dam, Rob M.] Harvard Univ, Brigham & Womens Hosp, Channing Lab, Sch Med, Boston, MA 02115 USA.
C3 Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University Medical Affiliates; Brigham & Women's Hospital
RP Olthof, MR (corresponding author), Vrije Univ Amsterdam, Dept Hlth Sci, Amsterdam, Netherlands.
EM margreet.olthof@falw.vu.nl
FU Dutch Diabetes Research Foundation [2006.11.020]
CR Andrade-Cetto A, 2001, J ETHNOPHARMACOL, V78, P145, DOI 10.1016/S0378-8741(01)00335-X
   Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874
   Bassoli BK, 2008, CELL BIOCHEM FUNCT, V26, P320, DOI 10.1002/cbf.1444
   Battram DS, 2006, J NUTR, V136, P1276, DOI 10.1093/jn/136.5.1276
   Clifford MN, 1999, J SCI FOOD AGR, V79, P362, DOI 10.1002/(SICI)1097-0010(19990301)79:3<362::AID-JSFA256>3.0.CO;2-D
   de Sotillo DVR, 2002, J NUTR BIOCHEM, V13, P717, DOI 10.1016/S0955-2863(02)00231-0
   Ishikawa A, 2007, J NUTR SCI VITAMINOL, V53, P166, DOI 10.3177/jnsv.53.166
   Johnston KL, 2003, AM J CLIN NUTR, V78, P728, DOI 10.1093/ajcn/78.4.728
   Louie JCY, 2008, ASIA PAC J CLIN NUTR, V17, P657
   Minamisawa M, 2004, ANAL SCI, V20, P325, DOI 10.2116/analsci.20.325
   MISHKINSKY J, 1967, LANCET, V2, P1311
   Slow S, 2004, INT J BIOCHEM CELL B, V36, P870, DOI 10.1016/j.biocel.2003.10.001
   TRUGO LC, 1984, ANALYST, V109, P263, DOI 10.1039/an9840900263
   van Dam RM, 2006, DIABETES CARE, V29, P398, DOI 10.2337/diacare.29.02.06.dc05-1512
   van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97
NR 15
TC 211
Z9 226
U1 1
U2 45
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD JUN 15
PY 2009
VL 32
IS 6
BP 1023
EP 1025
DI 10.2337/dc09-0207
PG 3
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 452EG
UT WOS:000266522200010
PM 19324944
DA 2025-04-28
ER

PT J
AU Tanaka, K
   Nishizono, S
   Tamaru, S
   Kondo, M
   Shimoda, H
   Tanaka, J
   Okada, T
AF Tanaka, Kazunari
   Nishizono, Shoko
   Tamaru, Shizuka
   Kondo, Mihoko
   Shimoda, Hiroshi
   Tanaka, Junji
   Okada, Tadashi
TI Anti-Obesity and Hypotriglyceridemic Properties of Coffee Bean Extract in SD Rats
SO FOOD SCIENCE AND TECHNOLOGY RESEARCH
LA English
DT Article
DE coffee bean extract; anti-obesity; hypotriglyceridemic activity; lipogenesis; lipolysis
ID fatty-acid synthesis; chlorogenic acid; green tea; long-term; caffeine; triacylglycerol; cholesterol; enzymes; mice; diet
AB Coffee bean extract (CBE) was prepared from raw green coffee beans and contained 10.0% caffeine and 27.0% chlorogenic acid. Male Sprague-Dawley rats were fed a diet containing 1% CBE for 4 weeks. Although there was no difference in food intake between rats fed the control diet without CBE and those fed the CBE-containing diet, body weight gain and white adipose tissue weight were significantly decreased in CBE-fed rats than in control rats. The CBE-fed group exerted a significant and extreme reduction in serum and liver triglyceride concentrations compared to the control group. Also, in the CBE-fed group, activities of fatty acid synthetic enzymes in the hepatic cytosol were significantly decreased, while that of fatty acid oxidative enzymes in the hepatic mitochondria was significantly, increased. Our results suggest that CBE has potent anti-obesity and hypotriglyceridemic properties, and there is a possibility that these effects are exerted at least in part by the suppression of lipogenesis and the acceleration of lipolysis.
C1 [Tanaka, Kazunari; Nishizono, Shoko; Tamaru, Shizuka; Kondo, Mihoko] Nagasaki Univ, Grad Sch Human Hlth Sci, Nagoya, Nagasaki 8512195, Japan.
   [Nishizono, Shoko] Miyazaki Univ, Cooperat Res Ctr, Miyazaki 8892191, Japan.
   [Shimoda, Hiroshi; Tanaka, Junji; Okada, Tadashi] Oryza Oil & Fat Chem Co Ltd, Ctr Res & Dev, Ichinomiya, Aichi 4938001, Japan.
C3 Nagasaki University; University of Miyazaki
RP Tanaka, K (corresponding author), Nagasaki Univ, Grad Sch Human Hlth Sci, 1-1-1 Manabino, Nagoya, Nagasaki 8512195, Japan.
EM katanaka@sun.ac.jp
CR Unknown -, 2006, BMC COMPLEM ALTERN M, V0, P0
   BUKOWIECKI LJ, 1983, AM J PHYSIOL, V244, PR500, DOI 10.1152/ajpregu.1983.244.4.R500
   CARSON CA, 1994, INT J EPIDEMIOL, V24, P243
   CHEN MD, 1994, CHIN MED J, V53, P257
   de Sotillo DVR, 2002, J NUTR BIOCHEM, V13, P717, DOI 10.1016/S0955-2863(02)00231-0
   del Castillo MD, 2002, J AGR FOOD CHEM, V50, P3698, DOI 10.1021/jf011702q
   FLETCHER MJ, 1968, CLIN CHIM ACTA, V22, P393, DOI 10.1016/0009-8981(68)90041-7
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Han LK, 1999, INT J OBESITY, V23, P98, DOI 10.1038/sj.ijo.0800766
   Han LK, 2001, INT J OBESITY, V25, P1459, DOI 10.1038/sj.ijo.0801747
   Hasegawa N, 2000, J HEALTH SCI, V46, P153
   Ikeda I, 2005, BIOSCI BIOTECH BIOCH, V69, P1049, DOI 10.1271/bbb.69.1049
   KELLEY DS, 1986, BIOCHEM J, V235, P87, DOI 10.1042/bj2350087
   KELLEY DS, 1984, BIOCHEM J, V217, P543, DOI 10.1042/bj2170543
   Kobayashi-Hattori K, 2005, BIOSCI BIOTECH BIOCH, V69, P2219, DOI 10.1271/bbb.69.2219
   Li BH, 2006, IUBMB LIFE, V58, P39, DOI 10.1080/15216540500507408
   Lopez-Garcia E, 2006, AM J CLIN NUTR, V83, P674, DOI 10.1093/ajcn.83.3.674
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Maki KC, 2002, AM J CLIN NUTR, V76, P1230, DOI 10.1093/ajcn/76.6.1230
   MARKWELL MA, 1973, J BIOL CHEM, V248, P3426
   Michna L, 2003, LIFE SCI, V73, P1383, DOI 10.1016/S0024-3205(03)00468-5
   Nosaka Naohisa, 2003, J ATHEROSCLER THROMB, V10, P290
   OCHOA S, 1955, METHOD ENZYMOL, V1, P739, DOI 10.1016/0076-6879(55)01129-4
   Post SM, 2000, ARTERIOSCL THROM VAS, V20, P1551, DOI 10.1161/01.ATV.20.6.1551
   REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939
   ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129
   SPERRY WM, 1950, J BIOL CHEM, V187, P97
   Thom E, 2007, J INT MED RES, V35, P900, DOI 10.1177/147323000703500620
   Urgert R, 1997, ANNU REV NUTR, V17, P305, DOI 10.1146/annurev.nutr.17.1.305
   WALTON PA, 1985, ANAL BIOCHEM, V151, P479, DOI 10.1016/0003-2697(85)90208-8
   Zheng GD, 2004, IN VIVO, V18, P55
NR 31
TC 28
Z9 29
U1 0
U2 18
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1344-6606
EI 
J9 FOOD SCI TECHNOL RES
JI Food Sci. Technol. Res.
PD MAR 15
PY 2009
VL 15
IS 2
BP 147
EP 152
DI 10.3136/fstr.15.147
PG 6
WC Food Science & Technology
SC Food Science & Technology
GA 435MK
UT WOS:000265347800007
DA 2025-04-28
ER

PT J
AU Zych, M
   Folwarczna, J
   Trzeciak, HI
AF Zych, Maria
   Folwarczna, Joanna
   Trzeciak, Henryk I.
TI Natural phenolic acids may increase serum estradiol level in ovariectomized rats
SO ACTA BIOCHIMICA POLONICA
LA English
DT Article
DE ferulic acid; caffeic acid; p-coumaric acid; chlorogenic acid; estradiol; body mass; rat
ID p-coumaric acid; ferulic acid; bone loss; estrogen; receptor; leptin
AB Natural phenolic acids are commonly present in plants consumed in the diet. Recently we have observed that different natural phenolic acids exert differential effects on the body mass gain in ovariectomized and non-ovariectomized female rats. The aim of the present study was to investigate the effects of ferulic, caffeic, p-coumaric and chlorogenic acids on serum estradiol and total cholesterol levels in ovariectomized and non-ovariectomized rats. The experiments were carried out on 3-month old female Wistar Cmd:(WI)WU rats, divided into following groups (n=8 in each group): non-ovariectomized control rats and non-ovariectomized rats receiving ferulic, caffeic, p-coumaric or chlorogenic acids, sham-operated control rats, ovariectomized control rats and ovariectomized rats receiving the same phenolic acids. The phenolic acids were administered at a dose of 10 mg/kg p.o. daily for 4 weeks. Serum estradiol and total cholesterol levels on the next day after the last administration of the phenolic acids were examined. The phenolic acids did not affect serum estradiol or total cholesterol levels in non-ovariectomized rats. In ovariectomized rats, caffeic acid and to a lesser extent p-coumaric acid increased serum estradiol level, which effect correlated with a decreased body mass gain. All the phenolic acids decreased serum cholesterol level in ovariectomized rats. Concluding, the anti-obesity activity of some phenolic acids may be, at least partially, connected with estrogenic pathways.
C1 [Folwarczna, Joanna; Trzeciak, Henryk I.] Med Univ Silesia, Dept Pharmacol, PL-41200 Katowice, Sosnowiec, Poland.
   [Zych, Maria] Med Univ Silesia, Dept Pharmacognosy & Phytochem, PL-41200 Katowice, Sosnowiec, Poland.
C3 Medical University Silesia; Medical University Silesia
RP Folwarczna, J (corresponding author), Med Univ Silesia, Dept Pharmacol, Jagiellonska 4, PL-41200 Katowice, Sosnowiec, Poland.
EM jfolwarczna@sum.edu.pl
CR Ardiansyah, 2008, J AGR FOOD CHEM, V56, P2825, DOI 10.1021/jf072896y
   Balasubashini MS, 2003, ACTA DIABETOL, V40, P118, DOI 10.1007/s00592-003-0099-6
   Chang CJ, 2006, EUR J CLIN INVEST, V36, P588, DOI 10.1111/j.1365-2362.2006.01676.x
   Clegg DJ, 2006, DIABETES, V55, P978, DOI 10.2337/diabetes.55.04.06.db05-1339
   Folwarczna J, 2009, PLANTA MED, V75, P1567, DOI 10.1055/s-0029-1185904
   Hany J, 1999, TOXICOL APPL PHARM, V158, P231, DOI 10.1006/taap.1999.8710
   Hsu CL, 2008, MOL NUTR FOOD RES, V52, P53, DOI 10.1002/mnfr.200890019
   Innocenti G, 2007, PHYTOMEDICINE, V14, P147, DOI 10.1016/j.phymed.2006.05.005
   Jung EH, 2007, J AGR FOOD CHEM, V55, P9800, DOI 10.1021/jf0714463
   Kim HK, 2003, CLIN CHIM ACTA, V327, P129, DOI 10.1016/S0009-8981(02)00344-3
   Lafay S, 2005, INT J VITAM NUTR RES, V75, P119, DOI 10.1024/0300-9831.75.2.119
   Lee JS, 2003, ANN NUTR METAB, V47, P144, DOI 10.1159/000070037
   Lee JS, 2001, CLIN CHIM ACTA, V314, P221, DOI 10.1016/S0009-8981(01)00700-8
   Liang YQ, 2002, INT J OBESITY, V26, P1103, DOI 10.1038/sj.ijo.0802054
   Meli R, 2004, ENDOCRINOLOGY, V145, P3115, DOI 10.1210/en.2004-0129
   PAKRASHI A, 1979, EXPERIENTIA, V35, P843, DOI 10.1007/BF01968287
   Sassa S, 2003, IN VIVO, V17, P277
   Setchell KDR, 2003, AM J CLIN NUTR, V78, P593S, DOI 10.1093/ajcn/78.3.593S
   SHARMA RD, 1979, LIPIDS, V14, P535, DOI 10.1007/BF02533528
   Stalikas CD, 2007, J SEP SCI, V30, P3268, DOI 10.1002/jssc.200700261
   Stromeier S, 2005, PLANTA MED, V71, P495, DOI 10.1055/s-2005-864148
   Yamaguchi M, 2008, MOL CELL BIOCHEM, V311, P31, DOI 10.1007/s11010-007-9689-x
   Zang LY, 2000, AM J PHYSIOL-CELL PH, V279, PC954, DOI 10.1152/ajpcell.2000.279.4.C954
   ZYCH M, 2009, ADM CAFFEIC AC UNPUB, V0, P0
NR 24
TC 24
Z9 25
U1 0
U2 10
PU ACTA BIOCHIMICA POLONICA
PI WARSAW
PA PASTEURA 3, 02-093 WARSAW, POLAND
SN 0001-527X
EI 1734-154X
J9 ACTA BIOCHIM POL
JI Acta Biochim. Pol.
PD JUN 15
PY 2009
VL 56
IS 3
BP 503
EP 507
DI 
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 505AR
UT WOS:000270660500017
PM 19753332
DA 2025-04-28
ER

PT J
AU Hu, G
   Jousilahti, P
   Tuomilehto, J
   Antikainen, R
   Sundvall, J
   Salomaa, V
AF Hu, Gang
   Jousilahti, Pekka
   Tuomilehto, Jaakko
   Antikainen, Riitta
   Sundvall, Jouko
   Salomaa, Veikko
TI Association of Serum C-Reactive Protein Level with Sex-Specific Type 2 Diabetes Risk: A Prospective Finnish Study
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID time physical-activity; coronary-heart-disease; middle-aged men; leisure-time; coffee consumption; inflammatory markers; postmenopausal women; insulin-resistance; metabolic syndrome; mellitus
AB Objective: Our objective was to assess whether the association of serum C-reactive protein (CRP) with type 2 diabetes risk is modified by sex. Design and Subjects: We prospectively followed 12,861 Finnish men and women who were 35-74 yr of age, and free of diabetes, coronary heart disease, stroke, and cancer at baseline. Hazard ratios of type 2 diabetes were estimated for different levels of serum CRP. Results: During the follow-up, 208 men and 113 women developed diabetes. The multivariable-adjusted (age, physical activity, education, smoking, alcohol and coffee drinking, family history of diabetes, use of antihypertensive drugs, cholesterol-lowering agents, and hormone replacement therapy in women, systolic blood pressure, serum high-density lipoprotein cholesterol, serum triglycerides, and body mass index) hazard ratios of diabetes at three different levels of CRP (0.05-0.99, 1.0-2.99, and >= 3.0 mg/liter) based on the recommendation by Centers for Disease Control and the American Heart Association were 1.00, 1.46, and 1.85 (P for trend = 0.006) in men, and 1.00, 3.83, and 8.37 (P for trend <0.001) in women, respectively. CRP had a stronger association with diabetes risk in women than men (P for interaction: chi(2) = 6.42; 1 df; P < 0.025). This positive association between CRP and diabetes risk did not change when participants were stratified by age group, smoking status, level of obesity, alcohol drinking habit, or family history of diabetes. Conclusions: High baseline level of serum CRP was associated with an increased risk of diabetes among both men and women, but this association was stronger in women than men. (J Clin Endocrinol Metab 94: 2099-2105, 2009)
C1 [Hu, Gang] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Chron Dis Epidemiol Lab, Baton Rouge, LA 70808 USA.
   [Hu, Gang; Jousilahti, Pekka; Tuomilehto, Jaakko; Salomaa, Veikko] Natl Publ Hlth Inst, Dept Hlth Promot & Chron Dis Prevent, FIN-00300 Helsinki, Finland.
   [Sundvall, Jouko] Natl Publ Hlth Inst, Dept Hlth & Funct Capac, FIN-00300 Helsinki, Finland.
   [Hu, Gang; Tuomilehto, Jaakko] Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland.
   [Tuomilehto, Jaakko] S Ostrobothnia Cent Hosp, Seinajoki 60220, Finland.
   [Antikainen, Riitta] Oulu City Hosp, Oulu 90015, Finland.
   [Antikainen, Riitta] Univ London Imperial Coll Sci Technol & Med, Div Med, London W12 0NN, England.
C3 Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Finland National Institute for Health & Welfare; Finland National Institute for Health & Welfare; University of Helsinki; Imperial College London
RP Hu, G (corresponding author), Louisiana State Univ Syst, Pennington Biomed Res Ctr, Chron Dis Epidemiol Lab, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.
EM gang.hu@pbrc.edu
FU Finnish Academy [108297, 119681]; Finnish Foundation for Cardiovascular Research; Special Research Funds of the Social Welfare and Health Board, City of Oulu; Academy of Finland (AKA) [119681] Funding Source: Academy of Finland (AKA)
CR Unknown -, 1999, DEFINITION, V0, P0
   Bidel S, 2008, EUR J CLIN NUTR, V62, P178, DOI 10.1038/sj.ejcn.1602712
   COX DR, 1972, J R STAT SOC B, V187, P220
   Ding EL, 2006, JAMA-J AM MED ASSOC, V295, P1288, DOI 10.1001/jama.295.11.1288
   Doi Y, 2005, DIABETES CARE, V28, P2497, DOI 10.2337/diacare.28.10.2497
   Duncan BB, 2003, DIABETES, V52, P1799, DOI 10.2337/diabetes.52.7.1799
   Festa A, 2000, CIRCULATION, V102, P42, DOI 10.1161/01.CIR.102.1.42
   Folsom AR, 2005, EUR J EPIDEMIOL, V20, P1015, DOI 10.1007/s10654-005-3657-0
   Freeman DJ, 2002, DIABETES, V51, P1596, DOI 10.2337/diabetes.51.5.1596
   Han TS, 2002, DIABETES CARE, V25, P2016, DOI 10.2337/diacare.25.11.2016
   Hu FB, 2004, DIABETES, V53, P693, DOI 10.2337/diabetes.53.3.693
   Hu G, 2006, INT J OBESITY, V30, P1742, DOI 10.1038/sj.ijo.0803341
   Hu G, 2004, ARCH INTERN MED, V164, P892, DOI 10.1001/archinte.164.8.892
   Hu G, 2003, DIABETOLOGIA, V46, P322, DOI 10.1007/s00125-003-1031-x
   Hu G, 2004, CIRCULATION, V110, P666, DOI 10.1161/01.CIR.0000138102.23783.94
   Hu G, 2005, STROKE, V36, P1994, DOI 10.1161/01.STR.0000177868.89946.0c
   Hu G, 2007, ATHEROSCLEROSIS, V194, P490, DOI 10.1016/j.atherosclerosis.2006.08.051
   Hu G, 2007, EUR HEART J, V28, P492, DOI 10.1093/eurheartj/ehl475
   Laaksonen DE, 2004, DIABETOLOGIA, V47, P1403, DOI 10.1007/s00125-004-1472-x
   Liu S, 2007, ARCH INTERN MED, V167, P1676, DOI 10.1001/archinte.167.15.1676
   Nakanishi S, 2003, DIABETES CARE, V26, P2754, DOI 10.2337/diacare.26.10.2754
   PAJAK A, 1988, WORLD HEALTH STATISTICS QUARTERLY, V41, P115
   Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45
   Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327
   Snijder MB, 2003, DIABETES CARE, V26, P1656, DOI 10.2337/diacare.26.5.1656
   Thorand B, 2003, ARCH INTERN MED, V163, P93, DOI 10.1001/archinte.163.1.93
   Thorand B, 2007, DIABETES CARE, V30, P854, DOI 10.2337/dc06-1693
   Tuomilehto J, 2004, JAMA-J AM MED ASSOC, V291, P1213, DOI 10.1001/jama.291.10.1213
   Vartiainen E, 2000, INT J EPIDEMIOL, V29, P49, DOI 10.1093/ije/29.1.49
   Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972
NR 30
TC 48
Z9 51
U1 0
U2 1
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0021-972X
EI 
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUN 15
PY 2009
VL 94
IS 6
BP 2099
EP 2105
DI 10.1210/jc.2008-2260
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 453CM
UT WOS:000266587800038
PM 19318443
DA 2025-04-28
ER

PT J
AU Winkvist, A
   Hörnell, A
   Hallmans, G
   Lindahl, B
   Weinehall, L
   Johansson, I
AF Winkvist, Anna
   Hornell, Agneta
   Hallmans, Goran
   Lindahl, Bernt
   Weinehall, Lars
   Johansson, Ingegerd
TI More distinct food intake patterns among women than men in northern Sweden: a population-based survey
SO NUTRITION JOURNAL
LA English
DT Article
ID low-energy reporters; dietary patterns; cluster-analysis; validation; disease; adults; health
AB Background: The need to promote a healthy diet to curb the current obesity epidemic has today been recognized by most countries. A prerequisite for planning and evaluating interventions on dietary intake is the existence of valid information on long-term average dietary intake in a population. Few large, population-based studies of dietary intake have been carried out in Sweden. The largest to date is the Vasterbotten Intervention Program ( VIP), which was initiated in 1985, with data collection still ongoing. This paper reports on the first comprehensive analyses of the dietary data and presents dietary intake patterns among over 60,000 women and men in northern Sweden during 1992-2005. Methods: Between 1992 and 2005, 71,367 inhabitants in Vasterbotten county aged 30, 40, 50, and 60 years visited their local health care center as part of the VIP. Participants of VIP filled in an 84- or 64-item food frequency questionnaire (FFQ) and provided sociodemographic information. Complete and realistic information on consumption frequency was provided by 62,531 individuals. Food intake patterns were analyzed using K-means cluster analyses. Results: The mean daily energy intake was 6,83 (+/- 1,77) MJ among women and 8,71 (+/- 2,26) MJ among men. More than half of both women and men were classified as Low Energy Reporters ( defined as individuals reporting a food intake level below the lower 95% confidence interval limit of the physical activity level). Larger variation in frequency of daily intake was seen among women than among men for most food groups. Among women, four dietary clusters were identified, labeled "Fruit and vegetables", "High fat", "Coffee and sandwich", and "Tea and ice cream". Among men, three dietary clusters were identified, labeled "Fruit and vegetables", "High fat", and "Tea, soda and cookies". Conclusion: More distinct food intake patterns were seen among women than men in this study in northern Sweden. Due to large proportions of Low Energy Reporters, our results on dietary intake may not be suitable for comparisons with recommended intake levels. However, the results on food intake patterns should still be valid and useful as a basis for targeting interventions to groups most in need.
C1 [Winkvist, Anna] Univ Gothenburg, Sahlgrenska Acad, Dept Clin Nutr, Gothenburg, Sweden.
   [Hornell, Agneta] Umea Univ, Dept Food & Nutr, Umea, Sweden.
   [Hallmans, Goran] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden.
   [Lindahl, Bernt; Weinehall, Lars] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden.
   [Weinehall, Lars] Vasterbotten Cty Council, Dept Community Med, Umea, Sweden.
   [Johansson, Ingegerd] Umea Univ, Dept Odontol, Umea, Sweden.
C3 University of Gothenburg; Umea University; Umea University; Umea University; Umea University
RP Winkvist, A (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Dept Clin Nutr, Gothenburg, Sweden.
EM anna.winkvist@nutrition.gu.se; Agneta.Hornell@kost.umu.se; Goran.Hallmans@nutrires.umu.se; Bernt.Lindahl@medicin.umu.se; Lars.Weinehall@epiph.umu.se; Ingegerd.Johansson@odont.umu.se
FU Swedish Council for Working Life and Social Research; Swedish Cancer Society; Swedish Research Council; Wallenberg Foundation; Vasterbotten County Council, Sweden
CR Unknown -, 2004, GLOB STRAT DIET PHYS, V0, P0
   Bailey RL, 2007, J AM DIET ASSOC, V107, P64, DOI 10.1016/j.jada.2006.10.009
   Bergstrom L, 1991, VAR FODA, V43, P439
   Cade J, 2002, PUBLIC HEALTH NUTR, V5, P567, DOI 10.1079/PHN2001318
   Dodd KW, 2006, J AM DIET ASSOC, V106, P1640, DOI 10.1016/j.jada.2006.07.011
   FAO/WHO/UNU, 1985, TECHNICAL REPORT SERIES, V724, P0
   Gnardellis C, 1998, PUBLIC HEALTH NUTR, V1, P131, DOI 10.1079/PHN19980020
   GOLDBERG GR, 1991, EUR J CLIN NUTR, V45, P569
   HEITMANN BL, 1995, BRIT MED J, V311, P986
   Johansson G, 2008, INT J OBESITY, V32, P1031, DOI 10.1038/ijo.2008.42
   Johansson I, 2002, PUBLIC HEALTH NUTR, V5, P487, DOI 10.1079/PHN2001315
   Leite MLC, 2003, EUR J CLIN NUTR, V57, P1514, DOI 10.1038/sj.ejcn.1601719
   *LIVSM, 2002, DIET HAB NUTR INT SW, V0, P0
   *LIVSM, 1999, WEIGHT TABL, V0, P0
   Newby P, 2003, AM J CLIN NUTR, V77, P1417, DOI 10.1093/ajcn/77.6.1417
   *NORD COUNC MIN, 2006, NORD PLAN ACT BETT H, V0, P0
   Price GM, 1997, BRIT J NUTR, V77, P833, DOI 10.1079/BJN19970083
   Pryer JA, 1997, INT J EPIDEMIOL, V26, P146, DOI 10.1093/ije/26.1.146
   SCHOFIELD WN, 1985, HUM NUTR CLIN N C S1, V39, P1
   Villegas R, 2004, PUBLIC HEALTH NUTR, V7, P1017, DOI 10.1079/PHN2004638
   Weinehall L, 1998, SCAND J PRIM HEALTH, V16, P171
   WHO, 2003, WHO TECH REP SER, V916, P1
   *WHO, 2008, C REP 2007 COP DENM, V0, P0
   Wirfält E, 2000, PUBLIC HEALTH NUTR, V3, P159, DOI 10.1017/S1368980000000197
   World Cancer Research Fund, 2007, FOOD NUTR PHYS ACT P, V0, P0
NR 25
TC 39
Z9 39
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1475-2891
EI 
J9 NUTR J
JI Nutr. J.
PD FEB 19
PY 2009
VL 8
IS 
BP 
EP 
DI 10.1186/1475-2891-8-12
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 424YV
UT WOS:000264605100001
PM 19228378
DA 2025-04-28
ER

PT J
AU Hursel, R
   Westerterp-Plantenga, MS
AF Hursel, Rick
   Westerterp-Plantenga, Margriet S.
TI Green tea catechin plus caffeine supplementation to a high-protein diet has no additional effect on body weight maintenance after weight loss
SO AMERICAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
ID ischemic-heart-disease; energy-expenditure; follow-up; fat oxidation; black tea; antioxidant activity; double-blind; milk; obesity; ephedrine
AB Background: Green tea (epigallocatechin gallate + caffeine) and protein each were shown to improve body weight maintenance after weight loss. Objective: We investigated the effect of a green tea - caffeine mixture added to a high-protein (HP) diet on weight maintenance (WM) after body weight loss in moderately obese subjects. Design: A randomized, placebo-controlled, double-blind parallel trial was conducted in 80 overweight and moderately obese subjects [age (mean +/- SD): 44 +/- 2 y; body mass index (BMI; in kg/m(2)): 29.6 +/- 2.0] matched for sex, age, BMI, height, body mass, and with a habitually low caffeine intake. A very-low-energy diet intervention during 4 wk was followed by 3 mo of WM; during the WM period, the subjects received a green tea - caffeine mixture (270 mg epigallocatechin gallate + 150 mg caffeine/d) or placebo, both in addition to an adequate protein (AP) diet (50 - 60 g protein/d) or an HP diet (100 - 120 g protein/d). Results: Subjects lost 7.0 +/- 1.6 kg, or 8.2 +/- 2.0%, body weight (P < 0.001). During the WM phase, WM, resting energy expenditure, and fat-free mass (FFM) increased relatively in both the HP groups and in the AP + green tea - caffeine mixture group (P < 0.05), whereas respiratory quotient and body fat mass decreased, all compared with the AP + placebo group. Satiety increased only in both HP groups (P < 0.05). The green tea - caffeine mixture was only effective with the AP diet. Conclusion: The green tea - caffeine mixture, as well as the HP diet, improved WM independently through thermogenesis, fat oxidation, sparing FFM, and, for the HP diet, satiety; a possible synergistic effect failed to appear. Am J Clin Nutr 2009; 89: 822-30.
C1 [Hursel, Rick] Maastricht Univ, Dept Human Biol, NL-6200 MD Maastricht, Netherlands.
C3 Maastricht University
RP Hursel, R (corresponding author), Maastricht Univ, Dept Human Biol, POB 616, NL-6200 MD Maastricht, Netherlands.
EM rick.hursel@hb.unimaas.nl
FU NUTRIM; Maastricht University, Maastricht, Netherlands
CR ARCIERO PJ, 1995, AM J PHYSIOL-ENDOC M, V268, PE1192, DOI 10.1152/ajpendo.1995.268.6.E1192
   Arts MJTJ, 2002, J AGR FOOD CHEM, V50, P1184, DOI 10.1021/jf010855a
   Arts MJTJ, 2001, FOOD CHEM TOXICOL, V39, P787, DOI 10.1016/S0278-6915(01)00020-5
   ASTRUP A, 1992, INT J OBESITY, V16, P269
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   BORCHARDT RT, 1975, J MED CHEM, V18, P120, DOI 10.1021/jm00235a030
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   BROWN PJ, 1963, J CHROMATOGR, V11, P504, DOI 10.1016/S0021-9673(01)80953-5
   Diepvens K, 2006, PHYSIOL BEHAV, V87, P185, DOI 10.1016/j.physbeh.2005.09.013
   Diepvens K, 2005, BRIT J NUTR, V94, P1026, DOI 10.1079/BJN20051580
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   DULLOO AG, 1992, METABOLISM, V41, P1233, DOI 10.1016/0026-0495(92)90015-3
   Ekelund U, 2000, INT J SPORTS MED, V21, P586, DOI 10.1055/s-2000-8487
   GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397
   Goris AHC, 2001, AM J CLIN NUTR, V73, P549
   Harris JA, 1918, P NATL ACAD SCI USA, V4, P370, DOI 10.1073/pnas.4.12.370
   HASLAM E, 1974, BIOCHEM J, V139, P285, DOI 10.1042/bj1390285
   Herman CP, 1980, OBESITY, V0, P208
   Hertog MGL, 1997, AM J CLIN NUTR, V65, P1489, DOI 10.1093/ajcn/65.5.1489
   Hollman PCH, 2001, FREE RADICAL RES, V34, P297, DOI 10.1080/10715760100300261
   HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968
   Hulshof KFAM, 2003, EUR J CLIN NUTR, V57, P128, DOI 10.1038/sj.ejcn.1601503
   ISAKSSON B, 1980, AM J CLIN NUTR, V33, P4, DOI 10.1093/ajcn/33.1.4
   Jöbstl E, 2006, J AGR FOOD CHEM, V54, P4077, DOI 10.1021/jf053259f
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   Kovacs EMR, 2004, BRIT J NUTR, V91, P431, DOI 10.1079/BJN20041061
   KRAMER FM, 1989, INT J OBESITY, V13, P123
   KROMHOUT D, 1983, AM J CLIN NUTR, V38, P591, DOI 10.1093/ajcn/38.4.591
   Krul C, 2001, MUTAT RES-FUND MOL M, V474, P71, DOI 10.1016/S0027-5107(00)00158-5
   Langley-Evans SC, 2000, INT J FOOD SCI NUTR, V51, P181, DOI 10.1080/09637480050029683
   Leenen R, 2000, EUR J CLIN NUTR, V54, P87, DOI 10.1038/sj.ejcn.1600900
   Lejeune MPGM, 2005, BRIT J NUTR, V93, P281, DOI 10.1079/BJN20041305
   LICHTENBELT WDV, 1994, BRIT J NUTR, V72, P491, DOI 10.1079/BJN19940053
   Lorenz M, 2007, EUR HEART J, V28, P219, DOI 10.1093/eurheartj/ehl442
   LUCK G, 1994, PHYTOCHEMISTRY, V37, P357, DOI 10.1016/0031-9422(94)85061-5
   NIEUWENHUIZEN AG, 2008, BR J NUTR, V0, P0
   NOPPA H, 1980, AM J EPIDEMIOL, V111, P693, DOI 10.1093/oxfordjournals.aje.a112947
   Pasman WJ, 1997, INT J OBESITY, V21, P1143, DOI 10.1038/sj.ijo.0800528
   Pasman WJ, 1997, INT J OBESITY, V21, P548, DOI 10.1038/sj.ijo.0800439
   Pasman WJ, 1999, METABOLISM, V48, P15, DOI 10.1016/S0026-0495(99)90004-5
   Pichon L, 2008, BRIT J NUTR, V99, P739, DOI 10.1017/S0007114507831709
   Reddy VC, 2005, ANN NUTR METAB, V49, P189, DOI 10.1159/000087071
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   SCHOELLER DA, 1980, AM J CLIN NUTR, V33, P2686, DOI 10.1093/ajcn/33.12.2686
   Schoffelen PFM, 1997, J APPL PHYSIOL, V83, P2064, DOI 10.1152/jappl.1997.83.6.2064
   SEIDELL JC, 1995, OBES RES, V3, PS89, DOI 10.1002/j.1550-8528.1995.tb00451.x
   Serafini M, 1996, EUR J CLIN NUTR, V50, P28
   Siebert KJ, 1996, J AGR FOOD CHEM, V44, P80, DOI 10.1021/jf9502459
   STUNKARD AJ, 1985, J PSYCHOSOM RES, V29, P71, DOI 10.1016/0022-3999(85)90010-8
   TOUBRO S, 1993, INT J OBESITY, V17, P0
   Trayhurn P, 1999, INTERNATIONAL JOURNAL OF OBESITY, V23, P0
   van het Hof KH, 1998, EUR J CLIN NUTR, V52, P356, DOI 10.1038/sj.ejcn.1600568
   VanGaal LF, 1997, INT J OBESITY, V21, P0
   WADDEN TA, 1988, J CONSULT CLIN PSYCH, V56, P925, DOI 10.1037/0022-006X.56.6.925
   WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   Westerterp-Plantenga MS, 2004, INT J OBESITY, V28, P57, DOI 10.1038/sj.ijo.0802461
   Westerterp-Plantenga MS, 1998, INT J OBESITY, V22, P1, DOI 10.1038/sj.ijo.0800536
   Westerterp-Plantenga MS, 1999, EUR J CLIN NUTR, V53, P495, DOI 10.1038/sj.ejcn.1600782
   WING RR, 1992, AM J CLIN NUTR, V55, P1086, DOI 10.1093/ajcn/55.6.1086
NR 62
TC 65
Z9 69
U1 1
U2 28
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0002-9165
EI 1938-3207
J9 AM J CLIN NUTR
JI Am. J. Clin. Nutr.
PD MAR 1
PY 2009
VL 89
IS 3
BP 822
EP 830
DI 10.3945/ajcn.2008.27043
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 410IS
UT WOS:000263571300016
PM 19176733
DA 2025-04-28
ER

PT J
AU Zheng, J
   DiLorenzo, DJ
   McLaughlin, L
   Roberts, AT
   Greenway, FL
AF Zheng, Jolene
   DiLorenzo, Daniel J.
   McLaughlin, Leslie
   Roberts, Andrew T.
   Greenway, Frank L.
TI Stimulation of sympathetic innervation in the upper gastrointestinal tract as a treatment for obesity
SO MEDICAL HYPOTHESES
LA English
DT Article
AB Sympathetic activity and obesity have a reciprocal relationship. Firstly, hypothalamic obesity is associated with decreased sympathetic activity. Caffeine and ephedrine increase sympathetic activity and induce weight loss, of which 25% is due to increased metabolic rate and 75% is due to a reciprocally decreased food intake. Secondly, hormones and drugs that affect body weight have an inverse relationship between food intake and metabolic rate. Neuropepticle Y decreases sympathetic activity and increases food intake and body weight. Thirdly, a gastric pacemaker Transcend (R) and vagotorny increase the ratio of sympathetic to parasympathetic activation, decrease food intake, and block gut satiety hormones. Weight loss with the pacemaker or vagotomy is variable. Significant weight reduction is seen only in a small group of those treated. This suggests that activation of the sympathetic arm of the autonomic nervous system may be most important for weight loss. Systemic sympathetic activation causes weight loss in obese patients, but side effects limited its use. We hypothesize that selective local electrical sympathetic stimulation of the upper gastrointestinal tract may induce weight loss and offer a safer, yet effective, obesity treatment. Celiac ganglia delivers sympathetic innervation to the upper gastrointestinal tract. Voltage regulated electrical simulation of the rat celiac ganglia increased metabolic rate in a dose-dependent manner. Stimulation of 6, 3, or 1.5 V increased metabolic rate 15.6%, 6.2%, and 5%, respectively in a single rat. These responses support our hypothesis that selective sympathetic stimulation of the upper GI tract may treat obesity while avoiding side effects of systemic sympathetic activation. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Zheng, Jolene] Louisiana State Univ, Dept Vet Sci, AgCtr, Baton Rouge, LA 70803 USA.
   [DiLorenzo, Daniel J.] Methodist Hosp, Dept Neurosurg, Houston, TX 77030 USA.
   [DiLorenzo, Daniel J.] DiLorenzo Biomed LLC, Houston, TX USA.
   [McLaughlin, Leslie] Louisiana State Univ, Sch Vet Med, Dept Pathobiol Sci, Baton Rouge, LA 70803 USA.
   [DiLorenzo, Daniel J.] Biogen Idec Inc, Cambridge, MA USA.
   [Greenway, Frank L.] LSU Syst, Pennington Biomed Res Ctr, Clin Unit, Baton Rouge, LA 70803 USA.
   [Greenway, Frank L.] Louisiana State Univ, Humman Ecol Dept, AgCtr, Baton Rouge, LA 70803 USA.
C3 Louisiana State University System; Louisiana State University; Houston Methodist; Louisiana State University System; Louisiana State University; Louisiana State University School of Veterinary Medicine; Biogen; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Louisiana State University System; Louisiana State University
RP Zheng, J (corresponding author), Louisiana State Univ, Dept Vet Sci, AgCtr, HD Wilson Bldg,Room 110,S Stadium Dr, Baton Rouge, LA 70803 USA.
EM zhengz@lsu.edu
FU NIDDK NIH HHS [P30 DK072476-04, P30 DK072476] Funding Source: Medline
CR ASTRUP A, 1992, METABOLISM, V41, P686, DOI 10.1016/0026-0495(92)90304-S
   ASTRUP A, 1992, AM J CLIN NUTR, V55, P246
   ASTRUP A, 1992, INT J OBESITY, V0, P269
   BABINSKI M, 1900, REV NEUROL, V0, P531
   BERTHOUD HR, 1983, J AUTONOM NERV SYST, V7, P97, DOI 10.1016/0165-1838(83)90039-5
   BRAY GA, 1991, J NUTR, V121, P1146, DOI 10.1093/jn/121.8.1146
   BRAY GA, 1992, PROG BRAIN RES, V93, P333
   BRAY GA, 1989, VITAM HORM, V0, P1
   BRAY GA, 2000, INT J OBESITY, V0, PS8
   BRAY GA, 1975, MED BALTIMORE, V0, P301
   BRUCH H, 1939, OBES, V0, P329
   Camilleri M, 2008, SURGERY, V143, P723, DOI 10.1016/j.surg.2008.03.015
   Cigaina V, 2003, OBES RES, V11, P1456, DOI 10.1038/oby.2003.195
   Cigaina V, 1996, OBES SURG, V6, P250, DOI 10.1381/096089296765556854
   COCKEY CD, 2004, AWHONN LIFELINES, V0, P19
   DULLOO AG, 1993, INT J OBESITY, V17, P0
   ERDHEIM J, 1904, SITZUNGSB AKAD WISSE, V0, P537
   Flaa A, 2008, AM J CLIN NUTR, V87, P1596, DOI 10.1093/ajcn/87.6.1596
   Frohlich A, 1901, WIEN KLIN RUNDSCH, V15, P883
   GREENWAY FL, 2001, OBES REV, V0, P199
   GREENWAY FL, 2008, ENDOCR PRACT, V0, P0
   GREENWAY FL, 2007, J DIABETES SCI TECHN, V0, P251
   INOUE S, 1977, ENDOCRINOLOGY, V100, P108, DOI 10.1210/endo-100-1-108
   INOUE S, 1978, AM J PHYSIOL, V235, PE266, DOI 10.1152/ajpendo.1978.235.3.E266
   JEANRENAUD B, 1983, EXPERIENTIA S, V0, P57
   KING BM, 1982, NEUROSCI BIOBEHAV R, V6, P205, DOI 10.1016/0149-7634(82)90056-2
   KING BM, 2006, PHYSIOL BEHAV, V0, P221
   KRAL JG, 1979, SURG CLIN N AM, V59, P1131
   NIIJIMA A, 1984, AM J PHYSIOL, V247, PR650, DOI 10.1152/ajpregu.1984.247.4.R650
   PASQUALI R, 1992, CLIN SSCI LOND, V0, P85
   PERKINS MN, 1981, NATURE, V289, P401, DOI 10.1038/289401a0
   PORIES WJ, 1995, ANN SURG, V222, P339, DOI 10.1097/00000658-199509000-00011
   REEVES AG, 1969, ARCH NEUROL-CHICAGO, V0, P616
   SAKAGUCHI T, 1988, BRAIN RES BULL, V20, P461, DOI 10.1016/0361-9230(88)90135-9
   SAUTER JF, 1983, PFLUGERS ARCH, V0, P68
   SEYDOUX J, 1982, ENDOCRINOLOGY, V110, P432, DOI 10.1210/endo-110-2-432
   SHIMIZU H, 1989, AM J PHYSIOL, V256, PR494, DOI 10.1152/ajpregu.1989.256.2.R494
   SMITH DK, 1983, LANCET, V1, P1330
   TOKUNAGA K, 1986, ENDOCRINOLOGY, V119, P1708, DOI 10.1210/endo-119-4-1708
   VANDERTUIG JG, 1982, LIFE SCI, V30, P913, DOI 10.1016/0024-3205(82)90619-1
   YORK DA, 1972, ENDOCRINOLOGY, V90, P885, DOI 10.1210/endo-90-4-885
   YOSHIDA T, 1984, AM J PHYSIOL, V246, PR558, DOI 10.1152/ajpregu.1984.246.4.R558
NR 42
TC 8
Z9 9
U1 0
U2 3
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUN 15
PY 2009
VL 72
IS 6
BP 706
EP 710
DI 10.1016/j.mehy.2008.12.046
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 437GF
UT WOS:000265474100023
PM 19246162
DA 2025-04-28
ER

PT J
AU Huang, C
   Dumanovsky, T
   Silver, LD
   Nonas, C
   Bassett, MT
AF Huang, Christina
   Dumanovsky, Tamara
   Silver, Lynn D.
   Nonas, Cathy
   Bassett, Mary T.
TI Calories From Beverages Purchased at 2 Major Coffee Chains in New York City, 2007
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID portion size; energy-intake; consumption; food; meal; overweight; weight; women
AB Introduction Calorie intake from beverages has increased in the past decades, which most likely contributes to higher obesity rates. Although coffee chains have grown in popularity in recent years, few data examine the calorie contribution of these drinks. We examined afternoon beverage purchases in New York City at 2 major coffee chains and estimated the mean calorie content of these beverages. Methods We collected purchase receipts and brief surveys from adult customers at 42 Starbucks and 73 Dunkin' Donuts stores during the spring of 2007. For each purchase, we obtained the calorie content from the company's Web site; these values were adjusted to account for self-reported customization of the drink. Results We included 1,127 beverage purchases at Starbucks and 1,830 at Dunkin' Donuts in our analyses. Brewed coffee or tea averaged 63 kcal, and blended coffee beverages averaged 239 kcal. Approximately two-thirds of purchases at Starbucks and one-fourth of purchases at Dunkin' Donuts were blended coffee beverages. Conclusion Calories in blended coffee beverages are high; on average, customers bought 12% of a 2,000-kcal diet. Policy changes to provide for calorie posting at the point of purchase could increase customer awareness of the calories in these beverages; modifying standard formulations of blended coffee beverages, such as using low-fat milk or smaller serving sizes, would also reduce calorie content.
C1 [Huang, Christina; Dumanovsky, Tamara; Silver, Lynn D.; Nonas, Cathy; Bassett, Mary T.] New York City Dept Hlth & Mental Hyg, New York, NY 10007 USA.
   [Bassett, Mary T.] Doris Duke Charitable Fdn, New York, NY USA.
C3 New York City Department of Health & Mental Hygiene
RP Huang, C (corresponding author), New York City Dept Hlth & Mental Hyg, 2 Lafayette St,20th Fl,CN 46, New York, NY 10007 USA.
EM chuang@health.nyc.gov
FU New York City DOHMH
CR Almiron-Roig E, 2003, PHYSIOL BEHAV, V79, P767, DOI 10.1016/S0031-9384(03)00212-9
   Unknown -, 2007, STARB MOV RED MILK, V0, P0
   Bassett MT, 2008, AM J PUBLIC HEALTH, V98, P1457, DOI 10.2105/AJPH.2008.135020
   DellaValle DM, 2005, APPETITE, V44, P187, DOI 10.1016/j.appet.2004.11.003
   Diliberti N, 2004, OBES RES, V12, P562, DOI 10.1038/oby.2004.64
   DiMeglio DP, 2000, INT J OBESITY, V24, P794, DOI 10.1038/sj.ijo.0801229
   Duffey KJ, 2007, OBESITY, V15, P2739, DOI 10.1038/oby.2007.326
   Flood JE, 2006, J AM DIET ASSOC, V106, P1984, DOI 10.1016/j.jada.2006.09.005
   Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847
   Higdon JV, 2006, CRIT REV FOOD SCI, V46, P101, DOI 10.1080/10408390500400009
   Jeffery RW, 2007, INT J BEHAV NUTR PHY, V4, P0, DOI 10.1186/1479-5868-4-27
   National Coffee Association, 2007, NAT COFF DRINK TREND, V0, P0
   Nielsen SJ, 2004, AM J PREV MED, V27, P205, DOI 10.1016/j.amepre.2004.05.005
   Popkin BM, 2006, AM J CLIN NUTR, V83, P529, DOI 10.1093/ajcn.83.3.529
   Raynor HA, 2007, OBESITY, V15, P2311, DOI 10.1038/oby.2007.274
   Roberts M, 2005, NYC VITAL SIGNS, V4, P1
   Rolls BJ, 2002, AM J CLIN NUTR, V76, P1207, DOI 10.1093/ajcn/76.6.1207
   Shields DH, 2004, J AM DIET ASSOC, V104, P650, DOI 10.1016/j.jada.2004.01.015
   Wansink B, 2005, OBES RES, V13, P93, DOI 10.1038/oby.2005.12
   Wansink B, 2005, J NUTR EDUC BEHAV, V37, P242, DOI 10.1016/S1499-4046(06)60278-9
NR 21
TC 6
Z9 7
U1 0
U2 10
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
EI 
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD OCT 15
PY 2009
VL 6
IS 4
BP 
EP 
DI 
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA V20RY
UT WOS:000208158300008
PM 19754994
DA 2025-04-28
ER

PT J
AU Rashti, SL
   Ratamess, NA
   Kang, J
   Faigenbaum, AD
   Chilakos, A
   Hoffman, JR
AF Rashti, Stefanie L.
   Ratamess, Nicholas A.
   Kang, Jie
   Faigenbaum, Avery D.
   Chilakos, Aristomen
   Hoffman, Jay R.
TI Thermogenic effect of meltdown RTD™ energy drink in young healthy women: a double blind, cross-over design study
SO LIPIDS IN HEALTH AND DISEASE
LA English
DT Article
ID metabolic-rate; beta-phenylethylamine; supplement meltdown; herbal supplement; body-weight; caffeine; expenditure; lipolysis; obesity; glucose
AB Background: The purpose of this study was to examine the acute metabolic effects of a high-energy drink in healthy, physically-active women. Methods: Ten women (20.4 +/- 0.70 y; 166.9 +/- 7.2 cm; 67.0 +/- 7.0 kg; 29.6 +/- 6.5% body fat) underwent two testing sessions administered in a randomized and double-blind fashion. Subjects reported to the laboratory in a 3-hr post-absorptive state and were provided either 140 ml of the high-energy drink (SUP; commercially marketed as Meltdown RTD (TM) or placebo (P). Subjects consumed two 70 ml doses of SUP or P, separated by 30 min and rested in a semi-recumbent position for 3 hours. Resting oxygen consumption (VO2) and heart rate (HR) were determined every 5 min during the first 30 min and every 10 min during the next 150 min. Blood pressure (BP) was determined every 15 min during the first 30 min and every 30 min thereafter. Area under the curve (AUC) analysis was computed for VO2, whereas a 3-hour average and hourly averages were calculated for respiratory quotient (RQ), total kcal, HR, BP, and profile of mood states (POMS). Results: AUC analysis revealed a 10.8% difference (p = 0.03) in VO2 between SUP and P. No difference in VO2 was seen between the groups in the first hour, but VO2 in SUP was significantly greater than P in the second (13.9%, p = 0.01) and third hours (11.9%, p = 0.03). A difference (p = 0.03) in energy expenditure was seen between SUP (1.09 +/- 0.10 kcal.min(-1)) and P (0.99 +/- 0.09 kcal.min(-1)) for the 3-hour period. Although no difference in energy expenditure was seen in the first hour, significant differences between SUP and P were observed in the second (1.10 +/- 0.11 kcal.min(-1) and 0.99 +/- 0.09 kcal.min(-1), respectively; p = 0.02) and third hour (1.08 +/- 0.11 kcal.min(-1) and 0.99 +/- 0.09 kcal.min(-1), respectively; p = 0.05). Average systolic BP was significantly higher (p = 0.007) for SUP (110.0 +/- 3.9 mmHg) compared to P (107.3 +/- 4.4 mmHg). No differences were seen in HR, diastolic BP, or POMS at any time point. Conclusions: Results showed a significant increase in energy expenditure in young, healthy women following an acute ingestion of a high-energy drink.
C1 [Rashti, Stefanie L.; Ratamess, Nicholas A.; Kang, Jie; Faigenbaum, Avery D.; Chilakos, Aristomen; Hoffman, Jay R.] Coll New Jersey, Ewing, NJ 08628 USA.
C3 College of New Jersey
RP Hoffman, JR (corresponding author), Coll New Jersey, Ewing, NJ 08628 USA.
EM rashti2@tcnj.edu; ratamess@tcnj.edu; kang@tcnj.edu; faigenba@tcnj.edu; chilako@tcnj.edu; hoffmanj@tcnj.edu
FU Vital Pharmaceuticals, Inc
CR ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   Bell A, 2004, J ADOLESCENT HEALTH, V34, P508, DOI 10.1016/j.jadohealth.2003.07.024
   Belza A, 2009, EUR J CLIN NUTR, V63, P57, DOI 10.1038/sj.ejcn.1602901
   BERLAN M, 1993, BRIT J PHARMACOL, V108, P927, DOI 10.1111/j.1476-5381.1993.tb13488.x
   Bloomer RJ, 2009, LIPIDS HEALTH DIS, V8, P0, DOI 10.1186/1476-511X-8-32
   Bloomer RJ, 2009, J INT SOC SPORT NUTR, V6, P0, DOI 10.1186/1550-2783-6-4
   Dodge TL, 2006, J ADOLESCENT HEALTH, V39, P367, DOI 10.1016/j.jadohealth.2005.12.025
   DOURISH CT, 1981, PROG NEURO-PSYCHOPHA, V5, P411, DOI 10.1016/0364-7722(81)90093-X
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Finnegan D, 2003, NUTRITION BULLETIN, V28, P147, DOI 10.1046/j.1467-3010.2003.00345.x
   Fugh-Berman A, 2004, EXP BIOL MED, V229, P698, DOI 10.1177/153537020422900802
   GALITZKY J, 1988, EUR J CLIN INVEST, V18, P587, DOI 10.1111/j.1365-2362.1988.tb01272.x
   Galuska DA, 2008, MORBIDITY AND MORTALITY WEEKLY REPORT, V57, P765
   Greenway FL, 2004, OBES RES, V12, P1152, DOI 10.1038/oby.2004.144
   Haller CA, 2004, CLIN PHARMACOL THER, V75, P259, DOI 10.1016/j.clpt.2003.11.375
   Heck CI, 2007, J FOOD SCI, V72, PR138, DOI 10.1111/j.1750-3841.2007.00535.x
   Hoffman JR, 2008, MED SCI SPORT EXER, V40, P15, DOI 10.1249/mss.0b013e31815a5181
   Hoffman JR, 2009, J INT SOC SPORT NUTR, V6, P0, DOI 10.1186/1550-2783-6-2
   Hoffman JR, 2009, J INT SOC SPORT NUTR, V6, P0, DOI 10.1186/1550-2783-6-1
   Hoffman Jay R, 2006, J INT SOC SPORTS NUTR, V3, P35, DOI 10.1186/1550-2783-3-1-35
   HOFSTETTER R, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1844
   Jitomir J, 2008, J INT SOC SPORT NUTR, V5, P0, DOI 10.1186/1550-2783-5-23
   LAFONTAN M, 1992, AM J CLIN NUTR, V55, P219
   Li C, 2007, OBESITY, V15, P216, DOI 10.1038/oby.2007.505
   Martyn-Nemeth P, 2009, RES NURS HEALTH, V32, P96, DOI 10.1002/nur.20304
   McNair D, 1971, MANUAL FOR THE PROFILE OF MOOD STATES, V0, P0, DOI DOI 10.5665/SLEEP.1272
   Nakamura M, 1998, EUR J PHARMACOL, V349, P163, DOI 10.1016/S0014-2999(98)00191-5
   Pang J, 2008, ARCH BIOCHEM BIOPHYS, V476, P178, DOI 10.1016/j.abb.2008.02.019
   Pittler MH, 2004, AM J CLIN NUTR, V79, P529
   Roberts AT, 2005, ALTERN MED REV, V10, P321
   Sabelli H, 1996, J NEUROPSYCH CLIN N, V8, P168
   Scholey AB, 2004, PSYCHOPHARMACOLOGY, V176, P320, DOI 10.1007/s00213-004-1935-2
   Smit HJ, 2004, NUTR NEUROSCI, V7, P127, DOI 10.1080/10284150400003041
   Smith A, 2002, FOOD CHEM TOXICOL, V40, P1243, DOI 10.1016/S0278-6915(02)00096-0
   Vaagenes H, 1999, BIOCHEM PHARMACOL, V58, P1133, DOI 10.1016/S0006-2952(99)00198-7
   Vukovich MD, 2005, CLIN EXP PHARMACOL P, V32, P47, DOI 10.1111/j.1440-1681.2005.04152.x
   Yach D, 2006, NAT MED, V12, P62, DOI 10.1038/nm0106-62
NR 38
TC 23
Z9 26
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1476-511X
J9 LIPIDS HEALTH DIS
JI Lipids Health Dis.
PD DEC 17
PY 2009
VL 8
IS 
BP 
EP 
DI 10.1186/1476-511X-8-57
PG 7
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA 543SN
UT WOS:000273598800002
PM 20017916
DA 2025-04-28
ER

PT J
AU Bondia-Pons, I
   Aura, AM
   Vuorela, S
   Kolehmainen, M
   Mykkänen, H
   Poutanen, K
AF Bondia-Pons, Isabel
   Aura, Anna-Marja
   Vuorela, Satu
   Kolehmainen, Marjukka
   Mykkanen, Hannu
   Poutanen, Kaisa
TI Rye phenolics in nutrition and health
SO JOURNAL OF CEREAL SCIENCE
LA English
DT Review
DE Rye; Health; Phenolic; Phytochemical; Antioxidant
ID whole-grain wheat; ferulic acid dehydrodimers; mammalian lignans enterolactone; vitro antioxidant activity; mass-spectrometric method; human fecal microbiota; in-vitro; cereal alkylresorcinols; chlorogenic acid; dietary-fiber
AB Dietary intake of whole-grain foods is associated with a decreased risk of chronic diseases such as diabetes, obesity and heart disease. In addition to dietary fibre, various phytochemicals have been suggested to contribute to the health effects of whole grain products. This review focuses on phenolic compounds in rye (Secale cereale L.), which is one of the major bread grains in Europe. Data on phenolic concentrations in rye grain and foods, their bioavailability to tissues and effects in vivo, and their potential contributions to health are presented. Phenolic compounds in rye, such as phenolic acids, alkylresorcinols and lignans, are concentrated in the outer layers of the grain. Phenolic acids are the major phenolic compounds in whole grain rye (103-300 mg/100 g grain), ferulic acid being the most abundant. Rye lignans are present at concentrations of 2 mg/100 g grain and had been shown to be converted by the intestinal microflora to the mammalian lignans enterodiol and enterolactone in human intervention studies. Alkylresorcinols (36-320 mg/100 g grain), which have been found to be incorporated into human erythrocyte membranes, are of particular interest due to their potential use as biomarkers of the intake of rye and wheat. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Bondia-Pons, Isabel; Kolehmainen, Marjukka; Mykkanen, Hannu; Poutanen, Kaisa] Univ Kuopio, Dept Clin Nutr, Food & Hlth Res Ctr, FIN-70211 Kuopio, Finland.
   [Aura, Anna-Marja; Vuorela, Satu; Poutanen, Kaisa] VIT Tech Res Ctr Finland, FIN-02044 Espoo, Finland.
C3 University of Eastern Finland; VTT Technical Research Center Finland
RP Poutanen, K (corresponding author), Univ Kuopio, Dept Clin Nutr, Food & Hlth Res Ctr, POB 1627, FIN-70211 Kuopio, Finland.
EM kaisa.poutanen@vtt.fi
FU Fundacion Alfonso Martin Escudero; Academy of Finland [209445]; Academy of Finland (AKA) [209445] Funding Source: Academy of Finland (AKA)
CR ADLERCREUTZ H, 1995, J STEROID BIOCHEM, V52, P97, DOI 10.1016/0960-0760(94)00146-D
   Adlercreutz H, 2007, CRIT REV CL LAB SCI, V44, P483, DOI 10.1080/10408360701612942
   Adom KK, 2002, J AGR FOOD CHEM, V50, P6182, DOI 10.1021/jf0205099
   Andreasen MF, 2001, FREE RADICAL BIO MED, V31, P304, DOI 10.1016/S0891-5849(01)00585-8
   Andreasen MF, 2001, J AGR FOOD CHEM, V49, P5679, DOI 10.1021/jf010668c
   Andreasen MF, 2001, J AGR FOOD CHEM, V49, P4090, DOI 10.1021/jf0101758
   Andreasen MF, 2000, J AGR FOOD CHEM, V48, P2837, DOI 10.1021/jf991266w
   Andreasen MF, 2000, J CEREAL SCI, V31, P303, DOI 10.1006/jcrs.1999.0296
   Aura AM, 2006, EUR J NUTR, V45, P45, DOI 10.1007/s00394-005-0561-z
   Aura AM, 2005, J SCI FOOD AGR, V85, P2085, DOI 10.1002/jsfa.2229
   AXELSON M, 1981, FEBS LETT, V123, P337, DOI 10.1016/0014-5793(81)80322-5
   Barron C, 2007, J CEREAL SCI, V45, P88, DOI 10.1016/j.jcs.2006.07.004
   Basly JP, 2005, PLANTA MED, V71, P287, DOI 10.1055/s-2005-864092
   Begum AN, 2004, J NUTR, V134, P120, DOI 10.1093/jn/134.1.120
   Bhathena SJ, 2002, AM J CLIN NUTR, V76, P1191, DOI 10.1093/ajcn/76.6.1191
   Blaut M, 2007, J NUTR, V137, P751S, DOI 10.1093/jn/137.3.751S
   BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25
   Bylund A, 2000, PROSTATE, V42, P304, DOI 10.1002/(SICI)1097-0045(20000301)42:4<304::AID-PROS8>3.0.CO;2-Z
   Cassidy A, 2000, J SCI FOOD AGR, V80, P1044, DOI 10.1002/(SICI)1097-0010(20000515)80:7<1044::AID-JSFA586>3.3.CO;2-E
   Chen JH, 1997, J AGR FOOD CHEM, V45, P2374, DOI 10.1021/jf970055t
   Chen Y, 2004, J AGR FOOD CHEM, V52, P8242, DOI 10.1021/jf049726v
   Chesson A, 1999, J SCI FOOD AGR, V79, P373, DOI 10.1002/(SICI)1097-0010(19990301)79:3<373::AID-JSFA257>3.0.CO;2-6
   Couteau D, 2001, J APPL MICROBIOL, V90, P873, DOI 10.1046/j.1365-2672.2001.01316.x
   Cyran MR, 2007, J AGR FOOD CHEM, V55, P2329, DOI 10.1021/jf062473g
   de Munter JSL, 2007, PLOS MED, V4, P1385, DOI 10.1371/journal.pmed.0040261
   Deszcz L, 1997, CELL MOL BIOL LETT, V2, P213
   DEWICK PM, 2001, NAT PROD REP, V18, P334
   Frankel EN, 2000, J SCI FOOD AGR, V80, P1925, DOI 10.1002/1097-0010(200010)80:13<1925::AID-JSFA714>3.0.CO;2-4
   Gallardo C, 2006, FOOD CHEM, V99, P455, DOI 10.1016/j.foodchem.2005.07.053
   Gasiorowski K, 1996, CANCER LETT, V106, P109, DOI 10.1016/0304-3835(96)04294-2
   Gasiorowski K, 2001, CELL MOL BIOL LETT, V6, P141
   Glitso LV, 2000, BRIT J NUTR, V84, P429
   Glitso LV, 1999, J CEREAL SCI, V29, P89, DOI 10.1006/jcrs.1998.0214
   Gonthier MP, 2006, BIOMED PHARMACOTHER, V60, P536, DOI 10.1016/j.biopha.2006.07.084
   Gonthier MP, 2003, J NUTR, V133, P1853, DOI 10.1093/jn/133.6.1853
   Hall C, 2006, ADV FOOD NUTR RES, V51, P1, DOI 10.1016/S1043-4526(06)51001-0
   Harder H, 2004, EUR J NUTR, V43, P230, DOI 10.1007/s00394-004-0463-5
   Heiniö RL, 2008, J CEREAL SCI, V47, P566, DOI 10.1016/j.jcs.2007.06.018
   Heiniö RL, 2003, LEBENSM-WISS TECHNOL, V36, P533, DOI 10.1016/S0023-6438(03)00057-4
   Heinonen S, 2001, J AGR FOOD CHEM, V49, P3178, DOI 10.1021/jf010038a
   HENGTRAKUL P, 1991, J NUTR BIOCHEM, V2, P20, DOI 10.1016/0955-2863(91)90044-6
   Jacobs DR, 2007, AM J CLIN NUTR, V85, P1606, DOI 10.1093/ajcn/85.6.1606
   Jacobs E, 1999, J STEROID BIOCHEM, V68, P211, DOI 10.1016/S0960-0760(99)00033-3
   Jensen MK, 2006, AM J CLIN NUTR, V83, P275
   Ji XF, 2008, PHYTOCHEMISTRY, V69, P1197, DOI 10.1016/j.phytochem.2007.12.008
   Johnsen NF, 2004, J NUTR, V134, P2691, DOI 10.1093/jn/134.10.2691
   Juntunen KS, 2000, BRIT J NUTR, V84, P839
   KANGAS L, 2002, EUROPEAN J CANC P S2, V11, P0
   Kariluoto S, 2006, J AGR FOOD CHEM, V54, P9522, DOI 10.1021/jf061734j
   Karppinen S, 2000, J SCI FOOD AGR, V80, P1469, DOI 10.1002/1097-0010(200008)80:10<1469::AID-JSFA675>3.0.CO;2-A
   Katcher HI, 2008, AM J CLIN NUTR, V87, P79, DOI 10.1093/ajcn/87.1.79
   Katina K, 2007, J CEREAL SCI, V46, P348, DOI 10.1016/j.jcs.2007.07.006
   Katina K, 2007, FOOD MICROBIOL, V24, P175, DOI 10.1016/j.fm.2006.07.012
   Katina K, 2006, LWT-FOOD SCI TECHNOL, V39, P479, DOI 10.1016/j.lwt.2005.03.013
   Kaukovirta-Norja A, 2004, AGR FOOD SCI, V13, P100, DOI 10.2137/1239099041838049
   Kern SM, 2003, J AGR FOOD CHEM, V51, P7884, DOI 10.1021/jf030470n
   Kilkkinen A, 2003, J NUTR, V133, P1830, DOI 10.1093/jn/133.6.1830
   Kilkkinen A, 2001, AM J CLIN NUTR, V73, P1094
   Kitts DD, 1999, MOL CELL BIOCHEM, V202, P91, DOI 10.1023/A:1007022329660
   Knudsen KEB, 2003, J NUTR, V133, P1368
   Konishi Y, 2004, J AGR FOOD CHEM, V52, P6418, DOI 10.1021/jf049560y
   KOZUBEK A, 1992, Z NATURFORSCH C, V47, P608
   Kozubek A, 1999, CHEM REV, V99, P1, DOI 10.1021/cr970464o
   KOZUBEK A, 1995, ACTA BIOCHIM POL, V42, P247
   KOZUBEK A, 1989, ACTA U WRATISL, V868, P27
   Kroon PA, 1997, J AGR FOOD CHEM, V45, P661, DOI 10.1021/jf9604403
   Kuijsten A, 2005, J NUTR, V135, P795, DOI 10.1093/jn/135.4.795
   Lampe JW, 2003, J NUTR, V133, P956S, DOI 10.1093/jn/133.3.956S
   Landberg R, 2008, AM J CLIN NUTR, V87, P832, DOI 10.1093/ajcn/87.4.832
   Landberg R, 2006, J NUTR, V136, P2760, DOI 10.1093/jn/136.11.2760
   Liggins J, 2000, ANAL BIOCHEM, V287, P102, DOI 10.1006/abio.2000.4811
   Linko AM, 2006, BRIT J NUTR, V95, P282, DOI 10.1079/BJN20051642
   Linko AM, 2005, J NUTR, V135, P580, DOI 10.1093/jn/135.3.580
   Linko AM, 2002, ANAL BIOCHEM, V308, P307, DOI 10.1016/S0003-2697(02)00226-9
   Linko-Parvinen AM, 2007, J NUTR, V137, P1137, DOI 10.1093/jn/137.5.1137
   Liukkonen KH, 2003, P NUTR SOC, V62, P117, DOI 10.1079/PNS2002218
   Lof M, 2006, NUTR RES, V26, P609, DOI 10.1016/j.nutres.2006.09.020
   Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727
   Manach C, 2005, CURR OPIN LIPIDOL, V16, P77, DOI 10.1097/00041433-200502000-00013
   Mattila P, 2005, J AGR FOOD CHEM, V53, P8290, DOI 10.1021/jf051437z
   Mazur W, 1998, PURE APPL CHEM, V70, P1759, DOI 10.1351/pac199870091759
   Mazur W, 1996, ANAL BIOCHEM, V233, P169, DOI 10.1006/abio.1996.0025
   Mazur W, 2000, THESIS, V0, P0
   Mellen PB, 2008, NUTR METAB CARDIOVAS, V18, P283, DOI 10.1016/j.numecd.2006.12.008
   Mellen PB, 2007, AM J CLIN NUTR, V85, P1495, DOI 10.1093/ajcn/85.6.1495
   Meyer AS, 1998, J AGR FOOD CHEM, V46, P1783, DOI 10.1021/jf9708960
   Michalska A, 2007, J AGR FOOD CHEM, V55, P734, DOI 10.1021/jf062425w
   Milder IEJ, 2005, BRIT J NUTR, V93, P393, DOI 10.1079/BJN20051371
   Milder IEJ, 2004, J AGR FOOD CHEM, V52, P4643, DOI 10.1021/jf0497556
   Milder IEJ, 2007, J NUTR, V137, P1266, DOI 10.1093/jn/137.5.1266
   Morelló JR, 2005, J AGR FOOD CHEM, V53, P2002, DOI 10.1021/jf048386a
   Natella F, 1999, J AGR FOOD CHEM, V47, P1453, DOI 10.1021/jf980737w
   Niemeyer HB, 2003, J FOOD ENG, V56, P255, DOI 10.1016/S0260-8774(02)00263-7
   Nienartowicz Barbara, 1993, POLISH JOURNAL OF FOOD AND NUTRITION SCIENCES, V2, P51
   Nilsson M, 1997, J SCI FOOD AGR, V73, P143, DOI 10.1002/(SICI)1097-0010(199702)73:2<143::AID-JSFA698>3.0.CO;2-H
   Nyström L, 2005, J AGR FOOD CHEM, V53, P2503, DOI 10.1021/jf048051t
   NYSTROM L, 2007, OCURRENCE PROPERTIES, V0, P1
   Nyström L, 2008, J AGR FOOD CHEM, V56, P9758, DOI 10.1021/jf801065r
   Ohta T, 1997, BIOSCI BIOTECH BIOCH, V61, P1942, DOI 10.1271/bbb.61.1942
   Olthof MR, 2003, J NUTR, V133, P1806, DOI 10.1093/jn/133.6.1806
   Ovaskainen ML, 2008, J NUTR, V138, P562
   Parikka K, 2006, J AGR FOOD CHEM, V54, P1646, DOI 10.1021/jf052486e
   Pekkarinen SS, 1999, J AGR FOOD CHEM, V47, P3036, DOI 10.1021/jf9813236
   Peñalvo JL, 2005, J AGR FOOD CHEM, V53, P9342, DOI 10.1021/jf051488w
   Plumb GW, 1999, J SCI FOOD AGR, V79, P390, DOI 10.1002/(SICI)1097-0010(19990301)79:3<390::AID-JSFA258>3.0.CO;2-0
   Rejman J, 2004, J AGR FOOD CHEM, V52, P246, DOI 10.1021/jf034745a
   REJMAN J, 1997, CELL MOL BIOL LETT, V2, P411
   Rickard SE, 1996, J NUTR, V126, P2012
   Roberts MS, 2002, CLIN PHARMACOKINET, V41, P751, DOI 10.2165/00003088-200241100-00005
   Rondini L, 2004, J AGR FOOD CHEM, V52, P4338, DOI 10.1021/jf0348323
   Rondini L, 2002, J AGR FOOD CHEM, V50, P3037, DOI 10.1021/jf011295i
   Ross AB, 2005, BRIT J NUTR, V94, P496, DOI 10.1079/BJN20051511
   Ross AB, 2004, NUTR REV, V62, P81, DOI 10.1301/nr.2004.mar.81-95
   Ross AB, 2004, J CHROMATOGR B, V809, P125, DOI 10.1016/j.jchromb.2004.06.015
   Ross AB, 2004, J NUTR, V134, P506, DOI 10.1093/jn/134.3.506
   Ross AB, 2003, BRIT J NUTR, V90, P787, DOI 10.1079/BJN2003965
   Ross AB, 2003, J NUTR, V133, P2222, DOI 10.1093/jn/133.7.2222
   Ross AB, 2003, J AGR FOOD CHEM, V51, P4111, DOI 10.1021/jf0340456
   Ross AB, 2001, J SCI FOOD AGR, V81, P1405, DOI 10.1002/jsfa.956
   Rowland I, 2003, BRIT J NUTR, V89, PS45, DOI 10.1079/BJN2002796
   RYBKA K, 1993, CEREAL CHEM, V70, P55
   Saarinen NM, 2000, NUTR CANCER, V36, P207, DOI 10.1207/S15327914NC3602_10
   Saarinen NM, 2002, J CHROMATOGR B, V777, P311, DOI 10.1016/S1570-0232(02)00339-2
   Salmenkallio-Marttila M, 2001, CEREAL CHEM, V78, P429, DOI 10.1094/CCHEM.2001.78.4.429
   Scalbert A, 2002, BIOMED PHARMACOTHER, V56, P276, DOI 10.1016/S0753-3322(02)00205-6
   SEITZ LM, 1992, J AGR FOOD CHEM, V40, P1541, DOI 10.1021/jf00021a014
   SETCHELL KDR, 1981, LANCET, V2, P4
   Singh M, 2008, J AGR FOOD CHEM, V56, P4855, DOI 10.1021/jf0735073
   Slavin J, 2003, P NUTR SOC, V62, P129, DOI 10.1079/PNS2002221
   Smeds AI, 2007, J AGR FOOD CHEM, V55, P1337, DOI 10.1021/jf0629134
   Stasiuk M, 2008, FOOD CHEM, V108, P996, DOI 10.1016/j.foodchem.2007.12.011
   TLUSCIK F, 1990, ACTA ALIMENTARIA POLONICA, V16, P119
   Touillaud MS, 2007, JNCI-J NATL CANCER I, V99, P475, DOI 10.1093/jnci/djk096
   Vanharanta M, 1999, LANCET, V354, P2112, DOI 10.1016/S0140-6736(99)05031-X
   Vuorela S, 2005, J AGR FOOD CHEM, V53, P5922, DOI 10.1021/jf050554r
   Vuorela S, 2004, J AGR FOOD CHEM, V52, P8202, DOI 10.1021/jf0487046
   Wang LQ, 2000, CHEM PHARM BULL, V48, P1606, DOI 10.1248/cpb.48.1606
   Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381
   Zhao ZH, 2004, J NUTR, V134, P3083, DOI 10.1093/jn/134.11.3083
   Zielinski H, 2007, FOOD CHEM, V104, P980, DOI 10.1016/j.foodchem.2007.01.002
NR 140
TC 112
Z9 117
U1 2
U2 82
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0733-5210
EI 1095-9963
J9 J CEREAL SCI
JI J. Cereal Sci.
PD MAY 15
PY 2009
VL 49
IS 3
BP 323
EP 336
DI 10.1016/j.jcs.2009.01.007
PG 14
WC Food Science & Technology
SC Food Science & Technology
GA 458DW
UT WOS:000266995600001
DA 2025-04-28
ER

PT J
AU Gregersen, NT
   Bitz, C
   Krog-Mikkelsen, I
   Hels, O
   Kovacs, EMR
   Rycroft, JA
   Frandsen, E
   Mela, DJ
   Astrup, A
AF Gregersen, Nikolaj T.
   Bitz, Christian
   Krog-Mikkelsen, Inger
   Hels, Ole
   Kovacs, Eva M. R.
   Rycroft, Jane A.
   Frandsen, Erik
   Mela, David J.
   Astrup, Arne
TI Effect of moderate intakes of different tea catechins and caffeine on acute measures of energy metabolism under sedentary conditions
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE Green tea catechins; Caffeine; Energy expenditure; Substrate oxidation
ID x-ray absorptiometry; green tea; fat oxidation; food ingredients; obese subjects; abdominal fat; body-weight; black tea; expenditure; humans
AB Green tea may stimulate energy metabolism; however, it is unclear if acute effects are caused by specific catechins, caffeine or their combination. The objective of the present study was to examine the separate and combined effects of different catechins and caffeine on energy expenditure (EE) and fat oxidation over a single day. Fifteen healthy, normal-weight males received capsules containing placebo, caffeine alone (150mg), or caffeine plus a catechin mixture (600 mg) enriched in either epigallocatechin-3-gallate (EGCG), epigallocatechin or a mix of catechins, in a randomised cross-over double-blinded design. On each test day EE, respiratory quotient (RQ) and substrate oxidation were measured under sedentary conditions in a respiratory chamber for 13.5h. We found no significant treatment effect on EE (P=0.20) or RQ (P=0.68). EGCG with caffeine insignificantly raised EE and fat oxidation v. caffeine-only and placebo (EE 5.71 (SE 0.12) v. 5.68 (SE, 0.14) v. 5.59 (SE 0.13) MJ/12.5h, respectively; fat oxidation 84.8 (SE, 5.2) v. 80.7 (SE 4.7) v. 76.8 (SE 4.0) g/12.5h). Catechin/caffeine combinations at these dosages and mode of application had non-significant acute effects on EE and fat oxidation. The maximum observed effect on EE of about 2 % could still be meaningful for energy balance over much longer period of exposure. However, higher short-term effects reported in the literature may reflect variations in green tea extracts, added caffeine, or synergies with physical activity. The specific mechanisms and conditions that may underpin observed longer-term benefits of catechin-enriched green tea consumption on body composition remain to be confirmed.
C1 [Gregersen, Nikolaj T.; Bitz, Christian; Krog-Mikkelsen, Inger; Astrup, Arne] Univ Copenhagen, Fac Life Sci, Dept Human Nutr, DK-1958 Frederiksberg C, Denmark.
   [Hels, Ole] Tech Univ Denmark, Natl Food Inst, Soborg, Denmark.
   [Kovacs, Eva M. R.] Unilever N Amer, Englewood Cliffs, NJ USA.
   [Rycroft, Jane A.] Unilever R&D Colworth Pk, Lipton Inst Tea, Sharnbrook, Beds, England.
   [Frandsen, Erik] Glostrup Univ Hosp, Dept Clin Physiol & Nucl Med, Glostrup, Denmark.
   [Mela, David J.] Unilever Res Labs, Vlaardingen, Netherlands.
C3 University of Copenhagen; Technical University of Denmark; Unilever; Unilever; University of Copenhagen; Copenhagen University Hospital; Unilever
RP Gregersen, NT (corresponding author), Univ Copenhagen, Fac Life Sci, Dept Human Nutr, Rolighedsvej 30, DK-1958 Frederiksberg C, Denmark.
EM ntg@life.ku.dk
FU Unilever R&D Vlaardingen, The Netherlands
CR ASTRUP A, 1994, AM J CLIN NUTR, V59, P350, DOI 10.1093/ajcn/59.2.350
   Belza A, 2007, INT J OBESITY, V31, P121, DOI 10.1038/sj.ijo.0803351
   Belza A, 2009, EUR J CLIN NUTR, V63, P57, DOI 10.1038/sj.ejcn.1602901
   Bérubé-Parent S, 2005, BRIT J NUTR, V94, P432, DOI 10.1079/BJN20051502
   BORCHARDT RT, 1975, J MED CHEM, V18, P120, DOI 10.1021/jm00235a030
   Chantre P, 2002, PHYTOMEDICINE, V9, P3, DOI 10.1078/0944-7113-00078
   Desbrow B, 2007, FOOD CHEM TOXICOL, V45, P1588, DOI 10.1016/j.fct.2007.02.020
   Després JP, 2006, NATURE, V444, P881, DOI 10.1038/nature05488
   Diepvens K, 2005, BRIT J NUTR, V94, P1026, DOI 10.1079/BJN20051580
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   DULLOO AG, 1992, METABOLISM, V41, P1233, DOI 10.1016/0026-0495(92)90015-3
   Elia M, 1992, WORLD REV NUTR DIET, V70, P68
   Flint A, 2000, INT J OBESITY, V24, P38, DOI 10.1038/sj.ijo.0801083
   HAARBO J, 1991, CLIN PHYSIOL, V11, P331, DOI 10.1111/j.1475-097X.1991.tb00662.x
   Hase T, 2001, JOURNAL OF OLEO SCIENCE, V50, P599, DOI 10.5650/jos.50.599
   Henning SM, 2004, AM J CLIN NUTR, V80, P1558
   Hill AM, 2007, J AM COLL NUTR, V26, P396S, DOI 10.1080/07315724.2007.10719628
   Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857
   Hsu TF, 2006, EUR J CLIN NUTR, V60, P1330, DOI 10.1038/sj.ejcn.1602464
   Jin Yinzhe, 2006, BIOTECHNOLOGY JOURNAL, V1, P209, DOI 10.1002/biot.200500019
   Kajimoto O, 2005, J HEALTH SCI, V51, P161, DOI 10.1248/jhs.51.161
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   Kovacs EMR, 2004, BRIT J NUTR, V91, P431, DOI 10.1079/BJN20041061
   Kovacs EMR, 2006, OBES REV, V7, P59, DOI 10.1111/j.1467-789X.2006.00203.x
   Maki KC, 2009, J NUTR, V139, P264, DOI 10.3945/jn.108.098293
   MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106, DOI 10.1093/ajcn/51.6.1106
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Nagao T, 2001, JOURNAL OF OLEO SCIENCE, V50, P717
   Reto M, 2007, PLANT FOOD HUM NUTR, V62, P139, DOI 10.1007/s11130-007-0054-8
   Rudelle S, 2007, OBESITY, V15, P349, DOI 10.1038/oby.2007.529
   TOUBRO S, 1995, INT J OBESITY, V19, P544
   TSUCHIDA T, 2002, PROGR MED, V22, P2189
   Van Amelsvoort JMM, 2001, XENOBIOTICA, V31, P891, DOI 10.1080/00498250110079149
   Venables MC, 2008, AM J CLIN NUTR, V87, P778, DOI 10.1093/ajcn/87.3.778
   Warden BA, 2001, J NUTR, V131, P1731, DOI 10.1093/jn/131.6.1731
   Westerterp-Plantenga M, 2006, PHYSIOL BEHAV, V89, P85, DOI 10.1016/j.physbeh.2006.01.027
NR 37
TC 43
Z9 46
U1 0
U2 29
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD OCT 28
PY 2009
VL 102
IS 8
BP 1187
EP 1194
DI 10.1017/S0007114509371779
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 513TX
UT WOS:000271347800011
PM 19445822
DA 2025-04-28
ER

PT J
AU Jalil, AMM
   Ismail, A
   Chong, PP
   Hamid, M
   Kamaruddin, SHS
AF Jalil, Abbe Maleyki Mhd
   Ismail, Amin
   Chong, Pei Pei
   Hamid, Muhajir
   Kamaruddin, Syed Hasbullah Syed
TI Effects of cocoa extract containing polyphenols and methylxanthines on biochemical parameters of obese-diabetic rats
SO JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE
LA English
DT Article
DE cocoa extract; obese-diabetic (Ob-db); lipid profiles; insulin sensitivity
ID insulin secretory dysfunction; caffeine ingestion; hdl-cholesterol; glucose-uptake; chocolate; model; fat; antioxidant; resistance; expression
AB BACKGROUND: Previous studies have indicated that cocoa extract possesses hypoglycaemic and hypocholesterolaemic properties in streptozotocin-induced diabetic rats. However, there has been limited research on the effects of cocoa extract on obese-diabetic (Ob-db) rats that mimic human diabetes syndrome. Hence this study was initiated to determine the effect of cocoa extract containing polyphenols and methylxanthines on several biochemical parameters, namely glucose level, insulin sensitivity and lipid profiles of Ob-db rats. RESULTS: Intake of cocoa extract supplemented with polyphenols (2.17 mg epicatechin, 1.52 mg catechin, 0.25 mg dimer and 0.13 mg trimer g(-1) cocoa extract) and methylxanthines (3.55 mg caffeine and 2.22 mg theobromine g(-1) cocoa extract) for 4 weeks significantly (P < 0.05) reduced the plasma total cholesterol, triglycerides and low-density lipoprotein cholesterol of obese-diabetic rats (Ob-db + cocoa) compared with non-supplemented animals (Ob-db). Short-term (acute) supplementation of cocoa extract significantly (P < 0.05) reduced the plasma glucose level at 60 and 90 min compared with untreated rats as assessed by the oral glucose tolerance test. However, no significant differences were observed in plasma glucose level, insulin level and insulin sensitivity after chronic (4 weeks) cocoa extract supplementation. CONCLUSION: The results of this study suggest that cocoa extract possesses hypocholesterolaemic properties and can exert a transient glucose-lowering effect but not long-term glucose control. (C) 2008 Society of Chemical Industry
C1 [Jalil, Abbe Maleyki Mhd; Ismail, Amin; Kamaruddin, Syed Hasbullah Syed] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Nutr & Dietet, Serdang 43400, Selangor, Malaysia.
   [Chong, Pei Pei] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Biomed Sci, Serdang 43400, Selangor, Malaysia.
   [Hamid, Muhajir] Univ Putra Malaysia, Fac Biotechnol & Mol Sci, Dept Microbiol, Serdang 43400, Selangor, Malaysia.
C3 Universiti Putra Malaysia; Universiti Putra Malaysia; Universiti Putra Malaysia
RP Ismail, A (corresponding author), Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Nutr & Dietet, Serdang 43400, Selangor, Malaysia.
EM amin@medic.upm.edu.my
CR Adamson GE, 1999, J AGR FOOD CHEM, V47, P4184, DOI 10.1021/jf990317m
   Amin I, 2004, NUTRITION & FOOD SCIENCE, V34, P116, DOI 10.1108/00346650410536737
   Amin I, 2004, J MED FOOD, V7, P7, DOI 10.1089/109662004322984635
   Baba S, 2007, J NUTR, V137, P1436, DOI 10.1093/jn/137.6.1436
   Baba S, 2007, AM J CLIN NUTR, V85, P709, DOI 10.1093/ajcn/85.3.709
   Brand-Miller J, 2003, J NUTR, V133, P3149, DOI 10.1093/jn/133.10.3149
   Buchanan Thomas A, 2003, CLINICAL THERAPEUTICS, V25, PB32, DOI 10.1016/S0149-2918(03)80241-2
   Chan PT, 1999, J NUTR, V129, P1094, DOI 10.1093/jn/129.6.1094
   Cooper KA, 2008, BRIT J NUTR, V99, P1, DOI 10.1017/S0007114507795296
   Grassi D, 2005, HYPERTENSION, V46, P398, DOI 10.1161/01.HYP.0000174990.46027.70
   Greer F, 2001, DIABETES, V50, P2349, DOI 10.2337/diabetes.50.10.2349
   Heishi M, 2006, DIABETOLOGIA, V49, P1647, DOI 10.1007/s00125-006-0271-y
   Heiss C, 2007, J CARDIOVASC PHARM, V49, P74, DOI 10.1097/FJC.0b013e31802d0001
   Ikeda I, 2005, J NUTR, V135, P155, DOI 10.1093/jn/135.2.155
   Johnston K, 2005, FEBS LETT, V579, P1653, DOI 10.1016/j.febslet.2004.12.099
   Kelm MA, 2006, J AGR FOOD CHEM, V54, P1571, DOI 10.1021/jf0525941
   Kobayashi Y, 2000, J AGR FOOD CHEM, V48, P5618, DOI 10.1021/jf0006832
   Lee S, 2005, DIABETES CARE, V28, P566, DOI 10.2337/diacare.28.3.566
   Lin CL, 2007, J LIPID RES, V48, P2334, DOI 10.1194/jlr.M700128-JLR200
   Matteucci E, 2008, J ETHNOPHARMACOL, V115, P163, DOI 10.1016/j.jep.2007.08.040
   Najjar N, 2004, NUTR RES, V24, P993, DOI 10.1016/j.nutres.2004.09.002
   Neukam K, 2007, EUR J NUTR, V46, P53, DOI 10.1007/s00394-006-0627-6
   Pal S, 2003, J NUTR, V133, P700, DOI 10.1093/jn/133.3.700
   Purintrapiban J, 2006, BIOL PHARM BULL, V29, P1995, DOI 10.1248/bpb.29.1995
   Ramljak D, 2005, MOL CANCER THER, V4, P537, DOI 10.1158/1535-7163.MCT-04-0286
   Reed MJ, 2000, METABOLISM, V49, P1390, DOI 10.1053/meta.2000.17721
   Rein D, 2000, J NUTR, V130, P2109S, DOI 10.1093/jn/130.8.2109S
   Rensen PCN, 1996, J BIOL CHEM, V271, P14791, DOI 10.1074/jbc.271.25.14791
   Rios LY, 2003, AM J CLIN NUTR, V77, P912, DOI 10.1093/ajcn/77.4.912
   Ruzaidi A, 2005, J ETHNOPHARMACOL, V98, P55, DOI 10.1016/j.jep.2004.12.018
   Srinivasan K, 2005, PHARMACOL RES, V52, P313, DOI 10.1016/j.phrs.2005.05.004
   Tomaru M, 2007, NUTRITION, V23, P351, DOI 10.1016/j.nut.2007.01.007
   Tomas-Barberán FA, 2007, J AGR FOOD CHEM, V55, P3926, DOI 10.1021/jf070121j
   Vinson JA, 1999, J AGR FOOD CHEM, V47, P4821, DOI 10.1021/jf990312p
   Vinson JA, 2006, J AGR FOOD CHEM, V54, P8071, DOI 10.1021/jf062175j
   Weyer C, 1999, J CLIN INVEST, V104, P787, DOI 10.1172/JCI7231
   Weyer C, 2001, DIABETES CARE, V24, P89, DOI 10.2337/diacare.24.1.89
   Wilcox LJ, 2001, J LIPID RES, V42, P725
   Zeggwagh NA, 2006, J ETHNOPHARMACOL, V108, P223, DOI 10.1016/j.jep.2006.05.005
   Zhang FL, 2003, EXP ANIM TOKYO, V52, P401, DOI 10.1538/expanim.52.401
   Ziai SA, 2005, J ETHNOPHARMACOL, V102, P202, DOI 10.1016/j.jep.2005.06.042
NR 41
TC 31
Z9 36
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-5142
EI 1097-0010
J9 J SCI FOOD AGR
JI J. Sci. Food Agric.
PD JAN 15
PY 2009
VL 89
IS 1
BP 130
EP 137
DI 10.1002/jsfa.3419
PG 8
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science & Technology
SC Agriculture; Chemistry; Food Science & Technology
GA 384VY
UT WOS:000261773500017
DA 2025-04-28
ER

PT J
AU Hursel, R
   Viechtbauer, W
   Westerterp-Plantenga, MS
AF Hursel, R.
   Viechtbauer, W.
   Westerterp-Plantenga, M. S.
TI The effects of green tea on weight loss and weight maintenance: a meta-analysis
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Review
DE green tea; caffeine; weight loss; weight maintenance; ethnicity
ID catechol-o-methyltransferase; energy-expenditure; black tea; fat oxidation; caffeine; extract; consumption; humans; trial; model
AB Introduction. Different outcomes of the effect of green tea on weight loss (WL) and weight maintenance (WM) have been reported in studies with subjects differing in ethnicity and habitual caffeine intake. Purpose. To elucidate by meta-analysis whether green tea indeed has a function in body weight regulation. Methods. English-language studies about WL and WM after green tea supplementation were identified through PubMed and based on the references from retrieved articles. Out of the 49 studies initially identified, a total of 11 articles fitted the inclusion criteria and provided useful information for the meta-analysis. Effect sizes (mean weight change in treatment versus control group) were computed and aggregated based on a random-effects model. The influence of several moderators on the effect sizes was examined. Results. Catechins significantly decreased body weight and significantly maintained body weight after a period of WL ((mu) over cap = -1.31 kg; P < 0.001). Inhibition of this effect by high habitual caffeine intake (> 300 mg per day) failed to reach significance ((mu) over cap = -0.27 kg for high and (mu) over cap = -1.60 kg for low habitual caffeine intake; P = 0.09). Also, the seemingly smaller effect of catechins in Caucasian ((mu) over cap = -0.82 kg) subjects compared with Asians ((mu) over cap = -1.51 kg; P = 0.37) did not reach significance. Interaction of ethnicity and caffeine intake was a significant moderator (P = 0.04). Conclusions. Catechins or an epigallocatechin gallate (EGCG)-caffeine mixture have a small positive effect on WL and WM. The results suggest that habitual caffeine intake and ethnicity may be moderators, as they may influence the effect of catechins. International Journal of Obesity (2009) 33, 956-961; doi: 10.1038/ijo.2009.135; published online 14 July 2009
C1 [Hursel, R.; Westerterp-Plantenga, M. S.] Maastricht Univ, Dept Human Biol, Nutr & Toxicol Res Inst Maastricht NUTRIM, NL-6200 MD Maastricht, Netherlands.
   [Viechtbauer, W.] Maastricht Univ, Dept Methodol & Stat, NL-6200 MD Maastricht, Netherlands.
C3 Maastricht University; Maastricht University
RP Hursel, R (corresponding author), Maastricht Univ, Dept Human Biol, Nutr & Toxicol Res Inst Maastricht NUTRIM, Univ Singel 50,POB 616, NL-6200 MD Maastricht, Netherlands.
EM rick.hursel@hb.unimaas.nl
CR Auvichayapat P, 2008, PHYSIOL BEHAV, V93, P486, DOI 10.1016/j.physbeh.2007.10.009
   Bérubé-Parent S, 2005, BRIT J NUTR, V94, P432, DOI 10.1079/BJN20051502
   Cornelis MC, 2007, AM J CLIN NUTR, V86, P240, DOI 10.1093/ajcn/86.1.240
   Diepvens K, 2005, BRIT J NUTR, V94, P1026, DOI 10.1079/BJN20051580
   Diepvens K, 2007, AM J PHYSIOL-REG I, V292, PR77, DOI 10.1152/ajpregu.00832.2005
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Grigg D, 2002, GEOJOURNAL, V57, P283, DOI 10.1023/B:GEJO.0000007249.91153.c3
   Hase T, 2001, JOURNAL OF OLEO SCIENCE, V50, P599, DOI 10.5650/jos.50.599
   Hodgson JM, 2006, BRIT J NUTR, V95, P14, DOI 10.1079/BJN20051621
   Hsu CH, 2008, CLIN NUTR, V27, P363, DOI 10.1016/j.clnu.2008.03.007
   Kovacs EMR, 2004, BRIT J NUTR, V91, P431, DOI 10.1079/BJN20041061
   Krul C, 2001, MUTAT RES-FUND MOL M, V474, P71, DOI 10.1016/S0027-5107(00)00158-5
   Langley-Evans SC, 2000, INT J FOOD SCI NUTR, V51, P181, DOI 10.1080/09637480050029683
   Nagao T, 2001, JOURNAL OF OLEO SCIENCE, V50, P717
   Nagao T, 2007, OBESITY, V15, P1473, DOI 10.1038/oby.2007.176
   Palmatier MA, 1999, BIOL PSYCHIAT, V46, P557, DOI 10.1016/S0006-3223(99)00098-0
   Serafini M, 1996, EUR J CLIN NUTR, V50, P28
   Shixian Q, 2006, J MED FOOD, V9, P451, DOI 10.1089/jmf.2006.9.451
   TSUCHIDA T, 2002, PROGR MED, V22, P2189
   Viechtbauer W, 2005, J EDUC BEHAV STAT, V30, P261, DOI 10.3102/10769986030003261
   WANG M, 2009, EUR J CLIN NUT UNPUB, V0, P0
   Westerterp-Plantenga M, 2006, PHYSIOL BEHAV, V89, P85, DOI 10.1016/j.physbeh.2006.01.027
   Westerterp-Plantenga MS, 2005, OBES RES, V13, P1195, DOI 10.1038/oby.2005.142
   Wolfram S, 2006, MOL NUTR FOOD RES, V50, P176, DOI 10.1002/mnfr.200500102
NR 25
TC 223
Z9 246
U1 2
U2 103
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
EI 
J9 INT J OBESITY
JI Int. J. Obes.
PD SEP 15
PY 2009
VL 33
IS 9
BP 956
EP 961
DI 10.1038/ijo.2009.135
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 500BT
UT WOS:000270272800002
PM 19597519
DA 2025-04-28
ER

PT J
AU Ko, JH
   Jang, EH
   Park, CS
   Kim, HK
   Cho, SG
   Shin, DW
   Yi, HG
   Kang, JH
AF Ko, Jeong-Hyeon
   Jang, Eun-Hee
   Park, Chang-Shin
   Kim, Hyoung-Kwang
   Cho, Soon Gu
   Shin, Dong Wun
   Yi, Hyeon Gyu
   Kang, Ju-Hee
TI Pharmacokinetic and Pharmacodynamic Interaction between Metformin and (-)-Epigallocatechin-3-gallate
SO MOLECULAR & CELLULAR TOXICOLOGY
LA English
DT Article
DE (-)-Epigallocatechin-3-gallate; Metformin; Pharmacokinetics; AMP-activated protein kinase
ID green tea; epigallocatechin gallate; protein-kinase; cancer cells; egcg; modulation; polyphenol; caffeine; catechin; ampk
AB (-)-Epigallocatechin-3-gallate (EGCG), a major flavonoid in green tea has multiple health benefits including chemoprevention, anti-inflammatory, anti-diabetic and anti-obesity effects. In connection with these effects, EGCG can be a candidate to help the treatment of metabolic diseases. Metformin is a widely used anti-diabetic drug regulating cellular energy homeostasis via AMP-activated protein kinase (AMPK) activation. Therefore, the combination of metformin with EGCG may have additive or synergistic effects on treatment of type 2 diabetes. Nevertheless, there is no report for the pharmacokinetic and/or pharmacodynamic interaction of EGCG with metformin. Here, we evaluated the pharmacokinetic and pharmacodynamic interaction between metformin and EGCG in rats. Pharmacokinetics parameters of metformin were measured after oral administration of metformin in rats pre-treated with EGCG (10 mg/kg) or saline for 7 days. The results showed that there is no significant difference in pharmacokinetic parameters between saline control and EGCG-treated group. In addition, the hepatic AMPK activation by metformin in EGCG-treated rats was also similar to the control. The lack of additive effects of EGCG on AMPK activation or intrarcellular uptake of metformin was also evaluated in cells in the presence or absence of EGCG. Treatment of HepG2 cells with EGCG inhibited the metformin-induced AMPK activation. Combined results suggested that EGCG has no effect on the pharmarcokinetics of metformin but may contribute to metformin action.
C1 [Ko, Jeong-Hyeon; Jang, Eun-Hee; Park, Chang-Shin; Kim, Hyoung-Kwang; Kang, Ju-Hee] Inha Univ, Coll Med, Ctr Adv Med Educ, Dept Pharmacol,Project BK 21, Inchon 400712, South Korea.
   [Ko, Jeong-Hyeon; Jang, Eun-Hee; Park, Chang-Shin; Kim, Hyoung-Kwang; Kang, Ju-Hee] Inha Univ, Coll Med, Ctr Adv Med Educ, Med Toxicol Res Ctr,Project BK 21, Inchon 400712, South Korea.
   [Jang, Eun-Hee; Kang, Ju-Hee] Inha Univ, Hosp Clin Trial Ctr, Inchon 400712, South Korea.
   [Cho, Soon Gu] Inha Univ Hosp, Dept Radiol, Inchon 400700, South Korea.
   [Shin, Dong Wun] Inje Univ, Ilsan Paik Hosp, Dept Emergency Med, Gyeonggi Do 411706, South Korea.
   [Yi, Hyeon Gyu] Inha Univ Hosp, Dept Internal Med, Inchon 400700, South Korea.
C3 Inha University; Inha University; Inha University; Inha University; Inha University Hospital; Inje University; Inha University; Inha University Hospital
RP Kang, JH (corresponding author), Inha Univ, Coll Med, Ctr Adv Med Educ, Dept Pharmacol,Project BK 21, Jungseok Bldg 6FL,3 Ga, Inchon 400712, South Korea.
EM johykang@inha.ac.kr
FU Inha University
CR Anderson RA, 2002, J AGR FOOD CHEM, V50, P7182, DOI 10.1021/jf020514c
   Choi YB, 2004, BRAIN RES, V1019, P47, DOI 10.1016/j.brainres.2004.05.079
   Collins QF, 2007, J BIOL CHEM, V282, P30143, DOI 10.1074/jbc.M702390200
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   GRAHAM HN, 1992, PREV MED, V21, P334, DOI 10.1016/0091-7435(92)90041-F
   Hwang JT, 2007, CANCER LETT, V247, P115, DOI 10.1016/j.canlet.2006.03.030
   Hwang JT, 2005, BIOCHEM BIOPH RES CO, V338, P694, DOI 10.1016/j.bbrc.2005.09.195
   Iso H, 2006, ANN INTERN MED, V144, P554, DOI 10.7326/0003-4819-144-8-200604180-00005
   Kao Y, 2000, AM J CLIN NUTR, V72, P1232
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   Lambert JD, 2003, J NUTR, V133, P3262S, DOI 10.1093/jn/133.10.3262S
   Lee CH, 2000, J IMAGING SCI TECHN, V44, P308
   Liao SS, 2001, VITAM HORM, V62, P1, DOI 10.1016/S0083-6729(01)62001-6
   Lin CL, 2008, MOL NUTR FOOD RES, V52, P930, DOI 10.1002/mnfr.200700437
   Lin CL, 2007, J LIPID RES, V48, P2334, DOI 10.1194/jlr.M700128-JLR200
   Monteiro R, 2005, N-S ARCH PHARMACOL, V372, P147, DOI 10.1007/s00210-005-0012-7
   Qanungo S, 2005, CARCINOGENESIS, V26, P958, DOI 10.1093/carcin/bgi040
   Raederstorff DG, 2003, J NUTR BIOCHEM, V14, P326, DOI 10.1016/S0955-2863(03)00054-8
   Shu Y, 2007, J CLIN INVEST, V117, P1422, DOI 10.1172/JCI30558
   Song EK, 2003, ARCH PHARM RES, V26, P559, DOI 10.1007/BF02976881
   Waltner-Law ME, 2002, J BIOL CHEM, V277, P34933, DOI 10.1074/jbc.M204672200
   Wang DS, 2002, J PHARMACOL EXP THER, V302, P510, DOI 10.1124/jpet.102.034140
NR 22
TC 0
Z9 1
U1 0
U2 13
PU KOREAN SOCIETY TOXICOGENOMICS & TOXICOPROTEOMICS-KSTT
PI GYEONGGI-DO
PA HANYANG UNIV, SCI & TECHNOL BLDG 1, RM 423, SA-DONG, SANGROK-GU, ANSAN, GYEONGGI-DO, 426 791, SOUTH KOREA
SN 1738-642X
EI 2092-8467
J9 MOL CELL TOXICOL
JI Mol. Cell. Toxicol.
PD DEC 31
PY 2009
VL 5
IS 4
BP 298
EP 303
DI 
PG 6
WC Biochemistry & Molecular Biology; Toxicology
SC Biochemistry & Molecular Biology; Toxicology
GA 540FG
UT WOS:000273316100004
DA 2025-04-28
ER

PT J
AU Mori, S
   Satou, M
   Kanazawa, S
   Yoshizuka, N
   Hase, T
   Tokimitsu, I
   Takema, Y
   Nishizawa, Y
   Yada, T
AF Mori, Shinobu
   Satou, Mayumi
   Kanazawa, Satoshi
   Yoshizuka, Naonobu
   Hase, Tadashi
   Tokimitsu, Ichiro
   Takema, Yoshinori
   Nishizawa, Yoshinori
   Yada, Toshihiko
TI Body fat mass reduction and up-regulation of uncoupling protein by novel lipolysis-promoting plant extract
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE beta adrenergic receptor; lipolysis; fat reduction; uncoupling protein; plant extract
ID brown adipose-tissue; obese women; white fat; beta-3-adrenergic receptor; metabolic-rate; weight-loss; expression; cells; adipocytes; mechanisms
AB We have found natural products exhibiting lipolysis-promoting activity in subcutaneous adipocytes, which are less sensitive to hormones than visceral adipocytes. The activities and a action mechanisms of a novel plant extract of Cirsium oligophyllum (CE) were investigated in isolated adipocytes from rat subcutaneous fat, and its fat-reducing effects by peroral administration and topical application were evaluated in vivo. CE-induced lipolysis was synergistically enhanced by caffeine, a phosphodiesterase inhibitor, and was reduced by propranolol, a beta adrenergic antagonist. The peroral administration of 10% CE solution to Wistar rats for 32 days reduced body weight gain, subcutaneous, and visceral fat weights by 6.6, 26.2, and 3.0%, respectively, as compared to the control group. By the topical application of 2% of this extract to rats for 7 days, weight of subcutaneous fat in the treated skin was reduced by 23.2%. This fat mass reduction was accompanied by the up-regulation of uncoupling protein 1 (UCP), a principal thermogenic mitochondrial molecule related to energy dissipating, in subcutaneous fat and UCP3 in skin except for the fat layer. These results indicate that CE promotes lipolysis via a mechanism involving the beta adrenergic receptor, and affects the body fat mass. This fat reduction may be partially due to UCP up-regulation in the skin including subcutaneous fat. This is the first report showing that repeated lipolysis promotion through CE administration may be beneficial for the systematic suppression of body fat accumulation or the control of fat distribution in obesity.
C1 [Mori, Shinobu; Satou, Mayumi; Kanazawa, Satoshi; Yoshizuka, Naonobu; Hase, Tadashi; Tokimitsu, Ichiro; Takema, Yoshinori; Nishizawa, Yoshinori] Kao Corp, Biol Sci Labs, Ichikai, Tochigi 3213497, Japan.
   [Mori, Shinobu; Yada, Toshihiko] Jichi Med Univ, Sch Med, Div Integrat Physiol, Dept Physiol, Shimotsuke, Tochigi 3290498, Japan.
C3 KAO Corporation; Jichi Medical University
RP Mori, S (corresponding author), Kao Corp, Biol Sci Labs, 2606 Akabane, Ichikai, Tochigi 3213497, Japan.
EM mori.shinobu@kao.co.jp
CR ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   Arner P, 1996, DIABETES REVIEWS, V4, P450
   Atgié C, 1998, COMP BIOCHEM PHYS A, V119, P629, DOI 10.1016/S1095-6433(97)00476-5
   Bairras C, 2007, J PHYSIOL BIOCHEM, V63, P287, DOI 10.1007/BF03165760
   Baumruk F, 1999, FEBS LETT, V444, P206, DOI 10.1016/S0014-5793(99)00053-8
   Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0
   Bottcher H, 1997, INT J OBESITY, V21, P439, DOI 10.1038/sj.ijo.0800425
   CANNON B, 1982, FEBS LETT, V150, P129, DOI 10.1016/0014-5793(82)81319-7
   Doucet E, 2002, EUR J CLIN NUTR, V56, P297, DOI 10.1038/sj.ejcn.1601334
   EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461
   Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269
   GREENWAY FL, 1987, CLIN THER, V9, P663
   HELLMER J, 1992, J CLIN ENDOCR METAB, V75, P15, DOI 10.1210/jc.75.1.15
   Hoffstedt J, 1997, J LIPID RES, V38, P795
   Inokuma K, 2006, AM J PHYSIOL-ENDOC M, V290, PE1014, DOI 10.1152/ajpendo.00105.2005
   Jezek P, 1999, J BIOENERG BIOMEMBR, V31, P457, DOI 10.1023/A:1005496306893
   KAWANOTAKAHASHI Y, 1984, INT J OBESITY, V8, P655
   Klaus S, 1998, AM J PHYSIOL-REG I, V274, PR287, DOI 10.1152/ajpregu.1998.274.2.R287
   LANGIN D, 1995, FUND CLIN PHARMACOL, V9, P97, DOI 10.1111/j.1472-8206.1995.tb00268.x
   Lupi Omar, 2007, J COSMET DERMATOL, V6, P102
   MAURIEGE P, 1995, AM J PHYSIOL-ENDOC M, V269, PE341, DOI 10.1152/ajpendo.1995.269.2.E341
   Mori S, 2008, J INVEST DERMATOL, V128, P1894, DOI 10.1038/jid.2008.20
   Nagase I, 1996, J CLIN INVEST, V97, P2898, DOI 10.1172/JCI118748
   Nagase I, 2001, FEBS LETT, V494, P175, DOI 10.1016/S0014-5793(01)02341-9
   NEDERGAARD J, 1985, AM J PHYSIOL, V248, PC365, DOI 10.1152/ajpcell.1985.248.3.C365
   RODBELL M, 1964, J BIOL CHEM, V239, P375
   Shen J, 2007, NEUROSCI LETT, V416, P241, DOI 10.1016/j.neulet.2006.12.063
   SHIMIZU Y, 1991, AM J PHYSIOL, V261, PR301, DOI 10.1152/ajpregu.1991.261.2.R301
   Solanes G, 1997, J BIOL CHEM, V272, P25433, DOI 10.1074/jbc.272.41.25433
   TAVERNIER G, 1995, AM J PHYSIOL-ENDOC M, V268, PE1135, DOI 10.1152/ajpendo.1995.268.6.E1135
   THOMAS RF, 1992, P NATL ACAD SCI USA, V89, P4490, DOI 10.1073/pnas.89.10.4490
   Vidal H, 2001, ANN MED, V33, P547, DOI 10.3109/07853890108995965
   Wang SP, 2008, MOL GENET METAB, V95, P117, DOI 10.1016/j.ymgme.2008.06.012
   YOSHIDA T, 1994, INT J OBESITY, V18, P345
   Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747
NR 35
TC 11
Z9 13
U1 0
U2 6
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-2288
EI 
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PD JUN 15
PY 2009
VL 5
IS 4
BP 311
EP 318
DI 
PG 8
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics
GA 468TF
UT WOS:000267843900003
PM 19421341
DA 2025-04-28
ER

